US20170233803A1 - Method for sequencing a heteropolymeric target nucleic acid sequence - Google Patents

Method for sequencing a heteropolymeric target nucleic acid sequence Download PDF

Info

Publication number
US20170233803A1
US20170233803A1 US15/491,505 US201715491505A US2017233803A1 US 20170233803 A1 US20170233803 A1 US 20170233803A1 US 201715491505 A US201715491505 A US 201715491505A US 2017233803 A1 US2017233803 A1 US 2017233803A1
Authority
US
United States
Prior art keywords
pore
seq
amino acids
sequence
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/491,505
Inventor
David Jackson Stoddart
Andrew John Heron
Giovanni Maglia
John Hagan Pryce Bayley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to US15/491,505 priority Critical patent/US20170233803A1/en
Publication of US20170233803A1 publication Critical patent/US20170233803A1/en
Priority to US15/848,116 priority patent/US10669581B2/en
Priority to US16/858,859 priority patent/US20200407785A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
    • G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Definitions

  • the invention relates to a method for sequencing a heteropolymeric target nucleic acid sequence that involves stochastic sensing.
  • the invention also relates to a method for improving a pore for sequencing a target nucleic acid sequence by modifying one or more sites in the pore.
  • Stochastic detection is an approach to sensing that relies on the observation of individual binding events between analyte molecules and a receptor.
  • Stochastic sensors can be created by placing a single pore of nanometer dimensions in an insulating membrane and measuring voltage-driven ionic transport through the pore in the presence of analyte molecules. The frequency of occurrence of fluctuations in the current reveals the concentration of an analyte that binds within the pore. The identity of an analyte is revealed through its distinctive current signature, notably the duration and extent of current block (Braha, O., Walker, B., Cheley, S., Kasianowicz, J. J., Song, L., Gouaux, J. E., and Bayley, H. (1997) Chem. Biol. 4, 497-505; and Bayley, H., and Cremer, P. S. (2001) Nature 413, 226-230).
  • Engineered versions of the bacterial pore forming toxin ⁇ -hemolysin ( ⁇ -HL) have been used for stochastic sensing of many classes of molecules (Bayley, H., and Cremer, P. S. (2001) Nature 413, 226-230; Shin, S., H., Luchian, T., Cheley, S., Braha, O., and Bayley, H. (2002) Angew. Chem. Int. Ed. 41, 3707-3709; and Guan, X., Gu, L.-Q., Cheley, S., Braha, O., and Bayley, H. (2005) Chem. BioChem. 6, 1875-1881).
  • Cyclodextrins become transiently lodged in the ⁇ -HL pore and produce a substantial but incomplete channel block.
  • Translocating homopolymer nucleic acid sequences can be distinguished by protein nanopores (for example Branton, D., Deamer, D. W., Marziali, A., Bayley, H., Benner, S. A., Butler, T., Di Ventra, M., Garaj, S., Hibbs, A., Huang, X., et al. (2008) Nature Biotechnology 26, 1146-1153).
  • the transition between two homopolymer sequences within a translocating single RNA strand can also be observed (Akeson, M., Branton, D., Kasianowicz, J. J., Brandin, E., & Deamer, D. W. (1999) Biophys. J. 77, 3227-3233).
  • a pore can discriminate between at least four different nucleotides in a nucleic acid sequence.
  • a pore may be used to sequence an intact heteropolymeric target nucleic acid sequence via stochastic sensing.
  • pores having two or more distinct sites that are capable of discriminating between different nucleotides display improved nucleotide recognition.
  • Such pores are advantageous for sequencing nucleic acid sequences.
  • the presence in a pore of more than one site that is capable of discriminating between different nucleotides not only allows the length of a nucleic acid sequence to be determined, but also allows the sequence of a nucleic acid sequence to be determined more efficiently.
  • pores for sequencing nucleic acids can be improved by modifying at least one site that is capable of discriminating between different nucleotides. If a pore has too few sites that are capable of discriminating between different nucleotides, it can be improved by introducing one or more additional sites. If a pore has too many sites that are capable of discriminating between different nucleotides, it can be improved by removing one or more of the sites. Pores may also be improved by enhancing or reducing the ability of one or more sites to discriminate between different nucleotides.
  • the invention provides a method for sequencing a heteropolymeric target nucleic acid sequence, comprising:
  • the invention also provides:
  • FIG. 1 shows discrimination of immobilized DNA homopolymers by ⁇ -HL pores.
  • A Schematic representation of a homopolymeric DNA oligonucleotide (blue circles, only the first 25 nucleotides of the 60 nucleotide long sequence are shown) immobilized inside an ⁇ -HL pore (grey, cross-section) through the use of a biotin (yellow)-streptavidin (red) linkage.
  • the ⁇ -HL pore can be divided into two halves, each approximately 5 nm in length; an upper vestibule located between the cis entrance and the central constriction, and a fourteen-stranded, transmembrane, antiparallel ⁇ barrel, located between the central constriction and trans exit.
  • the central constriction of 1.4 nm diameter is formed by the Glu-111, Lys-147 (shaded green) and Met-113 side chains contributed by all seven subunits. (B, C, left).
  • Typical event histograms displaying the residual current levels, caused by poly(dC) and poly(dA) oligonucleotide blockages, for the WT and E111N/K147N pores.
  • the mean residual current levels for each oligonucleotide were determined by performing Gaussian fits to the data.
  • FIG. 2 shows the probing of DNA recognition by the ⁇ -HL pore with A 5 oligonucleotides.
  • A The five oligonucleotides (i-v) containing 5 consecutive adenine nucleotides (A 5 , red circles) at different positions (numbered from the 3′ biotin tag) in an otherwise poly(dC) strand (cytidine nucleotides are shown as blue circles). Only the first 25 of the 40 nucleotide-long sequences are shown.
  • FIG. 3 shows discrimination of a single adenine nucleotide by ⁇ -HL.
  • the graph (middle) indicates the differences in residual current ( ⁇ I RES values) between blockades caused by a poly(dC) oligonucleotide containing a single adenine nucleotide (the sequence of each oligonucleotide is shown to the left) and blockades caused by poly(dC)40 for WT (green) and E111N/K147N (orange) ⁇ -HL pores.
  • R 1 , R 2 and R 3 represent the three proposed recognition sites in the ⁇ -HL nanopore. Their probable locations are indicated on the cross-section of the ⁇ barrel domain of the ⁇ -HL pore (right).
  • FIG. 4 shows recognition of all four DNA bases by the WT and E111N/K147N ⁇ -HL pores. Histograms of the residual current levels for WT (left) and E111N/K147N (right) pores are shown. Three sets of four poly(dC) oligonucleotides were used, with each set containing either a single G, A, T, or C nucleotide at a specific position. All experiments were conducted at least three times, and the results displayed in the figure are from a typical experiment. (A) The WT and E111N/K147N pores were interrogated with SEQ ID NOs: 35 to 38.
  • FIG. 5 shows probing the E111N/K147N ⁇ -HL pore for single nucleotide discrimination in a heteropolymeric oligonucleotide. Histogram (top) of residual current levels for E111N/K147N pores interrogated with four heteropolymeric DNA strands (center) that differ at only one position (large letter). Gaussian fits were performed for each peak, and the mean value of the residual current for each oligonucleotide (and the standard deviation) is displayed (bottom).
  • FIG. 6 shows typical current-voltage (IV) traces for WT (squares) and E111N/K147N (circles) ⁇ -HL pores, in 1 M KCl, 25 mM Tris.HCl, pH 8.0, containing 0.1 mM EDTA.
  • FIG. 7 shows the chemical structure of the biotin-TEG linker used to biotinylate the 3′ terminus of the DNA oligonucleotides.
  • the structure was produced with ChemBioDraw Ultra 11.
  • FIG. 8 shows voltage dependence of I RES for WT pores threaded with either poly(dA) (squares) or poly(dC) (diamonds).
  • the data for the graph was obtained by taking mean values from Gaussian fits to histograms of residual current levels for multiple blockades for each oligonucleotide, at various applied potentials. The standard deviation associated with the fitting of the Gaussians is shown.
  • FIG. 9 shows that two heads are better than one.
  • a) A hypothetical nanopore sensor (green) with two reading heads, R 1 and R 2 , which could in principle extract more sequence information from a DNA strand (red) than a device with a single reading head.
  • b) To illustrate the idea, we assume that the four bases of DNA at reading head R 1 produce 4 distinct current levels (widely dispersed as shown). Each of the levels is split into 4 additional levels (with a lesser dispersion, for the purpose of illustration) by the second reading head R 2 , yielding 16 current levels in total and providing redundant information about the DNA sequence.
  • FIG. 10 shows four-base discrimination at R 1 and R 2 , by an engineered ⁇ HL nanopore. Histograms of residual current levels for E111N/K147N/M113Y (NNY) pores are shown (left), for a set of 4 oligonucleotides (right). B represents the 3′ biotin-TEG extension. Each experiment was conducted at least three times, and the results displayed in the figure are from a single experiment. When the oligonucleotides are driven into the ⁇ -HL pore the substituted nucleotides are positioned at R 1 (red) or R 2 (green). Gaussian fits were performed for each peak in the histograms.
  • FIG. 11 shows the predicted and experimental residual current level differences ( ⁇ I RES ) observed when NNY pores are interrogated with oligonucleotides which simultaneously probe R 1 and R 2 .
  • E111N/K147N/M113Y (NNY) pores were probed with 16 oligonucleotides, with the sequence 5′-CCCCCCCCCCCCCCCCCCCCCCCCNCCCCNCCCCCCCCB-3′, where N is A, T, G or C (N 9 N 14 , Table 5).
  • a histogram displaying the residual current level differences for blockades by the various oligonucleotides, relative to the mean blockade produced by poly(dC) is shown. The current level for poly(dC) is set as zero.
  • Blockades which have a residual current level lower than poly(dC) have negative ⁇ I RES values and blockades which have higher residual current levels than poly(dC) have positive ⁇ I RES values.
  • the grey dashed lines show the predicted residual current levels, based on the ⁇ I RES data displayed in Table 5 (see Example 2).
  • the peak denoted * arises from non-specific blockades and is not considered in the analysis.
  • SEQ ID NO: 1 shows the polynucleotide sequence encoding one subunit of wild type ⁇ -hemolysin ( ⁇ -HL).
  • SEQ ID NO: 2 shows the amino acid sequence of one subunit of wild type ⁇ -HL.
  • Amino acids 2 to 6, 73 to 75, 207 to 209, 214 to 216 and 219 to 222 form ⁇ -helices.
  • Amino acids 22 to 30, 35 to 44, 52 to 62, 67 to 71, 76 to 91, 98 to 103, 112 to 123, 137 to 148, 154 to 159, 165 to 172, 229 to 235, 243 to 261, 266 to 271, 285 to 286 and 291 to 293 form ⁇ -strands.
  • All the other non-terminal amino acids namely 7 to 21, 31 to 34, 45 to 51, 63 to 66, 72, 92 to 97, 104 to 111, 124 to 136, 149 to 153, 160 to 164, 173 to 206, 210 to 213, 217, 218, 223 to 228, 236 to 242, 262 to 265, 272 to 274 and 287 to 290 form loop regions.
  • Amino acids 1 and 294 are terminal amino acids.
  • SEQ ID NO: 3 shows the polynucleotide sequence encoding one subunit of ⁇ -HL E111N/K147N.
  • SEQ ID NO: 4 shows the amino acid sequence of one subunit of ⁇ -HL E111N/K147N. The same amino acids that form ⁇ -helices, ⁇ -strands and loop regions in wild type ⁇ -HL form the corresponding regions in this subunit.
  • SEQ ID NO: 5 shows the codon optimised polynucleotide sequence derived from the sbcB gene from E. coli . It encodes the exonuclease I enzyme (EcoExo I) from E. coli.
  • SEQ ID NO: 6 shows the amino acid sequence of exonuclease I enzyme (EcoExo I) from E. coli .
  • This enzyme performs processive digestion of 5′ monophosphate nucleosides from single stranded DNA (ssDNA) in a 3′-5′ direction.
  • Amino acids 60 to 68, 70 to 78, 80 to 93, 107 to 119, 124 to 128, 137 to 148, 165 to 172, 182 to 211, 213 to 221, 234 to 241, 268 to 286, 313 to 324, 326 to 352, 362 to 370, 373 to 391, 401 to 454 and 457 to 475 form ⁇ -helices.
  • Amino acids 10 to 18, 28 to 26, 47 to 50, 97 to 101, 133 to 136, 229 to 232, 243 to 251, 258 to 263, 298 to 302 and 308 to 311 form ⁇ -strands. All the other non-terminal amino acids, 19 to 27, 37 to 46, 51 to 59, 69, 79, 94 to 96102 to 106, 120 to 123, 129 to 132, 149 to 164, 173 to 181, 212, 222 to 228 233, 242, 252 to 257, 264 to 267, 287 to 297, 303 to 307, 312, 325, 353 to 361, 371, 372, 392 to 400, 455 and 456, form loops.
  • Amino acids 1 to 9 are terminal amino acids.
  • the overall fold of the enzyme is such that three regions combine to form a molecule with the appearance of the letter C, although residues 355-358, disordered in the crystal structure, effectively convert this C into an O-like shape.
  • the amino terminus (1-206) forms the exonuclease domain and has homology to the DnaQ superfamily, the following residues (202-354) form an SH3-like domain and the carboxyl domain (359-475) extends the exonuclease domain to form the C-like shape of the molecule.
  • Four acidic residues of EcoExo I are conserved with the active site residues of the DnaQ superfamily (corresponding to D15, E17, D108 and D186).
  • SEQ ID NO: 7 shows the codon optimised polynucleotide sequence derived from the xthA gene from E. coli . It encodes the exonuclease III enzyme from E. coli.
  • SEQ ID NO: 8 shows the amino acid sequence of the exonuclease III enzyme from E. coli .
  • This enzyme performs distributive digestion of 5′ monophosphate nucleosides from one strand of double stranded DNA (dsDNA) in a 3′-5′ direction. Enzyme initiation on a strand requires a 5′ overhang of approximately 4 nucleotides.
  • Amino acids 11 to 13, 15 to 25, 39 to 41, 44 to 49, 85 to 89, 121 to 139, 158 to 160, 165 to 174, 181 to 194, 198 to 202, 219 to 222, 235 to 240 and 248 to 252 form ⁇ -helices.
  • Amino acids 2 to 7, 29 to 33, 53 to 57, 65 to 70, 75 to 78, 91 to 98, 101 to 109, 146 to 151, 195 to 197, 229 to 234 and 241 to 246 form ⁇ -strands. All the other non-terminal amino acids, 8 to 10, 26 to 28, 34 to 38, 42, 43, 50 to 52, 58 to 64, 71 to 74, 79 to 84, 90, 99, 100, 110 to 120, 140 to 145, 152 to 157, 161 to 164, 175 to 180, 203 to 218, 223 to 228, 247 and 253 to 261, form loops. Amino acids 1, 267 and 268 are terminal amino acids.
  • the enzyme active site is formed by loop regions connecting ⁇ 1 - ⁇ 1 , ⁇ 3 - ⁇ 4 , ⁇ 5 - ⁇ 6 , ⁇ III - ⁇ I , ⁇ IV - ⁇ II and ⁇ V - ⁇ VI (consisting of amino acids 8-10, 58-64, 90, 110-120, 152-164, 175-180, 223-228 and 253-261 respectively).
  • a single divalent metal ion is bound at residue E34 and aids nucleophilic attack on the phosphodiester bond by the D229 and H259 histidine-aspartate catalytic pair.
  • SEQ ID NO: 9 shows the codon optimised polynucleotide sequence derived from the recJ gene from T. thermophilus . It encodes the RecJ enzyme from T. thermophilus (TthRecJ-cd).
  • SEQ ID NO: 10 shows the amino acid sequence of the RecJ enzyme from T. thermophilus (TthRecJ-cd). This enzyme performs processive digestion of 5′ monophosphate nucleosides from ssDNA in a 5′-3′ direction. Enzyme initiation on a strand requires at least 4 nucleotides. Amino acids 19 to 33, 44 to 61, 80 to 89, 103 to 111, 136 to 140, 148 to 163, 169 to 183, 189 to 202, 207 to 217, 223 to 240, 242 to 252, 254 to 287, 302 to 318, 338 to 350 and 365 to 382 form ⁇ -helices.
  • Amino acids 36 to 40, 64 to 68, 93 to 96, 116 to 120, 133 to 135, 294 to 297, 321 to 325, 328 to 332, 352 to 355 and 359 to 363 form ⁇ -strands. All the other non-terminal amino acids, 34, 35, 41 to 43, 62, 63, 69 to 79, 90 to 92, 97 to 102, 112 to 115, 121 to 132, 141 to 147, 164 to 168, 184 to 188203 to 206, 218 to 222, 241, 253, 288 to 293, 298 to 301, 319, 320, 326, 327, 333 to 337, 351 to 358 and 364, form loops.
  • Amino acids 1 to 18 and 383 to 425 are terminal amino acids.
  • the crystal structure has only been resolved for the core domain of RecJ from Thermus thermophilus (residues 40-463). To ensure initiation of translation and in vivo expression of the RecJ core domain a methionine residue was added at its amino terminus, this is absent from the crystal structure information.
  • the resolved structure shows two domains, an amino (2-253) and a carboxyl (288-463) region, connected by a long ⁇ -helix (254-287).
  • the catalytic residues (D46, D98, H122, and D183) co-ordinate a single divalent metal ion for nucleophilic attack on the phosphodiester bond. D46 and H120 proposed to be the catalytic pair; however, mutation of any of these conserved residues in the E. coli RecJ was shown to abolish activity.
  • SEQ ID NO: 11 shows the codon optimised polynucleotide sequence derived from the bacteriphage lambda exo (redX) gene. It encodes the bacteriophage lambda exonuclease.
  • SEQ ID NO: 12 shows the amino acid sequence of the bacteriophage lambda exonuclease.
  • the sequence is one of three identical subunits that assemble into a trimer.
  • the enzyme performs highly processive digestion of nucleotides from one strand of dsDNA, in a 3′-5′ direction. Enzyme initiation on a strand preferentially requires a 5′ overhang of approximately 4 nucleotides with a 5′ phosphate.
  • Amino acids 3 to 10, 14 to 16, 22 to 26, 34 to 40, 52 to 67, 75 to 95, 135 to 149, 152 to 165 and 193 to 216 form ⁇ -helices.
  • Amino acids 100 to 101, 106 to 107, 114 to 116, 120 to 122, 127 to 131, 169 to 175 and 184 to 190 form ⁇ -strands. All the other non-terminal amino acids, 11 to 13, 17 to 21, 27 to 33, 41 to 51, 68 to 74, 96 to 99, 102 to 105, 108 to 113, 117 to 119, 123 to 126, 132 to 134, 150 to 151, 166 to 168, 176 to 183, 191 to 192, 217 to 222, form loops.
  • Amino acids 1, 2 and 226 are terminal amino acids.
  • Lambda exonuclease is a homo-trimer that forms a toroid with a tapered channel through the middle, apparently large enough for dsDNA to enter at one end and only ssDNA to exit at the other.
  • the catalytic residues are undetermined but a single divalent metal ion appears bound at each subunit by residues D119, E129 and L130.
  • SEQ ID NOs: 13 to 66 show the oligonucleotides used in the Examples. When used, all oligonucleotides had a 3′ biotin-TEG tag and linker ( FIG. 7 ).
  • nucleotide includes “nucleotides”
  • a pore includes two or more such pores
  • an enzyme includes two or more such enzymes, and the like.
  • the invention provides a method for sequencing a heteropolymeric target nucleic acid sequence.
  • the method comprises (a) passing the target sequence through a transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time with at least one site in the pore that is capable of discriminating between different nucleotides and (b) measuring the current passing through the pore during each interaction and thereby determining the sequence of the target sequence.
  • the nucleotides are identified one at a time sequentially as they interact with at least one site in the pore that is capable of discriminating between different nucleotides.
  • the method involves stochastic sensing of a proportion of the nucleotides in a target nucleic acid sequence as the nucleotides pass through the barrel or channel of a transmembrane pore in a successive manner in order to sequence the target sequence.
  • Pores comprising two or more distinct sites that are capable of discriminating between different nucleotides are particularly suited to this method.
  • presence of two or more distinct sites that are capable of discriminating between different nucleotides ensures that the nucleotides in the target sequence are read at least twice. This improves the accuracy of the sequencing.
  • the method may be carried out using any suitable membrane/transmembrane pore system in which a transmembrane pore is inserted into a membrane.
  • the method is typically carried out using (i) an artificial membrane comprising a transmembrane pore, (ii) an isolated, naturally occurring membrane comprising a transmembrane pore, or (iii) a cell expressing a transmembrane pore.
  • the method is preferably carried out using an artificial membrane.
  • the membrane may comprise other transmembrane and/or intramembrane proteins as well as other molecules in addition to the transmembrane pore used for sequencing.
  • the membrane forms a barrier to the flow of ions, nucleotides and nucleic acids.
  • the membrane is preferably a lipid bilayer.
  • Lipid bilayers suitable for use in accordance with the invention can be made using methods known in the art. For example, lipid bilayer membranes can be formed using the method of Montal and Mueller (1972). Lipid bilayers can also be formed using the method described in International Application No. PCT/GB08/000563 and PCT/GB07/002856.
  • the method of the invention may be carried out using lipid bilayers formed from any membrane lipid including, but not limited to, phospholipids, glycolipids, cholesterol and mixtures thereof. Any of the lipids described in International Application No. PCT/GB08/000563 may be used.
  • the method is typically carried out in vitro.
  • the whole or only part of the target sequence may be sequenced using the method of the invention.
  • the target sequence can be any length.
  • the target sequence can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides in length.
  • the target sequence may form part of a larger nucleic acid sequence.
  • the target sequence may correspond to a section, such as half, of a larger nucleic acid sequence.
  • the other part(s) of the sequence outside the target sequence do not have to be sequenced in accordance with the invention.
  • the target sequence used in the method of the invention is an intact sequence.
  • the target is not cleaved or digested to form shorter nucleic acid sequences or individual nucleotides before it is sequenced in accordance with the invention.
  • a nucleic acid is a macromolecule comprising two or more nucleotides.
  • the nucleic acid bound by the protein may comprise any combination of any nucleotides.
  • the nucleotides can be naturally occurring or artificial.
  • a nucleotide typically contains a nucleobase, a sugar and at least one phosphate group.
  • the nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine, guanine, thymine, uracil and cytosine.
  • the nucleobase may also be 5-methylcytosine or hydroxymethyl-cytosine.
  • the sugar is typically a pentose sugar.
  • Nucleotide sugars include, but are not limited to, ribose and deoxyribose.
  • the nucleotide is typically a ribonucleotide or deoxyribonucleotide.
  • the nucleotide typically contains a monophosphate, diphosphate or triphosphate. Phosphates may be attached on the 5′ or 3′ side of a nucleotide.
  • Nucleotides include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyadenosine diphosphate (dADP), deoxyadenos
  • the nucleotides are typically bonded together in the target sequence via phosphodiester bonds.
  • the target nucleic acid can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
  • the target nucleic acid may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA) or other synthetic polymers with nucleotide side chains.
  • the target sequence can be single stranded or double stranded. If the target sequence is double stranded, the method preferably involves passing only one strand of the target sequence through the pore.
  • the barrels or channels of many pores, especially transmembrane protein pores, are typically not large enough to allow a double stranded nucleic acid to pass through. Method for separating one strand from a double stranded target sequence and passing it through the pore are discussed in more detail below.
  • a heteropolymeric target nucleic sequence is one which comprises two or more, such as 3, 4, 5, 6 or more, different nucleotides.
  • the target sequence preferably comprises three or more different nucleotides.
  • the target sequence more preferably comprises four different nucleotides.
  • the four different nucleotides are preferably the four different nucleotides that make up DNA or RNA.
  • the four different nucleotides preferably independently comprise the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil and (d) cytosine.
  • the target sequence even more preferably comprises five different nucleotides.
  • the five different nucleotides preferably independently comprise the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil, (d) cytosine and (e) 5-methylcytosine.
  • the method is typically carried out using a target sequence whose sequence is unknown.
  • the method may be carried out using a target sequence whose sequence is known in whole or in part or can be predicted in whole or in part.
  • the target sequence can be naturally occurring or artificial.
  • the method may be used to verify the sequence of a manufactured oligonucleotide.
  • the method is typically carried out using a target sequence obtained from or extracted from any organism or microorganism.
  • the organism or microorganism is typically prokaryotic, eukaryotic or an archon and typically belongs to one the five kingdoms: plantae, animalia, fungi, monera and protista.
  • the method may be carried out on a target sequence obtained from or extracted from any virus.
  • the target sequence is human in origin, but alternatively it may be from another mammal animal such as from commercially farmed animals such as horses, cattle, sheep or pigs or may alternatively be pets such as cats or dogs.
  • the target sequence is typically processed prior to undergoing the method, for example by amplification, centrifugation or by passage through a membrane that filters out unwanted molecules or cells, such as red blood cells.
  • the target sequence may be used immediately upon being taken.
  • the target sequence may also be typically stored prior to undergoing the method, preferably below ⁇ 70° C.
  • the method of the invention involves passing the target sequence through the pore in a controlled and stepwise manner.
  • the target sequence is typically pushed or pulled through the pore. Any method for passing the target sequence through the pore may be used.
  • the target sequence may be passed through the pore cis to trans or trans to cis.
  • the target sequence may be passed through the pore either with or against an applied potential.
  • the target sequence is preferably passed through the pore using a nucleic acid handling enzyme.
  • a nucleic acid handling enzyme The majority of nucleic acid handling enzymes are suitable for use in this application provided they hydrolyse, polymerise or process nucleic acids.
  • the enzyme may handle single stranded or double stranded nucleic acid. If a transmembrane protein pore is used, the enzyme preferably passes a single strand of the target sequence through the pore. If the target sequence is double stranded, this may be achieved by using an enzyme that separates the two strands of double stranded nucleic acid. For instance, exonucleases that act progressively or processively on double stranded nucleic acids can be used on the cis side of the pore to feed the remaining single strand through under an applied potential or from the trans side under a reverse potential. Likewise, a helicase that unwinds double stranded nucleic acids can also be used in a similar manner.
  • the method preferably involves contacting the target sequence with a nucleic acid handling enzyme so that the target sequence is passed through a pore at a rate that allows a proportion of the nucleotides in the target sequence to interact one at a time with at least one site in the pore that is capable of discriminating between different nucleotides.
  • a nucleic acid handling enzyme capable of discriminating between different nucleotides.
  • a suitable rate of activity of a nucleic acid handling enzyme in the method of the invention involves handling of from 0.5 to 1000 nucleotides per second, from 0.6 to 500 nucleotides per second, 0.7 to 200 nucleotides per second, from 0.8 to 100 nucleotides per second, from 0.9 to 50 nucleotides per second or 1 to 20 or 10 nucleotides per second.
  • the rate is preferably 1, 10, 100, 500 or 1000 nucleotides per second.
  • the enzyme also preferably retains at least partial activity at temperatures from 0° C. to 100° C., such as from 10° C. to 60° C. or at room temperature. This allows the sequencing of the target sequence at a variety of temperatures, including room temperature.
  • a nucleic acid handling enzyme is a polypeptide that is capable of interacting with and modifying at least one property of a nucleic acid.
  • the enzyme preferably modifies the nucleic acid by orienting it or moving it to a specific position.
  • the nucleic acid handling enzyme is preferably derived from a nucleolytic enzyme or nuclease.
  • the nucleic acid handling enzyme used in the construct of the enzyme is more preferably derived from a member of any of the Enzyme Classification (EC) groups 3.1.11, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.21, 3.1.22, 3.1.25, 3.1.26, 3.1.27, 3.1.30 and 3.1.31.
  • the nucleic acid handling enzyme is more preferably derived from any one of the following enzymes:
  • the enzyme is most preferably derived from an exonuclease, such as an exodeoxyribonuclease, which cleaves nucleic acids to form individual nucleotides.
  • exodeoxyribonucleases are that they are active on both single stranded and double stranded nucleic acids and hydrolyse bases either in the 5′-3′ or 3′-5′ direction.
  • An individual nucleotide is a single nucleotide.
  • the nucleotide may be any of those discussed above.
  • An individual nucleotide is one which is not bound to another nucleotide or nucleic acid by any bond, such as a phosphodiester bond.
  • a phosphodiester bond involves one of the phosphate groups of a nucleotide being bound to the sugar group of another nucleotide.
  • An individual nucleotide is typically one which is not bound in any manner to another nucleic acid sequence of at least 5, at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000 or at least 5000 nucleotides.
  • Preferred enzymes for use in the invention include exonuclease I from E. coli (SEQ ID NO: 6), exonuclease III enzyme from E. coli (SEQ ID NO: 8), RecJ from T. thermophilus (SEQ ID NO: 10) and bacteriophage lambda exonuclease (SEQ ID NO: 12) and variants thereof.
  • exonuclease I from E. coli
  • SEQ ID NO: 8 exonuclease III enzyme from E. coli
  • RecJ from T. thermophilus
  • SEQ ID NO: 12 bacteriophage lambda exonuclease
  • Three identical subunits of SEQ ID NO: 12 interact to form a trimer exonuclease.
  • the enzyme is most preferably based on exonuclease I from E. coli (SEQ ID NO: 6).
  • the nucleic acid handling enzyme preferably comprises any of the sequences shown in SEQ ID NOs: 6, 8, 10 and 12 or a variant thereof.
  • a variant of SEQ ID NO: 6, 8, 10 or 12 is an enzyme that has an amino acid sequence which varies from that of SEQ ID NO: 6, 8, 10 or 12 and which retains nucleic acid handling ability.
  • the ability of a variant to handle nucleic acids can be assayed using any method known in the art. For instance, the ability of a variant to handle nucleic acids can be assayed by contacting the enzyme with a nucleic acid and assaying its ability to orient it or move it to a specific position.
  • the variant may include modifications that facilitate handling of the nucleic acid and/or facilitate its activity at high salt concentrations and/or room temperature.
  • the enzyme may be a naturally occurring variant which is expressed by an organism, for instance by an E. coli bacterium. Variants also include non-naturally occurring variants produced by recombinant technology. Over the entire length of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity. More preferably, the variant polypeptide may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 over the entire sequence. There may be at least 80%, for example at least 85%, 90% or 95%, amino acid identity over a stretch of 200 or more, for example 230, 250, 270 or 280 or more, contiguous amino acids (“hard homology”).
  • Standard methods in the art may be used to determine homology.
  • the UWGCG Package provides the BESTFIT program which can be used to calculate homology, for example used on its default settings (Devereux et al (1984) Nucleic Acids Research 12, p387-395).
  • the PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent residues or corresponding sequences (typically on their default settings)), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S. F et al (1990) J Mol Biol 215:403-10.
  • HSPs high scoring sequence pair
  • T some positive-valued threshold score
  • Altschul et al, supra these initial neighbourhood word hits act as seeds for initiating searches to find HSP's containing them.
  • the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
  • Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
  • the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787.
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two amino acid sequences would occur by chance.
  • P(N) the smallest sum probability
  • a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 in addition to those discussed above, for example up to 1, 2, 3, 4, 5, 10, 20 or 30 substitutions.
  • Conservative substitutions may be made, for example, according to Table 1 below.
  • One or more amino acid residues of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.
  • Variants may be fragments of SEQ ID NO: 6, 8, 10 or 12. Such fragments retain nucleic acid handling activity. Fragments may be at least 50, 100, 200 or 250 amino acids in length. A fragment preferably comprises the nucleic acid handling domain of SEQ ID NO: 6, 8, 10 or 12.
  • One or more amino acids may be alternatively or additionally added to the polypeptides described above.
  • An extension may be provided at the amino terminus or carboxy terminus of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 or a variant or fragment thereof.
  • the extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids.
  • a carrier protein may be fused to a subunit or variant.
  • a variant of SEQ ID NO: 6, 8, 10 or 12 is a protein that has an amino acid sequence which varies from that of SEQ ID NO: 6, 8, 10 or 12 and which retains its ability to handle nucleic acids.
  • a variant typically contains the regions of SEQ ID NO: 6, 8, 10 or 12 that are responsible for handling nucleic acids.
  • the catalytic domains of SEQ ID NOs: 6, 8, 10 or 12 are discussed above in the description of the sequence listing.
  • a variant of SEQ ID NO: 6, 8, 10 or 12 preferably comprises the relevant catalytic domain.
  • a variant SEQ ID NO: 6, 8, 10 or 12 typically includes one or more modifications, such as substitutions, additions or deletions, outside the relevant catalytic domain.
  • the variant may be modified for example by the addition of histidine or aspartic acid residues to assist its identification or purification or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence.
  • the polymerase is preferably a member of any of the Enzyme Classification (EC) groups 2.7.7.6, 2.7.7.7, 2.7.7.19, 2.7.7.48 and 2.7.7.49.
  • the polymerase is preferably a DNA-dependent DNA polymerase, an RNA-dependent DNA polymerase, a DNA-dependent RNA polymerase or an RNA-dependent RNA polymerase.
  • the helicase is preferably based on a member of any of the Enzyme Classification (EC) groups 3.6.1.- and 2.7.7.-.
  • the helicase is preferably an ATP-dependent DNA helicase (EC group 3.6.1.8), an ATP-dependent RNA helicase (EC group 3.6.1.8) or an ATP-independent RNA helicase.
  • the nucleic acid handling enzyme may be labelled with a revealing label.
  • the revealing label may be any suitable label which allows the enzyme to be detected. Suitable labels include, but are not limited to, fluorescent molecules, radioisotopes, e.g. 125 I, 35 S, 14 C, enzymes, antibodies, antigens, polynucleotides and ligands such as biotin.
  • the nucleic acid handling enzyme may be isolated from an enzyme producing organism, such as E. coli, T. thermophilus or bacteriophage, or made synthetically or by recombinant means.
  • the nucleic acid handling enzyme may be synthesized by in vitro translation and transcription.
  • the amino acid sequence of the nucleic acid handling enzyme may be modified to include non-naturally occurring amino acids or to increase the stability of the protein.
  • the nucleic acid handling enzyme is produced by synthetic means, such amino acids may be introduced during production.
  • the nucleic acid handling enzyme may also be altered following either synthetic or recombinant production.
  • the nucleic acid handling enzyme may also be produced using D-amino acids.
  • the nucleic acid handling enzyme may comprise a mixture of L-amino acids and D-amino acids. This is conventional in the art for producing such proteins or peptides.
  • the nucleic acid handling enzyme may also contain other non-specific chemical modifications as long as they do not interfere with its ability to handle nucleic acids or attach to the pore.
  • a number of non-specific side chain modifications are known in the art and may be made to the side chains of the pores. Such modifications include, for example, reductive alkylation of amino acids by reaction with an aldehyde followed by reduction with NaBH 4 , amidination with methylacetimidate or acylation with acetic anhydride.
  • the nucleic acid handling enzyme can be produced using standard methods known in the art. Polynucleotide sequences encoding a nucleic acid handling enzyme may be isolated and replicated using standard methods in the art. Such sequences are discussed in more detail below. Polynucleotide sequences encoding a nucleic acid handling enzyme may be expressed in a bacterial host cell using standard techniques in the art. The nucleic acid handling enzyme may be produced in a cell by in situ expression of the polypeptide from a recombinant expression vector. The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.
  • Polynucleotide sequences may be isolated and replicated using standard methods in the art. Chromosomal DNA may be extracted from an enzyme producing organism, such as E. coli, T. thermophilus or bacteriophage. The gene encoding the enzyme may be amplified using PCR involving specific primers. The amplified sequences may then be incorporated into a recombinant replicable vector such as a cloning vector. The vector may be used to replicate the polynucleotide in a compatible host cell.
  • polynucleotide sequences encoding the enzyme may be made by introducing a polynucleotide encoding the enzyme into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.
  • the vector may be recovered from the host cell.
  • Suitable host cells for cloning of polynucleotides are known in the art and described in more detail below.
  • the polynucleotide sequence may be cloned into suitable expression vector.
  • the polynucleotide sequence encoding a construct is typically operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell.
  • Such expression vectors can be used to express a construct.
  • operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a control sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. Multiple copies of the same or different polynucleotide may be introduced into the vector.
  • the expression vector may then be introduced into a suitable host cell.
  • a construct can be produced by inserting a polynucleotide sequence encoding a construct into an expression vector, introducing the vector into a compatible bacterial host cell, and growing the host cell under conditions which bring about expression of the polynucleotide sequence.
  • the recombinantly-expressed construct may self-assemble into a pore in the host cell membrane.
  • the recombinant construct produced in this manner may be isolated from the host cell and inserted into another membrane.
  • the construct and different subunits may be expressed separately in different host cells as described above, removed from the host cells and assembled into a pore in a separate membrane, such as a rabbit cell membrane.
  • the vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide sequence and optionally a regulator of the promoter.
  • the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene. Promoters and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. A T7, trc, lac, ara or ⁇ L promoter is typically used.
  • the host cell typically expresses the construct at a high level. Host cells transformed with a polynucleotide sequence encoding a construct will be chosen to be compatible with the expression vector used to transform the cell.
  • the host cell is typically bacterial and preferably E.
  • Any cell with a ⁇ DE3 lysogen for example C41 (DE3), BL21 (DE3), JM109 (DE3), B834 (DE3), TUNER, Origami and Origami B, can express a vector comprising the T7 promoter.
  • a nucleic acid handling enzyme may be produced in large scale following purification by any protein liquid chromatography system from pore producing organisms or after recombinant expression as described below.
  • Typical protein liquid chromatography systems include FPLC, AKTA systems, the Bio-Cad system, the Bio-Rad BioLogic system and the Gilson HPLC system.
  • the target sequence is passed through the transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time (i.e. sequentially) with at least one site in the pore that is capable of discriminating between different nucleotides.
  • the sequence of the target sequence may be determined by identifying at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% of the nucleotides in the target sequence.
  • all of the nucleotides in the target sequence interact with the at least one site and are identified.
  • the target sequence may be contacted with the pore on either side of the membrane.
  • the target sequence may be introduced to the pore on either side of the membrane. If a nucleic acid handling enzyme is used as discussed above, the target sequence is typically contacted with the side of the membrane on which the enzyme is present. This allows the enzyme to handle the nucleic acid during the method.
  • a proportion of the nucleotides in the target nucleic acid sequence interacts with at least one site in the pore that is capable of discriminating between different nucleotides as the sequence passes across the membrane through the barrel or channel of the pore. As discussed in more detail below, a proportion of the nucleotides preferably interacts with two or more distinct sites that are capable of discriminating between different nucleotides.
  • the nucleotides interact with the site(s) capable of discriminating different nucleotides one at a time in a sequential manner. This means that at any one time a site that is capable of discriminating between different nucleotides interacts with only one nucleotide in the target sequence. If the pore comprises two or more distinct sites that are capable of discriminating between different nucleotides, at any one time each of the distinct sites will interact with a different nucleotide in the target sequence. For instance, if the pore comprises two distinct sites that are capable of discriminating between different nucleotides, at any one time the distinct sites will interact with two different nucleotides in the target sequence.
  • the target sequence is passed through the pore one nucleotide at a time and each nucleotide is identified sequentially. Hence, at one time point, each of the distinct sites that are capable of discriminating between different nucleotides interacts with a different nucleotide in the target sequence. At the next time point, the target sequence is passed one nucleotide further through the pore and each of the distinct sites that are capable of discriminating between different nucleotides interacts with the a nucleotide that is adjacent to the nucleotide with which it interacted at the previous time point. If there are two or more distinct sites in the pore, a selected nucleotide in the target sequence will interact with each dintinct site in a sequential manner as it passed through the pore.
  • the current passing through the pore is measured during each interaction and this allows the identity of the nucleotide interacting with the site(s) to be determined. Identification of a proportion of the nucleotides in the target sequence in a successive manner allows the sequence of the target sequence to be determined.
  • the nucleotides may interact with the pore in any manner and at any site.
  • the nucleotides preferably reversibly bind to the sites(s) in the pore capable of discriminating between different nucleotides.
  • the nucleotides most preferably reversibly bind to the site(s) in the pore in the pore as they pass through the pore across the membrane.
  • the nucleotides can reversibly bind to the site(s) via or in conjunction with an adaptor that facilitates an interaction between the pore and the nucleotide.
  • the pore does not contain a molecular adaptor that facilitates an interaction between the pore and nucleotides.
  • the nucleotide affects the current flowing through the pore in a manner specific for that nucleotide. For example, a particular nucleotide will reduce the current flowing through the pore to a particular extent. In other words, the current flowing through the pore is distinctive for the interaction between a particular nucleotide and a site capable of discriminating between different nucleotides. Hence, when different nucleotides move through the pore and interact with the pore in a successive manner, the current flowing through the pore changes for each interaction.
  • the overall current passing through the pore at any one time will be influenced by the interaction between each site and the nucleotide located each site.
  • the presence of multiple sites that are capable of discriminating between different nucleotides increases the number of current levels seen and therefore provides more sequence information. For instance, a pore having a single site may produce four current levels for four different nucleotides (named A, B, C and D for illustrative purposes).
  • a pore having two sites may produce sixteen levels: four current levels when A is at site 1 and A, B, C or D is at site 2; four different current levels when B is at site 1 and A, B, C or D is at site 2; four different current levels when C is at site 1 and A, B, C or D is at site 2; and four different current levels when D is at site 1 and A, B, C or D is at site 2.
  • the dwell time of a selected nucleotide at a site that is capable of discriminating between different nucleotides will be determined by the way in which the target sequence is passed through the pore. For instance, if a nucleic acid handling enzyme is used, the dwell time of a selected nucleotide at a site that is capable of discriminating between different nucleotides will be determined by the rate at which the enzyme pushes or pulls the target sequence through the pore.
  • Control experiments may be carried out to determine the effect a particular nucleic acid sequence has on the current flowing through the pore. Results from carrying out the method of the invention on a test sample can then be compared with those derived from such a control experiment in order to identify the target sequence.
  • a site in the pore is capable of discriminating between different nucleotides if it can discriminate between at least two, such as 3 or 4, different nucleotides.
  • the nucleotides may be any of those discussed above.
  • Each site in the pore is preferably capable of discriminating between four different nucleotides.
  • Each site is most preferably capable of discriminating between the four nucleotides of DNA or RNA.
  • each site is preferably capable of discriminating between four different nucleotides independently comprising the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil and (d) cytosine.
  • Each site is more preferably capable of discriminating between five different nucleotides independently comprising the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil, (d) cytosine and (e) 5-methylcytosine.
  • a site is typically capable of discriminating between different nucleotides because it interacts with, preferably reversibly binds to, a nucleotide and the nucleotide affects the current flowing through the pore in a manner specific for that nucleotide.
  • the way in which a site interacts with a selected nucleotide will depend on a variety of factors including the size of the site, the conformation of the site, the charge of the site, the ability of the site to form hydrogen bonds and the ability of the site to form other intermolecular interactions, such as dipole interactions.
  • a site may have a net charge. The net charge may be negative, but is typically positive. A site may have no net charge. As discussed below, the ability of a site to discriminate between different nucleotides can be altered by altering the size of the site, the conformation of the site and/or the charge of the site.
  • Each site is preferably present in the barrel or channel of the pore. This allows the interaction between a site and a nucleotide to affect the current flowing through the pore. Site(s) in transmembrane protein pores that are capable of discriminating between different nucleotides are discussed in more detail below.
  • the pore comprises at least one, such as 2, 3 or 4, sites that are capable of discriminating between different nucleotides.
  • the pore preferably comprises two or more, such as 2, 3 or 4 or more, distinct sites that are capable of discriminating between different nucleotides.
  • a proportion of the nucleotides in the target sequence preferably interacts one at a time with two or more distinct sites in the pore that are capable of discriminating between different nucleotides.
  • the pore most preferably comprises two distinct sites that are capable of discriminating between different nucleotides.
  • a proportion of the nucleotides in the target sequence most preferably interacts with two distinct sites in the pore that are capable of discriminating between different nucleotides.
  • Each nucleotide in the target sequence preferably interacts with each specific site, one site at a time.
  • Sites are distinct if they are separated from one another by sufficient distance to allow the interaction of a selected nucleotide with each site to be distinguished as described herein. Distinct sites are typically separated from one another by at least 10, at least 20, at least 30, at least 40 or at least 50 Angstroms. Distinct sites are preferably separated by from each other by about 20 to about 30 Angstroms.
  • the two or more distinct sites each discriminate between different nucleotides in a different manner. This makes it possible to determine when a selected nucleotide is interacting with each of the two or more sites.
  • the two or more sites may differ in the way in which they discriminate between different nucleotides in any manner. Some sites may discriminate between different nucleotides on the basis of different steric interactions with each of the nucleotides. Such interactions are typically dependent on the size and/or conformation of the sites. Other sites with a net charge may discriminate between different nucleotides on the basis of different ionic interactions with each of the nucleotides.
  • each of the two or more sites differs in the way in which its interactions with the different nucleotides affect the current passing through the pore.
  • the interaction of a selected nucleotide with each of the two or more distinct sites results in a different current passing through the pore.
  • the interaction of an adenine-containing nucleotide with each of the two or more distinct sites results in a different current passing through the pore.
  • the interaction of different nucleotides with each of the two or more distinct sites results in differing currents passing through the pore and the separation between the mean value of the differing currents differs between each of the two or more distinct sites. This is illustrated in FIG. 4 .
  • the presence in the pore of two or more distinct sites that are capable of discriminating between different nucleotides in different ways offers a couple advantages.
  • a continuous stretch of five identical nucleotides will not result in any change in the current level as they each of the five nucleotides sequentially interacts with the site. It would be necessary to to try to predict, based on the rate at which the target sequence is passed through the pore, how many nucleotides interact with the site. However, if the pore has two sites that are capable of discriminating between different nucleotides, downstream nucleotides sequentially interacting with the second site will alter the current level passing through the pore as each of the five identical nucleotides in the continuous stretch sequentially interacts with the first site. This permits the number of identical nucleotides sequentially interacting with the first site to be counted.
  • the presence in the pore of two or more distinct sites that are capable of discriminating between different nucleotides allows the sequence of the target nucleic acid to be determined more efficiently. Having two distinct sites that discriminate between different nucleotides in different ways ensures that, when the target sequence is sequenced, each nucleotide is not merely observed once, but is in fact interrogated twice. This gives greater certainty that each position in the target sequence has been observed and that the aggregate call for both nucleotides at each position is of a greater quality score than would be possible with a single observation.
  • the key advantage of the preferred method of the invention is that it allows each nucleotide position of a target sequence to be effectively interrogated twice without having to repeat the method. This ensures that the quality of the sequence generated is consequently very much higher, with a reduced potential for misidentified nucleotide calls, or completely missed nucleotides.
  • the method preferably involves the use of a pore which has been modified to alter the ability of at least one site, such as 2 or 3 sites, to discriminate between different nucleotides.
  • the pore may be modified to introduce one or more, such as 2, distinct sites that are capable of discriminating between different nucleotides. This increases the number of distinct sites that are capable of discriminating between different nucleotides in the pore.
  • the pore may be modified to abolish one or more, such as 2, distinct sites that are capable of discriminating between different nucleotides. This decreases the number of distinct sites that are capable of discriminating between different nucleotides in the pore.
  • at least one site, such as 2 or 3 sites, that is capable of discriminating between different nucleotides must remain for the pore to be useful.
  • the pore may be modified to enhance or reduce the ability of one or more distinct sites to discriminate between different nucleotides. For instance, the ability of one site to discriminate different nucleotides may be increased, while the ability of another distinct site to discriminate different nucleotides may be reduced. This allows the pore to be ‘fine tuned’ for sequencing specific target nucleic acid sequences.
  • the pore may be modified in any way to alter the ability of at least one site to discriminate between different nucleotides. One or more, such as 2, 3, 4 or 5 or more, modifications may be made. The one or more modifications preferably alter the current flowing through the pore when a selected nucleotide interacts with the at least one site.
  • the modification(s) may alter the size and/or conformation of the at least one site and thereby alter its steric interaction with different nucleotides.
  • the modification(s) may alter the net charge of the at least one site and thereby alters its ionic interaction with different nucleotides.
  • the net charge of the at least one site may be altered by (1) introducing positive charge or negative charge, (2) removing positive or negative charge without replacing it, (3) substituting neutral charge or negative charge with positive charge and/or (4) substituting neutral charge or positive charge with negative charge.
  • the modification(s) cannot alter the net charge in such a manner that it interferes with translocation of the target sequence through the pore.
  • introducing too much positive charge into the barrel or channel of the pore may reduce the current flowing through the pore and thereby prevent discrimination of different nucleotides.
  • introducing too much negative charge into the barrel or channel of the pore may prevent entry of the target sequence into the pore.
  • a pore contains two or more distinct sites that are capable of discriminating between different nucleotides
  • modification of one distinct site may alter the ability of the other distinct site(s) to discriminate between different nucleotides.
  • the pore is modified at one of the two or more distinct sites and this alters the ability of at least one of the other two or more distinct sites to discriminate between different nucleotides.
  • the pore is modified at one of the two or more distinct sites and this alters the ability of all of the other distinct sites to discriminate between different nucleotides.
  • the pore is modified at one of the two or more distinct sites and this alters the ability of all of the distinct sites to discriminate between different nucleotides. Any of the modifications described above may be used. Most preferably, the pore is modified at one of the two or more distinct sites to increase the difference between the currents passing through the pore when a selected nucleotide interacts with each of the two or more distinct sites.
  • altering the net charge at one site may reduce the current flowing through the pore when the site interacts with nucleotides and thereby make it less easy to discriminate between different nucleotides at the other more distal site(s).
  • modifying one site to increase the current flowing the pore may improve discrimination between different nucleotides at the other more distal site(s). This is discussed in more detail below with reference to transmembrane protein pores.
  • a transmembrane pore is a pore that permits ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane.
  • the pore allows a nucleic acid, such as DNA or RNA, to be passed through the pore.
  • the pore is preferably a transmembrane protein pore.
  • a transmembrane protein pore is a polypeptide or a collection of polypeptides that permits ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane.
  • the pore may be isolated, substantially isolated, purified or substantially purified.
  • a pore is isolated or purified if it is completely free of any other components, such as lipids or other pores.
  • a pore is substantially isolated if it is mixed with carriers or diluents which will not interfere with its intended use.
  • a pore is substantially isolated or substantially purified if it present in a form that comprises less than 10%, less than 5%, less than 2% or less than 1% of other components, such as lipids or other pores.
  • the pore is typically present in a lipid bilayer.
  • the pore may be a monomer or an oligomer.
  • the pore is preferably made up of several repeating subunits, such as 6, 7 or 8 subunits.
  • the pore is more preferably a heptameric pore.
  • the pore typically comprises a barrel or channel through which the ions may flow.
  • the subunits of the pore typically surround a central axis and contribute strands to a transmembrane ⁇ barrel or channel or a transmembrane ⁇ -helix bundle or channel.
  • the pore comprises at least one site that is capable of discriminating between different nucleotides.
  • the site(s) are preferably in the barrel or channel of the pore.
  • Each site typically comprises several, such as 10, 20 or 30, amino acids that facilitate interaction with nucleotides. If the pore is an oligomer, each monomer may contribute one or more, such as 2, 3, or 4, amino acids to each site. These amino acids are preferably located near a constriction of the barrel or channel.
  • Each site typically comprises one or more positively charged amino acids, such as arginine, lysine or histidine. These amino acids typically facilitate the interaction between the site and the nucleotides.
  • Pores for use in accordance with the invention can be ⁇ -barrel pores, ⁇ -helix bundle pores or solid state pores.
  • ⁇ -barrel pores comprise a barrel or channel that is formed from ⁇ -strands.
  • Suitable ⁇ -barrel pores include, but are not limited to, ⁇ -toxins, such as ⁇ -hemolysin, anthrax toxin and leukocidins, and outer membrane proteins/porins of bacteria, such as Mycobacterium smegmatis porin A (MspA), outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A and Neisseria autotransporter lipoprotein (NalP).
  • ⁇ -helix bundle pores comprise a barrel or channel that is formed from ⁇ -helices.
  • Suitable ⁇ -helix bundle pores include, but are not limited to, inner membrane proteins and ⁇ outer membrane proteins, such as Wza.
  • the pore may be a solid state pore.
  • Suitable solid state pores include, but are not limited to, silicon nitride pores, silicon dioxide pores and graphene pores. Other suitable solid state pores and methods of producing them are discussed in U.S. Pat. No. 6,464,842, WO 03/003446, WO 2005/061373, U.S. Pat. No. 7,258,838, U.S. Pat. No. 7,466,069, U.S. Pat. No. 7,468,271 and U.S. Pat. No. 7,253,434.
  • the pore is preferably derived from ⁇ -hemolysin ( ⁇ -HL).
  • the wild type ⁇ -HL pore is formed of seven identical monomers or subunits (i.e. it is heptameric).
  • the sequence of one wild type monomer or subunit of ⁇ -hemolysin is shown in SEQ ID NO: 2.
  • the pore preferably comprises seven subunits comprising the sequence shown in SEQ ID NO: 2 or a variant thereof.
  • the pore may be a homoheptamer comprising seven identical subunits of SEQ ID NO: 2 or a variant thereof.
  • the pore may be a heteroheptamer comprising two or more, such as 2, 3, 4, 5, 6 or 7, different subunits. Each subunit in the heteroheptamer may comprise SEQ ID NO: 2 or a variant thereof.
  • Residues 111, 113 and 147 of SEQ ID NO: 2 form part of a constriction of the barrel or channel of ⁇ -HL.
  • a variant of SEQ ID NO: 2 is a subunit that has an amino acid sequence which varies from that of SEQ ID NO: 2 and which retains its pore forming ability.
  • the ability of a variant to form a pore can be assayed using any method known in the art.
  • the variant may be inserted into a membrane along with other appropriate subunits and its ability to oligomerise to form a pore may be determined.
  • Methods are known in the art for inserting subunits into membranes, such as lipid bilayers.
  • subunits may be suspended in a purified form in a solution containing a lipid bilayer such that it diffuses to the lipid bilayer and is inserted by binding to the lipid bilayer and assembling into a functional state.
  • subunits may be directly inserted into the membrane using the “pick and place” method described in M. A. Holden, H. Bayley. J. Am. Chem. Soc. 2005, 127, 6502-6503 and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).
  • pores formed from SEQ ID NO: 2 or a variant thereof have three sites that are capable of discriminating different nucleotides (named R 1 , R 2 and R 3 ).
  • R 1 is near the central constriction at position 147 of SEQ ID NO: 2.
  • R 1 has a net charge.
  • R 2 is about 20 to about 30 angstroms further down the ⁇ -barrel from R 1 .
  • R 2 is near position 139 of SEQ ID NO: 2.
  • R 3 is about 20 to about 30 angstroms further down the ⁇ -barrel from R 2.
  • R 3 is about 40 to about 60 angstroms down the ⁇ -barrel from R 1 .
  • R 2 has no net charge.
  • R 3 is near the trans exit of the barrel or channel at position(s) 127, 128, 129 and 131 of SEQ ID NO: 2.
  • R 3 has a net charge.
  • Variants of SEQ ID NO: 2 may comprise modifications that affect these sites as described above and below.
  • the variant may include one or more modifications that alter the ability of at least one of R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the variant may be modified to alter the ability of (1) R 1 , (2) R 2 , (3) R 3 , (4) R 1 and R 2 , (5) R 2 and R 3 (6) R 1 and R 3 , or (7) R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the variant may be modified in any way.
  • the modification(s) may enhance or reduce the ability of at least one of R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the modification(s) can abolish the ability of at least one of R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the modification(s) preferably increase the difference between the currents passing through the pore when a selected nucleotide interacts with at least one of of R 1 , R 2 and R 3 compared with the others.
  • R 1 , R 2 and R 3 It will be necessary to balance the effects of particular modifications at each of R 1 , R 2 and R 3 .
  • altering the net charge of R 1 may reduce the current flowing through the pore when it interacts with and thereby make it less easy to discriminate between different nucleotides at R 2 and/or R 3 .
  • modifying R 1 to increase the current flowing the pore when it interacts with nucleotides may improve discrimination between different nucleotides at R 2 and/or R 3 .
  • the modifications may alter the size and/or conformation of at least one of R 1 , R 2 and R 3 and thereby alter their steric interactions with different nucleotides.
  • Discrimination between different nucleotides by at least one of R 1 , R 2 and R 3 is preferably enhanced by introducing one or more amino acids having large side chains, such as tyrosine, arginine or tryptophan.
  • the one or more amino acids may be introduced by addition.
  • the one or more amino acids are preferably introduced by substitution.
  • Discrimination between different nucleotides by at least one of R 1 , R 2 and R 3 is preferably enhanced by substituting one or more amino acids in at least one of R 1 , R 2 and R 3 with one or more amino acids having larger side chains.
  • Discrimination between different nucleotides by at least one of R 1 , R 2 and R 3 is preferably reduced by introducing one or more amino acids having small side chains, such as glycine, alanine or serine.
  • the one or more amino acids may be introduced by addition.
  • the one or more amino acids are preferably introduced by substitution.
  • Discrimination between different nucleotides by at least one of R 1 , R 2 and R 3 is preferably reduced by substituting one or more amino acids in at least one of R 1 , R 2 and R 3 with one or more amino acids having larger side chains.
  • the relative size of the side chains of amino acids can be determined by comparing their van der Waal volumes.
  • glycine with arginine constitutes substitution with an amino acid having a large side chain.
  • the modification(s) may alter the net charge of at least one of R 1 , R 2 and R 3 and thereby alter their ionic interactions with different nucleotides.
  • the modification(s) preferably increase the net positive charge of at least one of R 1 , R 2 and R 3 and thereby alter their interaction with different nucleotides.
  • the modification(s) do not have to alter the net charge of at least one of R 1 , R 2 and R 3 as long as the ability of at least one of R 1 , R 2 and R 3 to discriminate between different nucleotides is altered.
  • the net positive charge of at least one of R 1 , R 2 and R 3 is preferably increased by introducing one or more positively charged amino acids.
  • the one or more positively charged amino acids may be introduced by addition.
  • the one or more positively charged amino acids are preferably introduced by substitution.
  • a positively charged amino acid is an amino acid with a net positive charge.
  • the positively charged amino acid(s) can be naturally-occurring or non-naturally-occurring.
  • the positively charged amino acids may be synthetic or modified.
  • modified amino acids with a net positive charge may be specifically designed for use in the invention.
  • a number of different types of modification to amino acids are well known in the art.
  • Preferred naturally-occurring positively charged amino acids include, but are not limited to, histidine (H), lysine (K) and arginine (R). Any number and combination of H, K and/or R may be introduced.
  • methionine (M) may be substituted with arginine (R) by replacing the codon for methionine (ATG) with a codon for arginine (AGA) at the relevant position in a polynucleotide encoding the pore.
  • AGA codon for arginine
  • non-naturally-occurring amino acids may be introduced by including synthetic aminoacyl-tRNAs in the IVTT system used to express the pore.
  • they may be introduced by expressing the pore in E. coli that are auxotrophic for specific amino acids in the presence of synthetic (i.e. non-naturally-occurring) analogues of those specific amino acids. They may also be produced by native ligation if the pore is produced using partial peptide synthesis.
  • Any amino acid may be substituted with a positively charged amino acid.
  • One or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted with one or more positively charged amino acids.
  • Uncharged amino acids have no net charge. Suitable uncharged amino acids include, but are not limited to, cysteine (C), serine (S), threonine (T), methionine (M), asparagine (N) and glutamine (Q).
  • Non-polar amino acids have non-polar side chains. Suitable non-polar amino acids include, but are not limited to, glycine (G), alanine (A), proline (P), isoleucine (I), leucine (L) and valine (V).
  • Aromatic amino acids have an aromatic side chain.
  • Suitable aromatic amino acids include, but are not limited to, histidine (H), phenylalanine (F), tryptophan (W) and tyrosine (Y).
  • one or more negatively charged amino acids are substituted with one or more positively charged amino acids.
  • Suitable negatively charged amino acids include, but are not limited to, aspartic acid (D) and glutamic acid (E).
  • Preferred introductions include, but are not limited to, substitution of M with R, substitution of M with H, substitution of M with K, substitution of D with R, substitution of D with H, substitution of D with K, substitution of E with R, substitution of E with H and substitution of E with K.
  • any number of positively charged amino acids may be introduced. For instance, 1, 2, 5, 10, 15, 20, 25 or more positively charged amino acids may be introduced.
  • the one or more positively charged amino acids may be introduced into 1, 2, 3, 4, 5, 6 or 7 of the subunits in the pore. In each of the seven subunits, the one or more positively charged amino acids may be introduced at the same or different positions.
  • the pore is a homoheptamer and one or more positive amino acids are introduced at the same position(s) in each subunit.
  • the net positive charge of at least one of R 1 , R 2 and R 3 may also be increased by replacing by substitution one or more negatively charged amino acids with one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids.
  • the removal of negative charge increases the net positive charge.
  • the uncharged amino acids, non-polar amino acids and/or aromatic amino acids can be naturally-occurring or non-naturally-occurring. They may be synthetic or modified. Suitable uncharged amino acids, non-polar amino acids and aromatic amino acids are discussed above.
  • Preferred substitutions include, but are not limited to, substitution of E with N, substitution of D with N, substitution of E with T, substitution of D with T, substitution of E with G and substitution of D with G.
  • any number and combination of uncharged amino acids, non-polar amino acids and/or aromatic amino acids may substituted into at least one of R 1 , R 2 and R 3 .
  • 1, 2, 5, 10, 15, 20, 25 or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be may substituted.
  • the uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted into 1, 2, 3, 4, 5, 6 or 7 of the subunits in the pore.
  • the one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted into the same or different positions.
  • the pore is a homoheptamer and uncharged amino acids, non-polar amino acids and/or aromatic amino acids are substituted into the same position(s) in each subunit.
  • Negatively charged amino acids may be substituted with (1) uncharged amino acids; (2) non-polar amino acids; (3) aromatic amino acids; (4) uncharged amino acids and non-polar amino acids; (5) uncharged amino acids and aromatic amino acids; and (5) non-polar amino acids and aromatic amino acids; or (6) uncharged amino acids, non-polar amino acids and aromatic amino acids.
  • the net negative charge of at least one of R 1 , R 2 and R 3 is preferably increased by introducing one or more negatively charged amino acids into the barrel or channel and/or entrance of the pore.
  • the one or more negatively charged amino acids may be introduced by addition.
  • the one or more negatively charged amino acids are preferably introduced by substitution. Methods for adding and substituting amino acids are well known in the art.
  • Suitable negatively charged amino acids are discussed above.
  • the negatively charged amino acid(s) can be naturally-occurring or non-naturally-occurring.
  • the negatively charged amino acids may be synthetic or modified.
  • Any amino acid may be substituted with a negatively charged amino acid.
  • One or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted with one or more negatively charged amino acids.
  • one or more positively charged amino acids are substituted with one or more negatively charged amino acids. Any number of negatively charged amino acids may be introduced as discussed above.
  • the net negative charge may also be increased by replacing by substitution one or more positively charged amino acids with one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids.
  • the removal of positive charge increases the net negative charge.
  • the uncharged amino acids, non-polar amino acids and/or aromatic amino acids can be naturally-occurring or non-naturally-occurring. They may be synthetic or modified.
  • Any number and combination of uncharged amino acids, non-polar amino acids and/or aromatic amino acids may substituted into the barrel or channel and/or entrance as discussed above.
  • the modification(s) do not have to alter the net charge of at least one of R 1 , R 2 and R 3 .
  • at least one of R 1 , R 2 and R 3 may be modified by replacing a positively charged amino acid with an uncharged amino acid and a negatively charged amino acid with an uncharged amino acid.
  • R 1 , R 2 and/or R 3 are preferably made to amino acids that face inward into the barrel or channel of the pore.
  • amino acids can be identified as described in Song, L., Hobaugh, M. R., Shustak C., Cheley, S., Bayley, H., and Gouaux, J. E. (1996) Science 274, 1859-1866.
  • the variant of SEQ ID NO: 2 is modified at one of R 1 , R 2 and R 3 and this alters the ability of one of the other sites to discriminate between different nucleotides.
  • the variant is modified at one of R 1 , R 2 and R 3 and this alters the ability of all of R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the variant is modified at R 1 and this alters the ability of all of R 1 , R 2 and R 3 to discriminate between different nucleotides.
  • the variant preferably comprises an asparagine at position 111 of SEQ ID NO: 2 and an asparagine at position 147 of SEQ ID NO: 2.
  • SEQ ID NO: 4 shows the sequence of SEQ ID NO: 2 except that it has an asparagine at position 111 of SEQ ID NO: 2 (E111N) and an asparagine at position 147 of SEQ ID NO: 2 (K147N).
  • SEQ ID NO: 4 or a variant thereof may be used to form a pore in accordance with the invention.
  • the variant of SEQ ID NO: 4 may differ from SEQ ID NO: 4 in the same way and to the same extent as discussed for SEQ ID NO: 2 above except that it must have an asparagine at position 111 of SEQ ID NO: 4 and an asparagine at position 147 of SEQ ID NO: 4.
  • a preferred pore for use in the invention comprises one or more, preferably seven, subunits comprising SEQ ID NO: 4.
  • the variant may also include other modifications that facilitate an interaction with nucleotides.
  • the variant preferably has a glutamine at position 139 of SEQ ID NO: 2.
  • the variant preferably has an arginine or a tyrosine at position 113 of SEQ ID NO: 2.
  • the variant may include modifications that facilitate covalent attachment to or interaction with a nucleic acid handling protein.
  • the variant preferably comprises one or more reactive cysteine residues that facilitate attachment to the nucleic acid handling enzyme.
  • the variant may include a cysteine at one or more of positions 8, 9, 17, 18, 19, 44, 45, 50, 51, 237, 239 and 287 and/or on the amino or carboxy terminus of SEQ ID NO: 2.
  • Preferred variants comprise a substitution of the residue at position 8, 9, 17, 237, 239 and 287 of SEQ ID NO: 2 with cysteine (K8C, T9C, N17C, K237C, S239C or E287C).
  • the variant may be a naturally occurring variant which is expressed naturally by an organism, for instance by a Staphylococcus bacterium, or expressed recombinantly by a bacterium such as Escherichia coli .
  • Variants also include non-naturally occurring variants produced by recombinant technology. Over the entire length of the amino acid sequence of SEQ ID NO: 2 or 4, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity.
  • the variant polypeptide may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 2 or 4 over the entire sequence.
  • Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 2 or 4 in addition to those discussed above, for example up to 1, 2, 3, 4, 5, 10, 20 or 30 substitutions.
  • Conservative substitutions may be made, for example, according to Table 1 above.
  • One or more amino acid residues of the amino acid sequence of SEQ ID NO: 2 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.
  • Variants may include fragments of SEQ ID NO: 2 or 4. Such fragments retain pore forming activity. Fragments may be at least 50, 100, 200 or 250 amino acids in length. A fragment preferably comprises the pore forming domain of SEQ ID NO: 2 or 4. Fragments typically include residues 119, 121, 135. 113 and 139 of SEQ ID NO: 2 or 4.
  • One or more amino acids may be alternatively or additionally added to the polypeptides described above.
  • An extension may be provided at the amino terminus or carboxy terminus of the amino acid sequence of SEQ ID NO: 2 or 4 or a variant or fragment thereof.
  • the extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids.
  • a carrier protein may be fused to a pore or variant.
  • a variant of SEQ ID NO: 2 or 4 is a subunit that has an amino acid sequence which varies from that of SEQ ID NO: 2 or 4 and which retains its ability to form a pore.
  • a variant typically contains the regions of SEQ ID NO: 2 or 4 that are responsible for pore formation.
  • the pore forming ability of ⁇ -HL, which contains a ⁇ -barrel, is provided by 3-strands in each subunit.
  • a variant of SEQ ID NO: 2 or 4 typically comprises the regions in SEQ ID NO: 2 that form ⁇ -strands.
  • the amino acids of SEQ ID NO: 2 or 4 that form ⁇ -strands are discussed above.
  • One or more modifications can be made to the regions of SEQ ID NO: 2 or 4 that form ⁇ -strands as long as the resulting variant retains its ability to form a pore. Specific modifications that can be made to the ⁇ -strand regions of SEQ ID NO: 2 or 4 are discussed above.
  • a variant of SEQ ID NO: 2 or 4 preferably includes one or more modifications, such as substitutions, additions or deletions, within its ⁇ -helices and/or loop regions. Amino acids that form ⁇ -helices and loops are discussed above.
  • the variant may be modified for example by the addition of histidine or aspartic acid residues to assist its identification or purification or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence.
  • Variants may also comprise any of the non-specific modifications discussed above for the nucleic acid handling enzyme. Subunits or pores can be made as discussed above.
  • Transmembrane protein pores can be produced as described above for nucleic acid handling enzymes.
  • the enzyme should handle the target nucleic acid sequence in a specific manner. For instance, the target sequence must be passed through the pore in a processive manner as described above. This ensures that a proportion of the nucleotides in the target nucleic acid sequence interacts with the pore and is identified. The lack of any interruption in the signal is important when sequencing nucleic acids.
  • the best way to ensure the specific handling of the target sequence by the enzyme is to attach the enzyme to the pore.
  • the enzyme is fixed to the pore, they can be stored together, thereby allowing the production of a ready-to-use sensor.
  • a nucleic acid handling enzyme is attached to the pore. This allows the target nucleic acid sequence is pushed through the barrel or channel of the pore in a stepwise manner and a proportion of the nucleotides in the target sequence to interacts with site(s) capable of discriminating different nucleotides. Suitable enzymes are discussed above.
  • the enzyme is preferably attached to the pore at a site in close proximity to the opening of the barrel of channel of the pore.
  • the enzyme is more preferably attached to the pore such that its active site is orientated towards the opening of the barrel of channel of the pore. This means that the target nucleic acid sequence is fed into the barrel or channel.
  • the enzyme is preferably attached to the cis side of the pore.
  • the nucleic acid handling enzyme can be attached to the pore using any method known in the art.
  • the nucleic acid handling enzyme and pore may be produced separately and then attached together.
  • the two components may be attached in any configuration. For instance, they may be attached via their terminal (i.e. amino or carboxy terminal) amino acids. Suitable configurations include, but are not limited to, the amino terminus of the nucleic acid handling enzyme being attached to the carboxy terminus of the pore and vice versa.
  • the two components may be attached via amino acids within their sequences.
  • the nucleic acid handling enzyme may be attached to one or more amino acids in a loop region of the pore.
  • terminal amino acids of the nucleic acid handling enzyme are attached to one or more amino acids in the loop region of the pore. Terminal amino acids and loop regions are discussed above.
  • the nucleic acid handling enzyme is preferably chemically fused to the pore.
  • a nucleic acid handling enzyme is chemically fused to a pore if the two parts are chemically attached, for instance via a linker molecule. Any method of chemical fusion or attachment can be used. Suitable methods include, but are not limited to, histidine tag binding to a metal affinity matrix, Ni-NTA, biotin binding to streptavidin, antibody binding to an antigen, primary amine coupling, GST tags binding to glutathione, MBP tags binding to dextrin, Protein A binding to IgG, reaction between thiols, nucleic acid hybridization linkers and cysteine linkage. DNA hybridization linkers and cysteine linkage are discussed in more detail below.
  • the nucleic acid handling enzyme is preferably covalently attached to the pore.
  • the nucleic acid handling enzyme may be genetically fused to the pore.
  • a nucleic acid handling enzyme is genetically fused to a protein pore if the whole construct is expressed from a single polynucleotide sequence.
  • the coding sequences of the nucleic acid handling enzyme and pore may be combined in any way to form a single polynucleotide sequence encoding the construct.
  • the nucleic acid handling enzyme and pore may be genetically fused in any configuration, such as via their terminal amino acids.
  • the amino acid sequence of the nucleic acid handling enzyme is typically added in frame into the amino acid sequence of the pore.
  • the nucleic acid handling enzyme is inserted into a loop region of a transmembrane protein pore.
  • the nucleic acid handling enzyme is inserted between amino acids, 18 and 19, 44 and 45 or 50 and 51 of SEQ ID NO: 2.
  • the nucleic acid handling enzyme retains its ability to bind nucleic acids. This ability is typically provided by its secondary structural elements ( ⁇ -helices and ⁇ -strands) and tertiary structural elements. In order to avoid adversely affecting the nucleic acid binding ability of the protein, it is preferably attached to the pore in a manner that does not affect its secondary or tertiary structure.
  • the pore retains its ability to permit ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane.
  • the pore forming ability of pores is typically provided by their ⁇ -helices and ⁇ -strands.
  • ⁇ -barrel pores comprise a barrel or channel that is formed from ⁇ -strands
  • ⁇ -helix bundle pores comprise a barrel or channel that is formed from ⁇ -helices.
  • the ⁇ -helices and ⁇ -strands are typically connected by loop regions.
  • the nucleic acid handling enzyme is preferably attached to a loop region of the pore. The loop regions of specific pore subunits are discussed in more detail above.
  • the nucleic acid handling enzyme is preferably attached to the pore using one or more, such as 2, 3 or 4, linkers.
  • the one or more linkers may be designed to constrain the mobility of the nucleic acid handling enzyme.
  • the linkers are typically attached to the one or more accessible cysteine residues in the nucleic acid handling enzyme.
  • the linkers may be attached to one or more reactive groups, such as cysteine residues, reactive lysine residues or non-natural amino acids, in the pore.
  • Suitable linkers are well known in the art. Suitable linkers include, but are not limited to, chemical crosslinkers and peptide linkers. Preferred chemical crosslinkers are nucleic hybridization linkers.
  • the length, flexibility and hydrophilicity of the nucleic acid hybridization linkers are typically designed such that they do not to disturb the functions of the nucleic acid handling enzyme and pore.
  • the nucleic acid hybridization linkers can comprise any of the nucleic acids discussed above.
  • Linkers may be attached to the nucleic acid handling enzyme first and then the pore, the pore first and then the nucleic acid handling enzyme or the pore and nucleic acid handling enzyme at the same time.
  • the linker When the linker is attached to a pore subunit (as the pore), it may be a monomeric subunit, part of an oligomer of two or more monomers or part of complete oligomeric pore. It is preferred that the linker is reacted before any purification step to remove any unbound linker.
  • the preferred method of attaching the nucleic acid handling enzyme to the pore is via cysteine linkage.
  • This can be mediated by a bi-functional chemical linker or by a polypeptide linker with a terminal presented cysteine residue.
  • ⁇ -HL SEQ ID NO: 2 lacks native cysteine residues so the introduction of a cysteine into the sequence of SEQ ID NO: 2 enables the controlled covalent attachment of the nucleic acid handling enzyme to the subunit.
  • Cysteines can be introduced at various positions, such as position K8, T9 or N17 of SEQ ID NO: 2 or at the carboxy terminus of SEQ ID NO: 2.
  • the length, reactivity, specificity, rigidity and solubility of any bi-functional linker may be designed to ensure that the enzyme is positioned correctly in relation to the subunit and the function of both the subunit and enzyme is retained. Suitable linkers include those described above.
  • Cross-linkage of subunits or enzymes to themselves may be prevented by keeping the concentration of linker in a vast excess of the nucleic acid handling enzyme and/or the pore.
  • a “lock and key” arrangement may be used in which two linkers are used.
  • click chemistry such as azide alkyne Huisgen cycloaddition, may be used to ensure that the nucleic acid handling enzyme only binds to the pore and not to itself and vice versa.
  • the nucleic acid handling enzyme is preferably attached to the part of a pore or a subunit thereof that forms part of the cis side of a pore.
  • the cis side is the grounded side by convention. If a hemolysin pore is inserted correctly into an electrophysiology apparatus, the Cap region is on the cis side. It is well known that, under a positive potential, nucleotides will migrate from the cis to the trans side of pores used for stochastic sensing.
  • Positioning the nucleic acid handling enzyme at the cis side of a pore allows it to handle the target nucleic acid such that a proportion of the nucleotides in the sequence enters the barrel or channel of the pore and interacts with it.
  • at least 20%, at least 40%, at least 50%, at least 80% or at least 90% of the nucleotides in the sequence enters the barrel or channel of the pore and interacts with it.
  • the site and method of covalent attachment is preferably selected such that mobility of the nucleic acid handling enzyme is constrained.
  • This helps to ensure that the protein handles the target nucleic acid sequence in such a way that a proportion of the nucleotides in the target sequence interacts with the pore.
  • constraining the ability of nucleic acid handling enzyme to move means that its active site can be permanently orientated towards the part of the subunit that forms part of the opening of the barrel of channel of the pore.
  • the mobility of the nucleic acid handling enzyme may be constrained by increasing the number of points at which the protein is attached to the pore and/or the use of specific linkers.
  • the method may be carried out using any apparatus that is suitable for investigating a membrane/pore system in which a pore is inserted into a membrane.
  • the method may be carried out using any apparatus that is suitable for stochastic sensing.
  • the apparatus comprises a chamber comprising an aqueous solution and a barrier that separates the chamber into two sections.
  • the barrier has an aperture in which the membrane containing the pore is formed.
  • the target sequence may be contacted with the pore by introducing the sequence into the chamber.
  • the target sequence may be introduced into either of the two sections of the chamber, but, if a nucleic acid handling enzyme used, is preferably introduced into the section of the chamber containing the enzyme.
  • the method may be carried out using the apparatus described in International Application No. PCT/GB08/000562.
  • the method involves measuring the current passing through the pore during interaction with the nucleotides. Therefore the apparatus also comprises an electrical circuit capable of applying a potential and measuring an electrical signal across the membrane and pore.
  • the method may be carried out using a patch clamp or a voltage clamp.
  • the method preferably involves the use of a voltage clamp.
  • the method of the invention involves the measuring of a current passing through the pore during interaction with nucleotides of a target nucleic acid sequence. Suitable conditions for measuring ionic currents through transmembrane pores are known in the art and disclosed in the Examples. The method is carried out with a voltage applied across the membrane and pore. The voltage used is typically from ⁇ 400mV to +400mV.
  • the voltage used is preferably in a range having a lower limit selected from ⁇ 400 mV, ⁇ 300mV, ⁇ 200 mV, ⁇ 150 mV, ⁇ 100 mV, ⁇ 50 mV, ⁇ 20mV and 0 mV and an upper limit independently selected from +10 mV, +20 mV, +50 mV, +100 mV, +150 mV, +200 mV, +300 mV and +400 mV.
  • the voltage used is more preferably in the range 120 mV to 170 mV. It is possible to increase discrimination between different nucleotides by at least one site capable of discriminating between different nucleotides by varying the applied potential.
  • the method is carried out in the presence of any alkali metal chloride salt.
  • the salt is present in the aqueous solution in the chamber. Potassium chloride (KCl), sodium chloride (NaCl) or caesium chloride (CsCl) is typically used. KCl is preferred.
  • the salt concentration is typically from 0.1 to 2.5M, from 0.3 to 1.9M, from 0.5 to 1.8M, from 0.7 to 1.7M, from 0.9 to 1.6M or from 1M to 1.4M.
  • High salt concentrations provide a high signal to noise ratio and allow for currents indicative of the presence of a nucleotide to be identified against the background of normal current fluctuations. However, lower salt concentrations may have to be used so that the enzyme is capable of functioning.
  • the method is typically carried out in the presence of a buffer.
  • the buffer is present in the aqueous solution in the chamber. Any buffer may be used in the method.
  • One suitable buffer is Tris-HCl buffer.
  • the method is typically carried out at a pH of from 4.0 to 13.0, from 4.5 to 12, from 5.0 to 11, from 5.5 to 10, from 6.0 to 9 or from 7.0 to 8.8 or 7.5 to 8.5. DNA denatures at a pH of around 11.
  • the pH used is preferably about 7.5.
  • the method is typically carried out at from 0° C. to 100° C., from 15° C. to 95° C., from 16° C. to 90° C., from 17° C. to 85° C., from 18° C. to 80° C., 19° C. to 70° C., or from 20° C. to 60° C.
  • the method may be carried out at room temperature.
  • the method is preferably carried out at a temperature that supports enzyme function, such as about 37° C. Good nucleotide discrimination can be achieved at low salt concentrations if the temperature is increased. However, lower temperatures, particularly those below room temperature, result in longer dwell times and can therefore be used to obtain a higher degree of accuracy.
  • lipid bilayer to divide two different concentrations of salt solution, a low salt concentration of salt on the enzyme side and a higher concentration on the opposite side.
  • This approach is to use 200 mM of KCl on the cis side of the membrane and 500 mM KCl in the trans chamber. At these conditions, the conductance through the pore is expected to be roughly equivalent to 400 mM KCl under normal conditions, and the enzyme only experiences 200 mM if placed on the cis side.
  • Another possible benefit of using asymmetric salt conditions is the osmotic gradient induced across the pore.
  • This net flow of water could be used to pull nucleotides into the pore for detection.
  • a similar effect can be achieved using a neutral osmolyte, such as sucrose, glycerol or PEG.
  • a neutral osmolyte such as sucrose, glycerol or PEG.
  • Another possibility is to use a solution with relatively low levels of KCl and rely on an additional charge carrying species that is less disruptive to enzyme activity.
  • the invention also provides a method for improving a transmembrane pore for sequencing a target nucleic sequence.
  • the target sequence may be homopolymeric or hetropolymeric.
  • a homopolymeric nucleic acid sequence is one made of one type of nucleotide.
  • the nucleotide may be any of those discussed above.
  • the method is intended to engineer or design an improved transmembrane pore that may be used to sequence nucleic acids as described above. Pores improved in accordance with the invention can be used in a sequencing method of invention.
  • the method comprises modifying a pore comprising one site that is capable of discriminating between different nucleotides.
  • the pore may be modified in any of the ways discussed above.
  • the pore is typically modified to introduce at least one more site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides.
  • the method then comprises determining whether or not the resulting pore comprises two or more distinct sites that are capable of discriminating between different nucleotides.
  • the determining step can be done using any method known in the art. For instance, it may be done as described in the Example. The advantages of having two or more sites that are capable of discriminating between different nucleotides are discussed above.
  • the method comprises modifying a pore comprising two or more distinct sites that are capable of discriminating between different nucleotides.
  • the pore may be modified in any of the ways discussed above.
  • the pore is typically modified to remove at least one site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides.
  • the method then comprises determining whether or not the resulting pore comprises only two distinct sites that are capable of discriminating between different nucleotides.
  • the determining step can be done using any method known in the art. For instance, it may be done as described in the Example. The advantages of having two sites that are capable of discriminating between different nucleotides are discussed above.
  • the method comprises modifying a pore, comprising more than one site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides.
  • the pore may be modified in any of the ways discussed above.
  • the pore is typically modified to remove at least one site, such as 1, 2 or 3 sites, that are capable of discriminating between different nucleotides.
  • the method then comprises determining whether or not the resulting pore comprises only one site that is capable of discriminating between different nucleotides.
  • the determining step can be done using any method known in the art. For instance, it may be done as described in the Example. Pores with only one site that is capable of discriminating between different nucleotides produce a simple current signal when used to sequence target nucleic acid sequences.
  • the method comprises modifying a pore comprising two or more sites that are capable of discriminating between different nucleotides at one of the distinct sites.
  • the pore may be modified in any of the ways discussed above.
  • the pore is typically modified to enhance or reduce the ability of at least one, such as 2, 3 or 4, of the distinct sites to discriminate between different nucleotides.
  • the method then comprises determining whether or not the resulting pore the ability of at least one of the distinct sites to discriminate between different nucleotides is altered.
  • the determining step can be done using any method known in the art. For instance, it may be done as described in the Example.
  • the invention also provides a pore improved using a method of the invention
  • ⁇ -HL was produced as described in detail elsewhere (Cheley, S., Braha, O., Lu, X., Conlan, S., & Bayley, H. (1999) A functional protein pore with a “Retro” Transmembrane domain. Protein Sci. 8, 1257-1267). In brief, the protein was expressed in the presence of [ 35 S]methionine in an E. coli in vitro transcription and translation (IVTT) system ( E. coli T7 S30 Extract System for Circular DNA, Cat. #L1130, Promega). IVTT reactions (100 ⁇ L) containing ⁇ -HL monomers were incubated with rabbit red blood cell membranes for 1 h at 37° C. to form ⁇ -HL heptamers.
  • IVTT E. coli T7 S30 Extract System for Circular DNA, Cat. #L1130, Promega
  • the solution was centrifuged at 25,000 ⁇ g and the pellet containing heptamers was loaded onto a 5% SDS-polyacrylamide gel, which was run for 4 h at 100 V and subsequently vacuum dried for 3 to 4 h onto Whatman 3M filter paper.
  • the dried gel was exposed to photographic film for 2 h and the developed film was used to locate the position of the heptameric protein in the gel. This region of the gel was excised, rehydrated and crushed in 400 ⁇ L of 10 mM Tris.HCl, pH 8.0, containing 100 ⁇ M EDTA.
  • the mutant ⁇ -HL gene was prepared by using a kit for site-directed mutagenesis (QuickChange II XL, Cat. #200522-5, Stratagene). The DNA sequence of each gene was verified.
  • Bilayers were formed by first pre-treating the aperture with 10 mg mL ⁇ 1 hexadecane in n-pentane. Electrolyte solution (0.5 mL: 1 M KCl, 25 mM Tris.HCl, 0.1 mM EDTA, pH 8.0) was added to both compartments. Then, DPhPC in n-pentane (10 mg mL ⁇ 1 ) was added to both compartments. The solvent was allowed to evaporate and the bilayer was formed by lowering and raising the electrolyte level past the aperture.
  • Lipid bilayers were formed from 1,2-diphytanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids). Both compartments of the recording chamber contained 0.5 mL of 1 M KCl, 25 mM Tris.HCl, pH 8.0, with 0.1 mM EDTA. Planar bilayer current recordings were performed with a patch clamp amplifier (Axopatch 200B, Axon Instruments, Foster City, Calif.) with the cis compartment connected to ground. The ⁇ -HL pores and the DNA were added to the cis compartment. ssDNA molecules, with a biotinyl group covalently attached to the 3′ end through a linker, were obtained from Sigma-Aldrich (UK) ( FIG.
  • the capture of a ssDNA strand by an ⁇ -HL pore is observed as a stepwise decrease in the open pore current level (I O ) to a lower, but stable, current level (I B ).
  • a voltage of ⁇ 140 mV was then applied for 100 ms (Example 1) or 50 ms (Example 2) to eject the immobilized DNA from the pore.
  • the applied potential was then stepped to 0 mV for 100 ms (Example 1) or 50 ms (Example 2). This two-second or one-second sequence was repeated for at least 100 cycles for each ssDNA species added.
  • the amplified signal (arising from the ionic current passing through the pore) was low-pass filtered at 1 kHz and sampled at 5 kHz with a computer equipped with a Digidata 1440A digitizer (Molecular Devices).
  • oligonucleotides used are shown in SEQ ID NOs: 13 to 66. All oligonucleotides have a 3′ biotin-TEG tag and linker as shown in FIG. 7 .
  • I B The mean I B value for each oligonucleotide was determined by performing a Gaussian fit to a histogram of the I B values.
  • oligonucleotide species In general, when comparing several oligonucleotide species, a single oligonucleotide species was first added to the cis chamber and the current trace required for the determination of I B and I RES was recorded. Subsequently, a second (and if required, a third and a fourth) oligonucleotide was added and additional currents recorded.
  • the data in FIGS. 4 and 5 come from four oligonucleotide species, with sequences that differ by a single nucleotide.
  • the experiment displayed in FIG. 11 which involves the probing of pores with 16 different sequences, was obtained by adding sets of 4 oligonucleotides at a time rather than adding individual oligonucleotides.
  • Each of the 4 oligonucleotides within a set differed in the base at R 1 , but had the same base at R 2 , and each set had a different base at R 2 .
  • the peaks in the derived histograms were assigned based on previous experiments with the separate sets of 4 oligonucleotides.
  • the oligonucleotides were added to the chamber in a different order, and in the case of the 16 oligonucleotide experiment ( FIG. 11 ), the sets of oligonucleotides were added in a different order.
  • ssDNA oligonucleotides SEQ ID NOs: 13 and 14
  • biotin tags at the 3′ terminus
  • the immobilized DNA molecules caused a sequence-dependent decrease in the current flow through the pore ( FIG. 1B ), and here we quote the residual current (I RES ) as a percentage of the open pore current (I O ).
  • I RES residual current
  • I O open pore current
  • I RES Residual currents
  • the I o and I RES values given for each oligonucleotide are mean values taken from Gaussian fits to event histograms for individual experiments.
  • ⁇ I RES is the difference in residual current between the poly(dA) and poly(dC) blockades (I RES poly(dA) ⁇ I RES poly(dC) ).
  • Nucleic acid homopolymers have been distinguished with the WT ⁇ -HL pore by several groups on the basis of differences in I RES . Meller and colleagues found that poly(dA) and poly(dC) were difficult to distinguish during translocation through the pore, in part due to the broad distributions of I RES values (Meller, A., Nivon, L., Brandin, E., Golovchenko, J., & Branton, D. (2000) Proc. Natl. Acad. Sci. USA 97, 1079-1084).
  • the ssDNA was immobilized by 5′ or 3′ terminal hairpins, which probably enter the pore and perturb recognition that occurs at the constriction. Together, the results imply that more than one recognition element might be present in the ⁇ barrel of the ⁇ -HL pore. Further experimentation, as described below, supports this view.
  • I RES Residual currents
  • the ssDNA in the pore is elongated compared to its conformation in solution.
  • the applied potential produces a force on the DNA, which can be estimated to be ⁇ 8 pN, by the following argument.
  • the experimentally determined effective charge on each base is ⁇ 0.1e (Sauer-Budge, A. F., Nyamwanda, J. A., Lubensky, D. K., & Branton, D. (2003) Phys. Rev. Lett.
  • the results of the A 5 scan show that the ⁇ -HL pore can recognize bases in ssDNA and contains at least three recognition sites within the ⁇ barrel.
  • the recognition sites by moving a single A base through a poly(dC) background and comparing the residual current with that of poly(dC) itself.
  • a set of fourteen poly(dC) oligonucleotides was made (SEQ ID NOs: 21 to 34), each containing a single adenine (A 1 ) nucleotide (Askenashay and colleagues, supra).
  • I RES Residual currents
  • the I O and I RES values are the mean values from n experiments.
  • ⁇ I RES is defined as the difference in residual current between an A 1 oligonucleotides and poly(dC) (I RES A1oligo ⁇ I RES dC ). The errors given are standard deviations.
  • ⁇ -HL pores In addition to the detection of individual bases, to sequence ssDNA, ⁇ -HL pores must also be able to distinguish between G, A, T and C within a DNA chain. To examine this possibility, the WT and E111N/K147N pores were probed with three sets of four oligonucleotides (SEQ ID NOs: 35 to 46). Each oligonucleotide was a homopolymer (poly(dC)), except at a specific position, where it was substituted with either G, A, T and C (the latter oligonucleotide being poly(dC) itself). Each of the three sets had substitutions at a different position in the sequence, which were designed to probe the R 1 , R 2 and R 3 recognition sites.
  • the first set of oligonucleotides had the G, A, T or C substitution at position 9 (from the 3′ end) and was designed to probe R 1 ( FIG. 4A ). Although there is some discrimination between the four oligonucleotides in this set, neither the WT nor the E111N/K147N pore is able to distinguish all four bases.
  • the second set had the G, A, T or C substitution at position 14 and was designed to probe R 2 ( FIG. 4B ). In this case, both the WT and E111N/K147N pores clearly separated C, T, A and G, in order of increasing I RES .
  • the final set had the G, A, T or C substitution at position 18 to probe R 3 ( FIG. 4C ). In this case, only the E111N/K147N pores are able distinguish the four bases, but in the reverse order, viz. G, A, T and C, and the spread of I RES values is not as large as seen with the set substituted at position 14.
  • DNA strands can be immobilized within the ⁇ -HL pore by using a terminal hairpin or a biotin•streptavidin complex, which improves the resolution of the currents associated with individual nucleotides, because of the prolonged observation time (N. Ashkenasy, J. Sánchez-Quesada, H. Bayley, M. R. Ghadiri, Angew. Chem. Int. Ed. Engl. 2005, 44, 1401).
  • the immobilized strands reduce the open pore current level, I O , to a level I B .
  • R 1 is located near the internal constriction in the lumen of the pore and recognizes bases at positions ⁇ 8 to 12 (bases are numbered from the 3′ end of synthetic oligonucleotide probes).
  • R 2 is located near the middle of the ⁇ barrel and discriminates bases at positions ⁇ 12 to 16.
  • R 3 recognizes bases at positions ⁇ 17 to 20 and is located near the trans entrance of the barrel.
  • R 2 is capable of discriminating between each of the four DNA bases (when the bases are placed at position 14, in an otherwise poly(dC) oligonucleotide).
  • NN E111N/K147N mutant
  • I RES I RES in the NN mutant leads to a greater dispersion of the current levels arising from different DNAs, and thereby improves base discrimination at R 2 and R 3 , compared to WT.
  • NNY displayed vastly improved base recognition properties at R 1 compared to the WT and NN pores.
  • the single M113Y mutation is capable of turning a weakly discriminating R 1 site in the NN mutant into a strong site in the NNY mutant.
  • the tyrosines at position 113 improve discrimination at R 1 through aromatic stacking or hydrogen bonding interactions with the immobilized bases (G. Hu, P. D. Gershon, A. E. Hodel, F. A. Quiocho, Proc. Natl. Acad. Sci. USA 1999, 96, 7149).
  • NNY mutant which has two strong recognition points (R 1 and R 2 )
  • R 1 and R 2 Two strong recognition points
  • FIG. 9 The sequence of a given oligonucleotide is designated: X 9 X 14 , where X represents a defined base; G, A, T or C, and 9 and 14 gives the position of the base (relative to the biotin tag).
  • ⁇ I RES Mean residual current differences between poly(dC) oligonucleotides that contain nucleotide substitutions at position 9 (to probe R 1 ) and/or position 14 (to probe R 2 ). The positions of the substitutions are relative to the 3′ biotin tag.
  • the sequence of each oligonucleotide is abbreviated as X 9 X 14 (SEQ ID NOs: 51 to 66).
  • the mean ⁇ I RES value ( ⁇ s.d.) is for at least three experiments. ⁇ I RES is directly measured as the difference between the residual current levels of two specified oligonucleotides (FIG. 10).
  • ⁇ I RES I RES C9N14 ⁇ I RES C9C14 (FIG. 10a).
  • ⁇ I RES I RES N9X14 ⁇ I RES C9X14 (FIG. 10b-e).
  • recognition point R 1 produces a large current dispersion, while that produced by R 2 is more modest ( FIG. 9 b ).
  • the slight dependence of recognition at R 1 on the base occupying R 2 was not considered in the proposed scheme ( FIG. 9 ).
  • the predicted ⁇ I RES values match well with the measured ⁇ I RES values, with the observed mean ⁇ I RES values within the error of the predicted values.
  • current flow is restricted at R 1 and R 2 , and that the effects of the two recognition points are approximately additive, when ⁇ I RES values are small, like the effect of two small resistances in series in an electrical circuit.
  • the 16 DNA sequences did not produce 16 discrete current levels, we were able to resolve 11.
  • a perfect 16-level system of two reading heads would read each position in a sequence twice, while a perfect single reading head would read the sequence just once. Therefore, although the 11-level system is imperfect, it does yield additional, redundant information about each base, which would provide more secure base identification than a single reading head. It might be thought that a third reading head would improve matters.
  • the number of possible base combinations would increase from 16 to 64. Even if these levels could be dispersed across the entire current spectrum of the ⁇ -HL pore (from almost open to almost closed), it is unlikely that the 64 levels could be separated owing to the electrical noise in the system, even under the low bandwidth conditions used here.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

The invention relates to a method for sequencing a heteropolymeric target nucleic acid sequence that involves stochastic sensing. The invention also relates to a method for improving a pore for sequencing a target nucleic acid sequence by modifying one or more sites in the pore.

Description

    FIELD OF THE INVENTION
  • The invention relates to a method for sequencing a heteropolymeric target nucleic acid sequence that involves stochastic sensing. The invention also relates to a method for improving a pore for sequencing a target nucleic acid sequence by modifying one or more sites in the pore.
    • BACKGROUND OF THE INVENTION
  • Stochastic detection is an approach to sensing that relies on the observation of individual binding events between analyte molecules and a receptor. Stochastic sensors can be created by placing a single pore of nanometer dimensions in an insulating membrane and measuring voltage-driven ionic transport through the pore in the presence of analyte molecules. The frequency of occurrence of fluctuations in the current reveals the concentration of an analyte that binds within the pore. The identity of an analyte is revealed through its distinctive current signature, notably the duration and extent of current block (Braha, O., Walker, B., Cheley, S., Kasianowicz, J. J., Song, L., Gouaux, J. E., and Bayley, H. (1997) Chem. Biol. 4, 497-505; and Bayley, H., and Cremer, P. S. (2001) Nature 413, 226-230).
  • Engineered versions of the bacterial pore forming toxin α-hemolysin (α-HL) have been used for stochastic sensing of many classes of molecules (Bayley, H., and Cremer, P. S. (2001) Nature 413, 226-230; Shin, S., H., Luchian, T., Cheley, S., Braha, O., and Bayley, H. (2002) Angew. Chem. Int. Ed. 41, 3707-3709; and Guan, X., Gu, L.-Q., Cheley, S., Braha, O., and Bayley, H. (2005) Chem. BioChem. 6, 1875-1881). In the course of these studies, it was found that attempts to engineer α-HL to bind small organic analytes directly can prove taxing, with rare examples of success (Guan and colleague, supra). Fortunately, a different strategy was discovered, which utilised non-covalently attached molecular adaptors, notably cyclodextrins (Gu, L.-Q., Braha, O., Conlan, S., Cheley, S., and Bayley, H. (1999) Nature 398, 686-690), but also cyclic peptides (Sanchez-Quesada, J., Ghadiri, M. R., Bayley, H., and Braha, O. (2000) J. Am. Chem. Soc. 122, 11758-11766) and cucurbiturils (Braha, O., Webb, J., Gu, L.-Q., Kim, K., and Bayley, H. (2005) Chem. Phys. Chem 6, 889-892). Cyclodextrins become transiently lodged in the α-HL pore and produce a substantial but incomplete channel block. Organic analytes, which bind within the hydrophobic interiors of cyclodextrins, augment this block allowing analyte detection (Gu, L.-Q., Braha, O., Conlan, S., Cheley, S., and Bayley, H. (1999) Nature 398, 686-690).
  • There is currently a need for rapid and cheap DNA or RNA sequencing technologies across a wide range of applications. Existing technologies are slow and expensive mainly because they rely on amplification techniques to produce large volumes of nucleic acid and require a high quantity of specialist fluorescent chemicals for signal detection. Stochastic sensing has the potential to provide rapid and cheap DNA sequencing by reducing the quantity of nucleotide and reagents required.
  • Translocating homopolymer nucleic acid sequences can be distinguished by protein nanopores (for example Branton, D., Deamer, D. W., Marziali, A., Bayley, H., Benner, S. A., Butler, T., Di Ventra, M., Garaj, S., Hibbs, A., Huang, X., et al. (2008) Nature Biotechnology 26, 1146-1153). The transition between two homopolymer sequences within a translocating single RNA strand can also be observed (Akeson, M., Branton, D., Kasianowicz, J. J., Brandin, E., & Deamer, D. W. (1999) Biophys. J. 77, 3227-3233). Individual base pairs at the end of an immobilized DNA strand can also be identified within a nanopore (Winters-Hilt, S., Vercoutere, W., DeGuzman, V. S., Deamer, D., Akeson, M., & Haussler, D. (2003) Biophys. J. 84, 967-976), but it is not clear how this might be adapted for sequencing. Recently, individual modified nucleotide bases have been observed “on the fly” (Mitchell, N. & Howorka, S. (2008) Angew. Chem. Int. Ed Engl. 47, 5565-5568), but these structures were very bulky. There is currently no known method for sequencing heteropolymeric nucleic acid sequences using a nanopore.
    • SUMMARY OF THE INVENTION
  • The inventors have surprisingly demonstrated that a pore can discriminate between at least four different nucleotides in a nucleic acid sequence. In other words, the inventors have surprisingly demonstrated that a pore may be used to sequence an intact heteropolymeric target nucleic acid sequence via stochastic sensing.
  • The inventors have also surprisingly demonstrated that pores having two or more distinct sites that are capable of discriminating between different nucleotides display improved nucleotide recognition. Such pores are advantageous for sequencing nucleic acid sequences. As discussed in more detail below, the presence in a pore of more than one site that is capable of discriminating between different nucleotides not only allows the length of a nucleic acid sequence to be determined, but also allows the sequence of a nucleic acid sequence to be determined more efficiently.
  • Finally, the inventors have surprisingly demonstrated that pores for sequencing nucleic acids can be improved by modifying at least one site that is capable of discriminating between different nucleotides. If a pore has too few sites that are capable of discriminating between different nucleotides, it can be improved by introducing one or more additional sites. If a pore has too many sites that are capable of discriminating between different nucleotides, it can be improved by removing one or more of the sites. Pores may also be improved by enhancing or reducing the ability of one or more sites to discriminate between different nucleotides.
  • Accordingly, the invention provides a method for sequencing a heteropolymeric target nucleic acid sequence, comprising:
    • (a) passing the target sequence through a transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time with at least one site in the pore that is capable of discriminating between different nucleotides; and
    • (b) measuring the current passing through the pore during each interaction and thereby determining the sequence of the target sequence.
  • The invention also provides:
      • use of a transmembrane protein pore comprising seven subunits comprising the sequence shown SEQ ID NO: 4 or a variant thereof for sequencing a target nucleic acid sequence;
      • a method for improving a transmembrane pore for sequencing a target nucleic acid sequence, comprising:
        • (a) modifying a transmembrane pore comprising one site that is capable of discriminating between different nucleotides; and
        • (b) determining whether or not the resulting pore comprises two or more distinct sites that are capable of discriminating between different nucleotides;
      • a method for improving a transmembrane pore for sequencing a target nucleic acid sequence, comprising:
        • (a) modifying a transmembrane pore comprising more than two distinct sites that are capable of discriminating between different nucleotides; and
        • (b) determining whether or not the resulting pore comprises two distinct sites that are capable of discriminating between different nucleotides;
      • a method for improving a transmembrane pore for sequencing a target nucleic acid sequence, comprising:
        • (a) modifying a transmembrane pore comprising more than one distinct site that is capable of discriminating between different nucleotides; and
        • (b) determining whether or not the resulting pore comprises one site that is capable of discriminating between different nucleotides;
      • a method for improving a transmembrane pore for sequencing a target nucleic acid sequence, comprising:
        • (a) modifying a transmembrane pore comprising two or more sites that are capable of discriminating between different nucleotides at one of the distinct sites; and
        • (b) determining whether or not the ability of one or more of the other distinct sites to discriminate between different nucleotides is altered; and
      • a pore improved using a method of the invention.
    DESCRIPTION OF THE FIGURES
  • FIG. 1 shows discrimination of immobilized DNA homopolymers by α-HL pores. (A) Schematic representation of a homopolymeric DNA oligonucleotide (blue circles, only the first 25 nucleotides of the 60 nucleotide long sequence are shown) immobilized inside an α-HL pore (grey, cross-section) through the use of a biotin (yellow)-streptavidin (red) linkage. The α-HL pore can be divided into two halves, each approximately 5 nm in length; an upper vestibule located between the cis entrance and the central constriction, and a fourteen-stranded, transmembrane, antiparallel β barrel, located between the central constriction and trans exit. The central constriction of 1.4 nm diameter is formed by the Glu-111, Lys-147 (shaded green) and Met-113 side chains contributed by all seven subunits. (B, C, left). Current levels for the WT and E111N/K147N pores when blocked with immobilized poly(dC) and poly(dA) oligonucleotides. (B, C, right). Typical event histograms displaying the residual current levels, caused by poly(dC) and poly(dA) oligonucleotide blockages, for the WT and E111N/K147N pores. The mean residual current levels for each oligonucleotide were determined by performing Gaussian fits to the data.
  • FIG. 2 shows the probing of DNA recognition by the α-HL pore with A5 oligonucleotides. (A) The five oligonucleotides (i-v) containing 5 consecutive adenine nucleotides (A5, red circles) at different positions (numbered from the 3′ biotin tag) in an otherwise poly(dC) strand (cytidine nucleotides are shown as blue circles). Only the first 25 of the 40 nucleotide-long sequences are shown. (B, left) The stepwise reduction from the open current value (pore not blocked with DNA) to a residual current (IRES) level of ˜37% when the E111N/K147N pore becomes blocked with a poly(dC) oligonucleotide. (B, right) The IRES levels when a pore is blocked with oligonucleotides of different sequence (oligo iv and poly(dC) are shown). (C) Residual current difference (ΔIRES) between the blockade by oligonucleotides i-v (panel A) and poly(dC)40 for WT (green bars) and E111N/K147N (orange bars) α-HL pores (ΔIRES=IRES i-v−IRES poly(dC)). The probable location of the adenine (A5) stretch of each oligonucleotide when immobilized with an α-HL pore is indicated (right).
  • FIG. 3 shows discrimination of a single adenine nucleotide by α-HL. The graph (middle) indicates the differences in residual current (ΔIRES values) between blockades caused by a poly(dC) oligonucleotide containing a single adenine nucleotide (the sequence of each oligonucleotide is shown to the left) and blockades caused by poly(dC)40 for WT (green) and E111N/K147N (orange) α-HL pores. R1, R2 and R3 represent the three proposed recognition sites in the α-HL nanopore. Their probable locations are indicated on the cross-section of the β barrel domain of the α-HL pore (right).
  • FIG. 4 shows recognition of all four DNA bases by the WT and E111N/K147N α-HL pores. Histograms of the residual current levels for WT (left) and E111N/K147N (right) pores are shown. Three sets of four poly(dC) oligonucleotides were used, with each set containing either a single G, A, T, or C nucleotide at a specific position. All experiments were conducted at least three times, and the results displayed in the figure are from a typical experiment. (A) The WT and E111N/K147N pores were interrogated with SEQ ID NOs: 35 to 38. Gaussian fits were performed for each peak, and the mean value of the residual current for each oligonucleotide (and the standard deviation) is displayed in the table below the histograms. (B) WT and E111N/K147N pores were interrogated with SEQ ID NOs: 39 to 42. (C) WT and E111N/K147N pores were interrogated with SEQ ID NOs: 43 to 46.
  • FIG. 5 shows probing the E111N/K147N α-HL pore for single nucleotide discrimination in a heteropolymeric oligonucleotide. Histogram (top) of residual current levels for E111N/K147N pores interrogated with four heteropolymeric DNA strands (center) that differ at only one position (large letter). Gaussian fits were performed for each peak, and the mean value of the residual current for each oligonucleotide (and the standard deviation) is displayed (bottom).
  • FIG. 6 shows typical current-voltage (IV) traces for WT (squares) and E111N/K147N (circles) α-HL pores, in 1 M KCl, 25 mM Tris.HCl, pH 8.0, containing 0.1 mM EDTA.
  • FIG. 7 shows the chemical structure of the biotin-TEG linker used to biotinylate the 3′ terminus of the DNA oligonucleotides. The structure was produced with ChemBioDraw Ultra 11.
  • FIG. 8 shows voltage dependence of IRES for WT pores threaded with either poly(dA) (squares) or poly(dC) (diamonds). The data for the graph was obtained by taking mean values from Gaussian fits to histograms of residual current levels for multiple blockades for each oligonucleotide, at various applied potentials. The standard deviation associated with the fitting of the Gaussians is shown.
  • FIG. 9 shows that two heads are better than one. a) A hypothetical nanopore sensor (green) with two reading heads, R1 and R2, which could in principle extract more sequence information from a DNA strand (red) than a device with a single reading head. b) To illustrate the idea, we assume that the four bases of DNA at reading head R1 produce 4 distinct current levels (widely dispersed as shown). Each of the levels is split into 4 additional levels (with a lesser dispersion, for the purpose of illustration) by the second reading head R2, yielding 16 current levels in total and providing redundant information about the DNA sequence.
  • FIG. 10 shows four-base discrimination at R1 and R2, by an engineered αHL nanopore. Histograms of residual current levels for E111N/K147N/M113Y (NNY) pores are shown (left), for a set of 4 oligonucleotides (right). B represents the 3′ biotin-TEG extension. Each experiment was conducted at least three times, and the results displayed in the figure are from a single experiment. When the oligonucleotides are driven into the α-HL pore the substituted nucleotides are positioned at R1 (red) or R2 (green). Gaussian fits were performed for each peak in the histograms.
  • FIG. 11 shows the predicted and experimental residual current level differences (ΔIRES) observed when NNY pores are interrogated with oligonucleotides which simultaneously probe R1 and R2. E111N/K147N/M113Y (NNY) pores were probed with 16 oligonucleotides, with the sequence 5′-CCCCCCCCCCCCCCCCCCCCCCCCCCNCCCCNCCCCCCCCB-3′, where N is A, T, G or C (N9N14, Table 5). A histogram displaying the residual current level differences for blockades by the various oligonucleotides, relative to the mean blockade produced by poly(dC) is shown. The current level for poly(dC) is set as zero. Blockades which have a residual current level lower than poly(dC) have negative ΔIRES values and blockades which have higher residual current levels than poly(dC) have positive ΔIRES values. The grey dashed lines show the predicted residual current levels, based on the ΔIRES data displayed in Table 5 (see Example 2). The peak denoted * arises from non-specific blockades and is not considered in the analysis.
    •  DESCRIPTION OF THE SEQUENCE LISTING
  • SEQ ID NO: 1 shows the polynucleotide sequence encoding one subunit of wild type α-hemolysin (α-HL).
  • SEQ ID NO: 2 shows the amino acid sequence of one subunit of wild type α-HL. Amino acids 2 to 6, 73 to 75, 207 to 209, 214 to 216 and 219 to 222 form α-helices. Amino acids 22 to 30, 35 to 44, 52 to 62, 67 to 71, 76 to 91, 98 to 103, 112 to 123, 137 to 148, 154 to 159, 165 to 172, 229 to 235, 243 to 261, 266 to 271, 285 to 286 and 291 to 293 form β-strands. All the other non-terminal amino acids, namely 7 to 21, 31 to 34, 45 to 51, 63 to 66, 72, 92 to 97, 104 to 111, 124 to 136, 149 to 153, 160 to 164, 173 to 206, 210 to 213, 217, 218, 223 to 228, 236 to 242, 262 to 265, 272 to 274 and 287 to 290 form loop regions. Amino acids 1 and 294 are terminal amino acids.
  • SEQ ID NO: 3 shows the polynucleotide sequence encoding one subunit of α-HL E111N/K147N.
  • SEQ ID NO: 4 shows the amino acid sequence of one subunit of α-HL E111N/K147N. The same amino acids that form α-helices, β-strands and loop regions in wild type α-HL form the corresponding regions in this subunit.
  • SEQ ID NO: 5 shows the codon optimised polynucleotide sequence derived from the sbcB gene from E. coli. It encodes the exonuclease I enzyme (EcoExo I) from E. coli.
  • SEQ ID NO: 6 shows the amino acid sequence of exonuclease I enzyme (EcoExo I) from E. coli. This enzyme performs processive digestion of 5′ monophosphate nucleosides from single stranded DNA (ssDNA) in a 3′-5′ direction. Amino acids 60 to 68, 70 to 78, 80 to 93, 107 to 119, 124 to 128, 137 to 148, 165 to 172, 182 to 211, 213 to 221, 234 to 241, 268 to 286, 313 to 324, 326 to 352, 362 to 370, 373 to 391, 401 to 454 and 457 to 475 form α-helices. Amino acids 10 to 18, 28 to 26, 47 to 50, 97 to 101, 133 to 136, 229 to 232, 243 to 251, 258 to 263, 298 to 302 and 308 to 311 form β-strands. All the other non-terminal amino acids, 19 to 27, 37 to 46, 51 to 59, 69, 79, 94 to 96102 to 106, 120 to 123, 129 to 132, 149 to 164, 173 to 181, 212, 222 to 228 233, 242, 252 to 257, 264 to 267, 287 to 297, 303 to 307, 312, 325, 353 to 361, 371, 372, 392 to 400, 455 and 456, form loops. Amino acids 1 to 9 are terminal amino acids. The overall fold of the enzyme is such that three regions combine to form a molecule with the appearance of the letter C, although residues 355-358, disordered in the crystal structure, effectively convert this C into an O-like shape. The amino terminus (1-206) forms the exonuclease domain and has homology to the DnaQ superfamily, the following residues (202-354) form an SH3-like domain and the carboxyl domain (359-475) extends the exonuclease domain to form the C-like shape of the molecule. Four acidic residues of EcoExo I are conserved with the active site residues of the DnaQ superfamily (corresponding to D15, E17, D108 and D186). It is suggested a single metal ion is bound by residues D15 and 108. Hydrolysis of DNA is likely catalyzed by attack of the scissile phosphate with an activated water molecule, with H181 being the catalytic residue and aligning the nucleotide substrate.
  • SEQ ID NO: 7 shows the codon optimised polynucleotide sequence derived from the xthA gene from E. coli. It encodes the exonuclease III enzyme from E. coli.
  • SEQ ID NO: 8 shows the amino acid sequence of the exonuclease III enzyme from E. coli. This enzyme performs distributive digestion of 5′ monophosphate nucleosides from one strand of double stranded DNA (dsDNA) in a 3′-5′ direction. Enzyme initiation on a strand requires a 5′ overhang of approximately 4 nucleotides. Amino acids 11 to 13, 15 to 25, 39 to 41, 44 to 49, 85 to 89, 121 to 139, 158 to 160, 165 to 174, 181 to 194, 198 to 202, 219 to 222, 235 to 240 and 248 to 252 form α-helices. Amino acids 2 to 7, 29 to 33, 53 to 57, 65 to 70, 75 to 78, 91 to 98, 101 to 109, 146 to 151, 195 to 197, 229 to 234 and 241 to 246 form β-strands. All the other non-terminal amino acids, 8 to 10, 26 to 28, 34 to 38, 42, 43, 50 to 52, 58 to 64, 71 to 74, 79 to 84, 90, 99, 100, 110 to 120, 140 to 145, 152 to 157, 161 to 164, 175 to 180, 203 to 218, 223 to 228, 247 and 253 to 261, form loops. Amino acids 1, 267 and 268 are terminal amino acids. The enzyme active site is formed by loop regions connecting β1-α1, β3-β4, β5-β6, βIII-αI, βIV-αII and βV-βVI (consisting of amino acids 8-10, 58-64, 90, 110-120, 152-164, 175-180, 223-228 and 253-261 respectively). A single divalent metal ion is bound at residue E34 and aids nucleophilic attack on the phosphodiester bond by the D229 and H259 histidine-aspartate catalytic pair.
  • SEQ ID NO: 9 shows the codon optimised polynucleotide sequence derived from the recJ gene from T. thermophilus. It encodes the RecJ enzyme from T. thermophilus (TthRecJ-cd).
  • SEQ ID NO: 10 shows the amino acid sequence of the RecJ enzyme from T. thermophilus (TthRecJ-cd). This enzyme performs processive digestion of 5′ monophosphate nucleosides from ssDNA in a 5′-3′ direction. Enzyme initiation on a strand requires at least 4 nucleotides. Amino acids 19 to 33, 44 to 61, 80 to 89, 103 to 111, 136 to 140, 148 to 163, 169 to 183, 189 to 202, 207 to 217, 223 to 240, 242 to 252, 254 to 287, 302 to 318, 338 to 350 and 365 to 382 form α-helices. Amino acids 36 to 40, 64 to 68, 93 to 96, 116 to 120, 133 to 135, 294 to 297, 321 to 325, 328 to 332, 352 to 355 and 359 to 363 form β-strands. All the other non-terminal amino acids, 34, 35, 41 to 43, 62, 63, 69 to 79, 90 to 92, 97 to 102, 112 to 115, 121 to 132, 141 to 147, 164 to 168, 184 to 188203 to 206, 218 to 222, 241, 253, 288 to 293, 298 to 301, 319, 320, 326, 327, 333 to 337, 351 to 358 and 364, form loops. Amino acids 1 to 18 and 383 to 425 are terminal amino acids. The crystal structure has only been resolved for the core domain of RecJ from Thermus thermophilus (residues 40-463). To ensure initiation of translation and in vivo expression of the RecJ core domain a methionine residue was added at its amino terminus, this is absent from the crystal structure information. The resolved structure shows two domains, an amino (2-253) and a carboxyl (288-463) region, connected by a long α-helix (254-287). The catalytic residues (D46, D98, H122, and D183) co-ordinate a single divalent metal ion for nucleophilic attack on the phosphodiester bond. D46 and H120 proposed to be the catalytic pair; however, mutation of any of these conserved residues in the E. coli RecJ was shown to abolish activity.
  • SEQ ID NO: 11 shows the codon optimised polynucleotide sequence derived from the bacteriphage lambda exo (redX) gene. It encodes the bacteriophage lambda exonuclease.
  • SEQ ID NO: 12 shows the amino acid sequence of the bacteriophage lambda exonuclease. The sequence is one of three identical subunits that assemble into a trimer. The enzyme performs highly processive digestion of nucleotides from one strand of dsDNA, in a 3′-5′ direction. Enzyme initiation on a strand preferentially requires a 5′ overhang of approximately 4 nucleotides with a 5′ phosphate. Amino acids 3 to 10, 14 to 16, 22 to 26, 34 to 40, 52 to 67, 75 to 95, 135 to 149, 152 to 165 and 193 to 216 form α-helices. Amino acids 100 to 101, 106 to 107, 114 to 116, 120 to 122, 127 to 131, 169 to 175 and 184 to 190 form β-strands. All the other non-terminal amino acids, 11 to 13, 17 to 21, 27 to 33, 41 to 51, 68 to 74, 96 to 99, 102 to 105, 108 to 113, 117 to 119, 123 to 126, 132 to 134, 150 to 151, 166 to 168, 176 to 183, 191 to 192, 217 to 222, form loops. Amino acids 1, 2 and 226 are terminal amino acids. Lambda exonuclease is a homo-trimer that forms a toroid with a tapered channel through the middle, apparently large enough for dsDNA to enter at one end and only ssDNA to exit at the other. The catalytic residues are undetermined but a single divalent metal ion appears bound at each subunit by residues D119, E129 and L130.
  • SEQ ID NOs: 13 to 66 show the oligonucleotides used in the Examples. When used, all oligonucleotides had a 3′ biotin-TEG tag and linker (FIG. 7).
    • DETAILED DESCRIPTION OF THE INVENTION
  • It is to be understood that different applications of the disclosed products and methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.
  • In addition as used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a nucleotide” includes “nucleotides”, reference to “a pore” includes two or more such pores, reference to “an enzyme” includes two or more such enzymes, and the like.
  • All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
    • Method of Sequencing Nucleic Acids
  • The invention provides a method for sequencing a heteropolymeric target nucleic acid sequence. The method comprises (a) passing the target sequence through a transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time with at least one site in the pore that is capable of discriminating between different nucleotides and (b) measuring the current passing through the pore during each interaction and thereby determining the sequence of the target sequence. The nucleotides are identified one at a time sequentially as they interact with at least one site in the pore that is capable of discriminating between different nucleotides. Hence, the method involves stochastic sensing of a proportion of the nucleotides in a target nucleic acid sequence as the nucleotides pass through the barrel or channel of a transmembrane pore in a successive manner in order to sequence the target sequence.
  • Pores comprising two or more distinct sites that are capable of discriminating between different nucleotides are particularly suited to this method. In order to effectively sequence the nucleic acid, it is important to ensure that the nucleotides in the target sequence are identified in a successive manner. As discussed in more detail below, presence of two or more distinct sites that are capable of discriminating between different nucleotides ensures that the nucleotides in the target sequence are read at least twice. This improves the accuracy of the sequencing.
  • The method may be carried out using any suitable membrane/transmembrane pore system in which a transmembrane pore is inserted into a membrane. The method is typically carried out using (i) an artificial membrane comprising a transmembrane pore, (ii) an isolated, naturally occurring membrane comprising a transmembrane pore, or (iii) a cell expressing a transmembrane pore. The method is preferably carried out using an artificial membrane. The membrane may comprise other transmembrane and/or intramembrane proteins as well as other molecules in addition to the transmembrane pore used for sequencing.
  • The membrane forms a barrier to the flow of ions, nucleotides and nucleic acids. The membrane is preferably a lipid bilayer. Lipid bilayers suitable for use in accordance with the invention can be made using methods known in the art. For example, lipid bilayer membranes can be formed using the method of Montal and Mueller (1972). Lipid bilayers can also be formed using the method described in International Application No. PCT/GB08/000563 and PCT/GB07/002856.
  • The method of the invention may be carried out using lipid bilayers formed from any membrane lipid including, but not limited to, phospholipids, glycolipids, cholesterol and mixtures thereof. Any of the lipids described in International Application No. PCT/GB08/000563 may be used.
  • Methods are known in the art for inserting pores into membranes, such as lipid bilayers. Some of those methods are discussed above.
  • The method is typically carried out in vitro.
    • Heteropolymeric Target Nucleic Acid Sequence
  • The whole or only part of the target sequence may be sequenced using the method of the invention. The target sequence can be any length. For example, the target sequence can be at least 10, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 400 or at least 500 nucleotides in length.
  • The target sequence may form part of a larger nucleic acid sequence. For instance, the target sequence may correspond to a section, such as half, of a larger nucleic acid sequence. The other part(s) of the sequence outside the target sequence do not have to be sequenced in accordance with the invention.
  • The target sequence used in the method of the invention is an intact sequence. In other words, the target is not cleaved or digested to form shorter nucleic acid sequences or individual nucleotides before it is sequenced in accordance with the invention.
  • A nucleic acid is a macromolecule comprising two or more nucleotides. The nucleic acid bound by the protein may comprise any combination of any nucleotides. The nucleotides can be naturally occurring or artificial. A nucleotide typically contains a nucleobase, a sugar and at least one phosphate group. The nucleobase is typically heterocyclic. Nucleobases include, but are not limited to, purines and pyrimidines and more specifically adenine, guanine, thymine, uracil and cytosine. The nucleobase may also be 5-methylcytosine or hydroxymethyl-cytosine. The sugar is typically a pentose sugar. Nucleotide sugars include, but are not limited to, ribose and deoxyribose. The nucleotide is typically a ribonucleotide or deoxyribonucleotide. The nucleotide typically contains a monophosphate, diphosphate or triphosphate. Phosphates may be attached on the 5′ or 3′ side of a nucleotide.
  • Nucleotides include, but are not limited to, adenosine monophosphate (AMP), adenosine diphosphate (ADP), adenosine triphosphate (ATP), guanosine monophosphate (GMP), guanosine diphosphate (GDP), guanosine triphosphate (GTP), thymidine monophosphate (TMP), thymidine diphosphate (TDP), thymidine triphosphate (TTP), uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), deoxyadenosine monophosphate (dAMP), deoxyadenosine diphosphate (dADP), deoxyadenosine triphosphate (dATP), deoxyguanosine monophosphate (dGMP), deoxyguanosine diphosphate (dGDP), deoxyguanosine triphosphate (dGTP), deoxythymidine monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxythymidine triphosphate (dTTP), deoxyuridine monophosphate (dUMP), deoxyuridine diphosphate (dUDP), deoxyuridine triphosphate (dUTP), deoxycytidine monophosphate (dCMP), deoxycytidine diphosphate (dCDP) and deoxycytidine triphosphate (dCTP). The nucleotides are preferably selected from AMP, TMP, GMP, CMP, UMP, dAMP, dTMP, dGMP or dCMP.
  • The nucleotides are typically bonded together in the target sequence via phosphodiester bonds.
  • The target nucleic acid can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The target nucleic acid may be any synthetic nucleic acid known in the art, such as peptide nucleic acid (PNA), glycerol nucleic acid (GNA), threose nucleic acid (TNA), locked nucleic acid (LNA) or other synthetic polymers with nucleotide side chains.
  • The target sequence can be single stranded or double stranded. If the target sequence is double stranded, the method preferably involves passing only one strand of the target sequence through the pore. The barrels or channels of many pores, especially transmembrane protein pores, are typically not large enough to allow a double stranded nucleic acid to pass through. Method for separating one strand from a double stranded target sequence and passing it through the pore are discussed in more detail below.
  • A heteropolymeric target nucleic sequence is one which comprises two or more, such as 3, 4, 5, 6 or more, different nucleotides. The target sequence preferably comprises three or more different nucleotides. The target sequence more preferably comprises four different nucleotides. The four different nucleotides are preferably the four different nucleotides that make up DNA or RNA. In particular, the four different nucleotides preferably independently comprise the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil and (d) cytosine. The target sequence even more preferably comprises five different nucleotides. The five different nucleotides preferably independently comprise the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil, (d) cytosine and (e) 5-methylcytosine.
  • The method is typically carried out using a target sequence whose sequence is unknown. Alternatively, the method may be carried out using a target sequence whose sequence is known in whole or in part or can be predicted in whole or in part.
  • The target sequence can be naturally occurring or artificial. For instance, the method may be used to verify the sequence of a manufactured oligonucleotide. The method is typically carried out using a target sequence obtained from or extracted from any organism or microorganism. The organism or microorganism is typically prokaryotic, eukaryotic or an archon and typically belongs to one the five kingdoms: plantae, animalia, fungi, monera and protista. The method may be carried out on a target sequence obtained from or extracted from any virus. Typically, the target sequence is human in origin, but alternatively it may be from another mammal animal such as from commercially farmed animals such as horses, cattle, sheep or pigs or may alternatively be pets such as cats or dogs.
  • The target sequence is typically processed prior to undergoing the method, for example by amplification, centrifugation or by passage through a membrane that filters out unwanted molecules or cells, such as red blood cells. The target sequence may be used immediately upon being taken. The target sequence may also be typically stored prior to undergoing the method, preferably below −70° C.
    • Passing the Target Sequence Through the Pore
  • The method of the invention involves passing the target sequence through the pore in a controlled and stepwise manner. The target sequence is typically pushed or pulled through the pore. Any method for passing the target sequence through the pore may be used. The target sequence may be passed through the pore cis to trans or trans to cis. The target sequence may be passed through the pore either with or against an applied potential.
  • The target sequence is preferably passed through the pore using a nucleic acid handling enzyme. The majority of nucleic acid handling enzymes are suitable for use in this application provided they hydrolyse, polymerise or process nucleic acids.
  • The enzyme may handle single stranded or double stranded nucleic acid. If a transmembrane protein pore is used, the enzyme preferably passes a single strand of the target sequence through the pore. If the target sequence is double stranded, this may be achieved by using an enzyme that separates the two strands of double stranded nucleic acid. For instance, exonucleases that act progressively or processively on double stranded nucleic acids can be used on the cis side of the pore to feed the remaining single strand through under an applied potential or from the trans side under a reverse potential. Likewise, a helicase that unwinds double stranded nucleic acids can also be used in a similar manner.
  • The method preferably involves contacting the target sequence with a nucleic acid handling enzyme so that the target sequence is passed through a pore at a rate that allows a proportion of the nucleotides in the target sequence to interact one at a time with at least one site in the pore that is capable of discriminating between different nucleotides. Methods for doing this are well known in the art. The rate at which the nucleic acid handling enzyme functions can be altered by mutation compared to a wild type enzyme. For example, variant enzyme with a reduced or improved optimal rate of activity may be used in accordance with the invention. A suitable rate of activity of a nucleic acid handling enzyme in the method of the invention involves handling of from 0.5 to 1000 nucleotides per second, from 0.6 to 500 nucleotides per second, 0.7 to 200 nucleotides per second, from 0.8 to 100 nucleotides per second, from 0.9 to 50 nucleotides per second or 1 to 20 or 10 nucleotides per second. The rate is preferably 1, 10, 100, 500 or 1000 nucleotides per second.
  • The enzyme also preferably retains at least partial activity at temperatures from 0° C. to 100° C., such as from 10° C. to 60° C. or at room temperature. This allows the sequencing of the target sequence at a variety of temperatures, including room temperature.
  • A nucleic acid handling enzyme is a polypeptide that is capable of interacting with and modifying at least one property of a nucleic acid. The enzyme preferably modifies the nucleic acid by orienting it or moving it to a specific position.
  • The nucleic acid handling enzyme is preferably derived from a nucleolytic enzyme or nuclease. The nucleic acid handling enzyme used in the construct of the enzyme is more preferably derived from a member of any of the Enzyme Classification (EC) groups 3.1.11, 3.1.13, 3.1.14, 3.1.15, 3.1.16, 3.1.21, 3.1.22, 3.1.25, 3.1.26, 3.1.27, 3.1.30 and 3.1.31. The nucleic acid handling enzyme is more preferably derived from any one of the following enzymes:
      • 3. 1.11.—Exodeoxyribonucleases producing 5′-phosphomonoesters.
        • 3.1.11.1 Exodeoxyribonuclease I.
        • 3.1.11.2 Exodeoxyribonuclease III.
        • 3.1.11.3 Exodeoxyribonuclease (lambda-induced).
        • 3.1.11.4 Exodeoxyribonuelease (phage SP3-induced).
        • 3.1.11.5 Exodeoxyribonuclease V.
        • 3.1.11.6 Exodeoxyribonuclease VII.
      • 3. 1.13.—Exoribonucleases producing 5′-phosphomonoesters.
        • 3.1.13.1 Exoribonuclease
        • 3.1.13.2 Exoribonuclease H.
        • 3.1.13.3 Oligonucleotidase.
        • 3.1.13.4 Poly(A)-specific ribonuclease.
        • 3.1.13.5 Ribonuclease D.
      • 3. 1.14.—Exoribonucleases producing 3′-phosphomonoesters.
        • 3.1.14.1 Yeast ribonuclease.
      • 3. 1.15.—Exonucleases active with either ribo- or deoxyribonucleic acid producing 5′ phosphomonoesters
        • 3.1.15.1 Venom exonuclease.
      • 3. 1.16.—Exonucleases active with either ribo- or deoxyribonucleic acid producing 3′ phosphomonoesters
        • 3.1.16.1 Spleen exonuclease.
      • 3. 1.21.—Endodeoxyribonucleases producing 5′-phosphomonoesters.
        • 3.1.21.1 Deoxyribonuclease I.
        • 3.1.21.2 Deoxyribonuclease IV (phage-T(4)-induced).
        • 3.1.21.3 Type I site-specific deoxyribonuclease.
        • 3.1.21.4 Type II site-specific deoxyribonuclease.
        • 3.1.21.5 Type III site-specific deoxyribonuclease.
        • 3.1.21.6 CC-preferring endodeoxyribonuclease.
        • 3.1.21.7 Deoxyribonuclease V.
      • 3. 1.22.—Endodeoxyribonucleases producing other than 5′-phosphomonoesters.
        • 3.1.22.1 Deoxyribonuclease II.
        • 3.1.22.2 Aspergillus deoxyribonuclease K(1).
        • 3.1.22.3 Transferred entry: 3.1.21.7.
        • 3.1.22.4 Crossover junction endodeoxyribonuclease.
        • 3.1.22.5 Deoxyribonuclease X.
      • 3. 1.25.—Site-specific endodeoxyribonucleases specific for altered bases.
        • 3.1.25.1 Deoxyribonuclease (pyrimidine dimer).
        • 3.1.25.2 Transferred entry: 4.2.99.18.
      • 3. 1.26.—Endoribonucleases producing 5′-phosphomonoesters.
        • 3.1.26.1 Physarum polycephalum ribonuclease.
        • 3.1.26.2 Ribonuclease alpha.
        • 3.1.26.3 Ribonuclease III.
        • 3.1.26.4 Ribonuclease H.
        • 3.1.26.5 Ribonuclease P.
        • 3.1.26.6 Ribonuclease IV.
        • 3.1.26.7 Ribonuclease P4.
        • 3.1.26.8 Ribonuclease M5.
        • 3.1.26.9 Ribonuclease (poly-(U)-specific).
        • 3.1.26.10 Ribonuclease IX.
        • 3.1.26.11 Ribonuclease Z.
      • 3. 1.27.—Endoribonucleases producing other than 5′-phosphomonoesters.
        • 3.1.27.1 Ribonuclease T(2).
        • 3.1.27.2 Bacillus subtilis ribonuclease.
        • 3.1.27.3 Ribonuclease T(1).
        • 3.1.27.4 Ribonuclease U(2).
        • 3.1.27.5 Pancreatic ribonuclease.
        • 3.1.27.6 Enterobacter ribonuclease.
        • 3.1.27.7 Ribonuclease F.
        • 3.1.27.8 Ribonuclease V.
        • 3.1.27.9 tRNA-intron endonuclease.
        • 3.1.27.10 rRNA endonuclease.
      • 3. 1.30.—Endoribonucleases active with either ribo- or deoxyribonucleic producing 5′ phosphomonoesters
        • 3.1.30.1 Aspergillus nuclease S(1).
        • 3.1.30.2 Serratia marcescens nuclease.
      • 3. 1.31.—Endoribonucleases active with either ribo- or deoxyribonucleic producing 3′ phosphomonoesters
        • 3.1.31.1 Micrococcal nuclease.
  • The enzyme is most preferably derived from an exonuclease, such as an exodeoxyribonuclease, which cleaves nucleic acids to form individual nucleotides. The advantages of exodeoxyribonucleases are that they are active on both single stranded and double stranded nucleic acids and hydrolyse bases either in the 5′-3′ or 3′-5′ direction.
  • An individual nucleotide is a single nucleotide. The nucleotide may be any of those discussed above. An individual nucleotide is one which is not bound to another nucleotide or nucleic acid by any bond, such as a phosphodiester bond. A phosphodiester bond involves one of the phosphate groups of a nucleotide being bound to the sugar group of another nucleotide. An individual nucleotide is typically one which is not bound in any manner to another nucleic acid sequence of at least 5, at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000 or at least 5000 nucleotides.
  • Preferred enzymes for use in the invention include exonuclease I from E. coli (SEQ ID NO: 6), exonuclease III enzyme from E. coli (SEQ ID NO: 8), RecJ from T. thermophilus (SEQ ID NO: 10) and bacteriophage lambda exonuclease (SEQ ID NO: 12) and variants thereof. Three identical subunits of SEQ ID NO: 12 interact to form a trimer exonuclease. The enzyme is most preferably based on exonuclease I from E. coli (SEQ ID NO: 6).
  • The nucleic acid handling enzyme preferably comprises any of the sequences shown in SEQ ID NOs: 6, 8, 10 and 12 or a variant thereof. A variant of SEQ ID NO: 6, 8, 10 or 12 is an enzyme that has an amino acid sequence which varies from that of SEQ ID NO: 6, 8, 10 or 12 and which retains nucleic acid handling ability. The ability of a variant to handle nucleic acids can be assayed using any method known in the art. For instance, the ability of a variant to handle nucleic acids can be assayed by contacting the enzyme with a nucleic acid and assaying its ability to orient it or move it to a specific position.
  • The variant may include modifications that facilitate handling of the nucleic acid and/or facilitate its activity at high salt concentrations and/or room temperature.
  • The enzyme may be a naturally occurring variant which is expressed by an organism, for instance by an E. coli bacterium. Variants also include non-naturally occurring variants produced by recombinant technology. Over the entire length of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity. More preferably, the variant polypeptide may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 over the entire sequence. There may be at least 80%, for example at least 85%, 90% or 95%, amino acid identity over a stretch of 200 or more, for example 230, 250, 270 or 280 or more, contiguous amino acids (“hard homology”).
  • Standard methods in the art may be used to determine homology. For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology, for example used on its default settings (Devereux et al (1984) Nucleic Acids Research 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (such as identifying equivalent residues or corresponding sequences (typically on their default settings)), for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S. F et al (1990) J Mol Biol 215:403-10.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSP's containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.
  • The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 in addition to those discussed above, for example up to 1, 2, 3, 4, 5, 10, 20 or 30 substitutions. Conservative substitutions may be made, for example, according to Table 1 below.
  • TABLE 1
    Conservative substitutions
    Amino acids in the same block in the second column
    and preferably in the same line in the
    third column may be substituted for each other.
    NON-AROMATIC Non-polar G A P
    I L V
    Polar-uncharged C S T M
    N Q
    Polar-charged D E
    H K R
    AROMATIC H F W Y
  • One or more amino acid residues of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.
  • Variants may be fragments of SEQ ID NO: 6, 8, 10 or 12. Such fragments retain nucleic acid handling activity. Fragments may be at least 50, 100, 200 or 250 amino acids in length. A fragment preferably comprises the nucleic acid handling domain of SEQ ID NO: 6, 8, 10 or 12.
  • One or more amino acids may be alternatively or additionally added to the polypeptides described above. An extension may be provided at the amino terminus or carboxy terminus of the amino acid sequence of SEQ ID NO: 6, 8, 10 or 12 or a variant or fragment thereof. The extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids. A carrier protein may be fused to a subunit or variant.
  • As discussed above, a variant of SEQ ID NO: 6, 8, 10 or 12 is a protein that has an amino acid sequence which varies from that of SEQ ID NO: 6, 8, 10 or 12 and which retains its ability to handle nucleic acids. A variant typically contains the regions of SEQ ID NO: 6, 8, 10 or 12 that are responsible for handling nucleic acids. The catalytic domains of SEQ ID NOs: 6, 8, 10 or 12 are discussed above in the description of the sequence listing. A variant of SEQ ID NO: 6, 8, 10 or 12 preferably comprises the relevant catalytic domain. A variant SEQ ID NO: 6, 8, 10 or 12 typically includes one or more modifications, such as substitutions, additions or deletions, outside the relevant catalytic domain.
  • The variant may be modified for example by the addition of histidine or aspartic acid residues to assist its identification or purification or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence.
  • Other preferred enzymes that are capable of passing the target nucleic acid sequence through the pore include polymerases and helicases. The nucleic acid handling enzyme can be derived from any of these types of enzymes. The polymerase is preferably a member of any of the Enzyme Classification (EC) groups 2.7.7.6, 2.7.7.7, 2.7.7.19, 2.7.7.48 and 2.7.7.49. The polymerase is preferably a DNA-dependent DNA polymerase, an RNA-dependent DNA polymerase, a DNA-dependent RNA polymerase or an RNA-dependent RNA polymerase. The helicase is preferably based on a member of any of the Enzyme Classification (EC) groups 3.6.1.- and 2.7.7.-. The helicase is preferably an ATP-dependent DNA helicase (EC group 3.6.1.8), an ATP-dependent RNA helicase (EC group 3.6.1.8) or an ATP-independent RNA helicase.
  • The nucleic acid handling enzyme may be labelled with a revealing label. The revealing label may be any suitable label which allows the enzyme to be detected. Suitable labels include, but are not limited to, fluorescent molecules, radioisotopes, e.g. 125I, 35S, 14C, enzymes, antibodies, antigens, polynucleotides and ligands such as biotin.
  • The nucleic acid handling enzyme may be isolated from an enzyme producing organism, such as E. coli, T. thermophilus or bacteriophage, or made synthetically or by recombinant means. For example, the nucleic acid handling enzyme may be synthesized by in vitro translation and transcription. The amino acid sequence of the nucleic acid handling enzyme may be modified to include non-naturally occurring amino acids or to increase the stability of the protein. When the nucleic acid handling enzyme is produced by synthetic means, such amino acids may be introduced during production. The nucleic acid handling enzyme may also be altered following either synthetic or recombinant production.
  • The nucleic acid handling enzyme may also be produced using D-amino acids. For instance, the nucleic acid handling enzyme may comprise a mixture of L-amino acids and D-amino acids. This is conventional in the art for producing such proteins or peptides.
  • The nucleic acid handling enzyme may also contain other non-specific chemical modifications as long as they do not interfere with its ability to handle nucleic acids or attach to the pore. A number of non-specific side chain modifications are known in the art and may be made to the side chains of the pores. Such modifications include, for example, reductive alkylation of amino acids by reaction with an aldehyde followed by reduction with NaBH4, amidination with methylacetimidate or acylation with acetic anhydride.
  • The nucleic acid handling enzyme can be produced using standard methods known in the art. Polynucleotide sequences encoding a nucleic acid handling enzyme may be isolated and replicated using standard methods in the art. Such sequences are discussed in more detail below. Polynucleotide sequences encoding a nucleic acid handling enzyme may be expressed in a bacterial host cell using standard techniques in the art. The nucleic acid handling enzyme may be produced in a cell by in situ expression of the polypeptide from a recombinant expression vector. The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.
  • Polynucleotide sequences may be isolated and replicated using standard methods in the art. Chromosomal DNA may be extracted from an enzyme producing organism, such as E. coli, T. thermophilus or bacteriophage. The gene encoding the enzyme may be amplified using PCR involving specific primers. The amplified sequences may then be incorporated into a recombinant replicable vector such as a cloning vector. The vector may be used to replicate the polynucleotide in a compatible host cell. Thus polynucleotide sequences encoding the enzyme may be made by introducing a polynucleotide encoding the enzyme into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells for cloning of polynucleotides are known in the art and described in more detail below.
  • The polynucleotide sequence may be cloned into suitable expression vector. In an expression vector, the polynucleotide sequence encoding a construct is typically operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell. Such expression vectors can be used to express a construct.
  • The term “operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. Multiple copies of the same or different polynucleotide may be introduced into the vector.
  • The expression vector may then be introduced into a suitable host cell. Thus, a construct can be produced by inserting a polynucleotide sequence encoding a construct into an expression vector, introducing the vector into a compatible bacterial host cell, and growing the host cell under conditions which bring about expression of the polynucleotide sequence. The recombinantly-expressed construct may self-assemble into a pore in the host cell membrane. Alternatively, the recombinant construct produced in this manner may be isolated from the host cell and inserted into another membrane. When producing an oligomeric pore comprising a construct of the invention and at least one different subunit, the construct and different subunits may be expressed separately in different host cells as described above, removed from the host cells and assembled into a pore in a separate membrane, such as a rabbit cell membrane.
  • The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide sequence and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene. Promoters and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. A T7, trc, lac, ara or λL promoter is typically used. The host cell typically expresses the construct at a high level. Host cells transformed with a polynucleotide sequence encoding a construct will be chosen to be compatible with the expression vector used to transform the cell. The host cell is typically bacterial and preferably E. coli. Any cell with a λ DE3 lysogen, for example C41 (DE3), BL21 (DE3), JM109 (DE3), B834 (DE3), TUNER, Origami and Origami B, can express a vector comprising the T7 promoter.
  • A nucleic acid handling enzyme may be produced in large scale following purification by any protein liquid chromatography system from pore producing organisms or after recombinant expression as described below. Typical protein liquid chromatography systems include FPLC, AKTA systems, the Bio-Cad system, the Bio-Rad BioLogic system and the Gilson HPLC system.
    • Interaction Between the Nucleotides and Pore
  • The target sequence is passed through the transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time (i.e. sequentially) with at least one site in the pore that is capable of discriminating between different nucleotides. The sequence of the target sequence may be determined by identifying at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% of the nucleotides in the target sequence. Preferably, all of the nucleotides in the target sequence interact with the at least one site and are identified.
  • The target sequence may be contacted with the pore on either side of the membrane. The target sequence may be introduced to the pore on either side of the membrane. If a nucleic acid handling enzyme is used as discussed above, the target sequence is typically contacted with the side of the membrane on which the enzyme is present. This allows the enzyme to handle the nucleic acid during the method.
  • A proportion of the nucleotides in the target nucleic acid sequence interacts with at least one site in the pore that is capable of discriminating between different nucleotides as the sequence passes across the membrane through the barrel or channel of the pore. As discussed in more detail below, a proportion of the nucleotides preferably interacts with two or more distinct sites that are capable of discriminating between different nucleotides.
  • The nucleotides interact with the site(s) capable of discriminating different nucleotides one at a time in a sequential manner. This means that at any one time a site that is capable of discriminating between different nucleotides interacts with only one nucleotide in the target sequence. If the pore comprises two or more distinct sites that are capable of discriminating between different nucleotides, at any one time each of the distinct sites will interact with a different nucleotide in the target sequence. For instance, if the pore comprises two distinct sites that are capable of discriminating between different nucleotides, at any one time the distinct sites will interact with two different nucleotides in the target sequence.
  • The target sequence is passed through the pore one nucleotide at a time and each nucleotide is identified sequentially. Hence, at one time point, each of the distinct sites that are capable of discriminating between different nucleotides interacts with a different nucleotide in the target sequence. At the next time point, the target sequence is passed one nucleotide further through the pore and each of the distinct sites that are capable of discriminating between different nucleotides interacts with the a nucleotide that is adjacent to the nucleotide with which it interacted at the previous time point. If there are two or more distinct sites in the pore, a selected nucleotide in the target sequence will interact with each dintinct site in a sequential manner as it passed through the pore.
  • The current passing through the pore is measured during each interaction and this allows the identity of the nucleotide interacting with the site(s) to be determined. Identification of a proportion of the nucleotides in the target sequence in a successive manner allows the sequence of the target sequence to be determined.
  • The nucleotides may interact with the pore in any manner and at any site. The nucleotides preferably reversibly bind to the sites(s) in the pore capable of discriminating between different nucleotides. The nucleotides most preferably reversibly bind to the site(s) in the pore in the pore as they pass through the pore across the membrane. The nucleotides can reversibly bind to the site(s) via or in conjunction with an adaptor that facilitates an interaction between the pore and the nucleotide. Preferably however, the pore does not contain a molecular adaptor that facilitates an interaction between the pore and nucleotides.
  • During the interaction between the nucleotide and a site capable of discriminating between different nucleotides, the nucleotide affects the current flowing through the pore in a manner specific for that nucleotide. For example, a particular nucleotide will reduce the current flowing through the pore to a particular extent. In other words, the current flowing through the pore is distinctive for the interaction between a particular nucleotide and a site capable of discriminating between different nucleotides. Hence, when different nucleotides move through the pore and interact with the pore in a successive manner, the current flowing through the pore changes for each interaction.
  • If two or more distinct sites that are capable of discriminating between different nucleotides are present in the pore, the overall current passing through the pore at any one time will be influenced by the interaction between each site and the nucleotide located each site. The presence of multiple sites that are capable of discriminating between different nucleotides increases the number of current levels seen and therefore provides more sequence information. For instance, a pore having a single site may produce four current levels for four different nucleotides (named A, B, C and D for illustrative purposes). In contrast, a pore having two sites may produce sixteen levels: four current levels when A is at site 1 and A, B, C or D is at site 2; four different current levels when B is at site 1 and A, B, C or D is at site 2; four different current levels when C is at site 1 and A, B, C or D is at site 2; and four different current levels when D is at site 1 and A, B, C or D is at site 2.
  • The dwell time of a selected nucleotide at a site that is capable of discriminating between different nucleotides will be determined by the way in which the target sequence is passed through the pore. For instance, if a nucleic acid handling enzyme is used, the dwell time of a selected nucleotide at a site that is capable of discriminating between different nucleotides will be determined by the rate at which the enzyme pushes or pulls the target sequence through the pore.
  • Control experiments may be carried out to determine the effect a particular nucleic acid sequence has on the current flowing through the pore. Results from carrying out the method of the invention on a test sample can then be compared with those derived from such a control experiment in order to identify the target sequence.
    • Site(s) Capable of Discriminating Between Different Nucleotides
  • A site in the pore is capable of discriminating between different nucleotides if it can discriminate between at least two, such as 3 or 4, different nucleotides. The nucleotides may be any of those discussed above. Each site in the pore is preferably capable of discriminating between four different nucleotides. Each site is most preferably capable of discriminating between the four nucleotides of DNA or RNA. In particular, each site is preferably capable of discriminating between four different nucleotides independently comprising the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil and (d) cytosine. Each site is more preferably capable of discriminating between five different nucleotides independently comprising the nucleobases (a) adenine, (b) guanine, (c) thymine or uracil, (d) cytosine and (e) 5-methylcytosine.
  • A site is typically capable of discriminating between different nucleotides because it interacts with, preferably reversibly binds to, a nucleotide and the nucleotide affects the current flowing through the pore in a manner specific for that nucleotide. The way in which a site interacts with a selected nucleotide will depend on a variety of factors including the size of the site, the conformation of the site, the charge of the site, the ability of the site to form hydrogen bonds and the ability of the site to form other intermolecular interactions, such as dipole interactions. A site may have a net charge. The net charge may be negative, but is typically positive. A site may have no net charge. As discussed below, the ability of a site to discriminate between different nucleotides can be altered by altering the size of the site, the conformation of the site and/or the charge of the site.
  • Each site is preferably present in the barrel or channel of the pore. This allows the interaction between a site and a nucleotide to affect the current flowing through the pore. Site(s) in transmembrane protein pores that are capable of discriminating between different nucleotides are discussed in more detail below.
  • The pore comprises at least one, such as 2, 3 or 4, sites that are capable of discriminating between different nucleotides. The pore preferably comprises two or more, such as 2, 3 or 4 or more, distinct sites that are capable of discriminating between different nucleotides. Hence, a proportion of the nucleotides in the target sequence preferably interacts one at a time with two or more distinct sites in the pore that are capable of discriminating between different nucleotides. The pore most preferably comprises two distinct sites that are capable of discriminating between different nucleotides. Hence, a proportion of the nucleotides in the target sequence most preferably interacts with two distinct sites in the pore that are capable of discriminating between different nucleotides. Each nucleotide in the target sequence preferably interacts with each specific site, one site at a time.
  • Sites are distinct if they are separated from one another by sufficient distance to allow the interaction of a selected nucleotide with each site to be distinguished as described herein. Distinct sites are typically separated from one another by at least 10, at least 20, at least 30, at least 40 or at least 50 Angstroms. Distinct sites are preferably separated by from each other by about 20 to about 30 Angstroms.
  • Preferably, the two or more distinct sites each discriminate between different nucleotides in a different manner. This makes it possible to determine when a selected nucleotide is interacting with each of the two or more sites. The two or more sites may differ in the way in which they discriminate between different nucleotides in any manner. Some sites may discriminate between different nucleotides on the basis of different steric interactions with each of the nucleotides. Such interactions are typically dependent on the size and/or conformation of the sites. Other sites with a net charge may discriminate between different nucleotides on the basis of different ionic interactions with each of the nucleotides.
  • Typically, each of the two or more sites differs in the way in which its interactions with the different nucleotides affect the current passing through the pore. Preferably, the interaction of a selected nucleotide with each of the two or more distinct sites results in a different current passing through the pore. For instance, the interaction of an adenine-containing nucleotide with each of the two or more distinct sites results in a different current passing through the pore. More preferably, the interaction of different nucleotides with each of the two or more distinct sites results in differing currents passing through the pore and the separation between the mean value of the differing currents differs between each of the two or more distinct sites. This is illustrated in FIG. 4.
  • The presence in the pore of two or more distinct sites that are capable of discriminating between different nucleotides in different ways offers a couple advantages. First, it allows the number of nucleotides in the target sequence to be counted. If the distance between the two or more sites and the rate at which the target sequence passes through the pore is known, it is possible to count the number of nucleotides that pass through the pore as a selected nucleotide moves from one site to another. This is particularly helpful for determining the length of a continuous stretch of a particular nucleotide within the target sequence. Using a pore with only a single site that is capable of discriminating between different nucleotides, a continuous stretch of five identical nucleotides will not result in any change in the current level as they each of the five nucleotides sequentially interacts with the site. It would be necessary to to try to predict, based on the rate at which the target sequence is passed through the pore, how many nucleotides interact with the site. However, if the pore has two sites that are capable of discriminating between different nucleotides, downstream nucleotides sequentially interacting with the second site will alter the current level passing through the pore as each of the five identical nucleotides in the continuous stretch sequentially interacts with the first site. This permits the number of identical nucleotides sequentially interacting with the first site to be counted.
  • Second and more importantly, the presence in the pore of two or more distinct sites that are capable of discriminating between different nucleotides allows the sequence of the target nucleic acid to be determined more efficiently. Having two distinct sites that discriminate between different nucleotides in different ways ensures that, when the target sequence is sequenced, each nucleotide is not merely observed once, but is in fact interrogated twice. This gives greater certainty that each position in the target sequence has been observed and that the aggregate call for both nucleotides at each position is of a greater quality score than would be possible with a single observation. In other words, the key advantage of the preferred method of the invention is that it allows each nucleotide position of a target sequence to be effectively interrogated twice without having to repeat the method. This ensures that the quality of the sequence generated is consequently very much higher, with a reduced potential for misidentified nucleotide calls, or completely missed nucleotides.
    • Modification of the Site(s)
  • The method preferably involves the use of a pore which has been modified to alter the ability of at least one site, such as 2 or 3 sites, to discriminate between different nucleotides. The pore may be modified to introduce one or more, such as 2, distinct sites that are capable of discriminating between different nucleotides. This increases the number of distinct sites that are capable of discriminating between different nucleotides in the pore. The pore may be modified to abolish one or more, such as 2, distinct sites that are capable of discriminating between different nucleotides. This decreases the number of distinct sites that are capable of discriminating between different nucleotides in the pore. However, at least one site, such as 2 or 3 sites, that is capable of discriminating between different nucleotides must remain for the pore to be useful.
  • The pore may be modified to enhance or reduce the ability of one or more distinct sites to discriminate between different nucleotides. For instance, the ability of one site to discriminate different nucleotides may be increased, while the ability of another distinct site to discriminate different nucleotides may be reduced. This allows the pore to be ‘fine tuned’ for sequencing specific target nucleic acid sequences.
  • The pore may be modified in any way to alter the ability of at least one site to discriminate between different nucleotides. One or more, such as 2, 3, 4 or 5 or more, modifications may be made. The one or more modifications preferably alter the current flowing through the pore when a selected nucleotide interacts with the at least one site.
  • The modification(s) may alter the size and/or conformation of the at least one site and thereby alter its steric interaction with different nucleotides. The modification(s) may alter the net charge of the at least one site and thereby alters its ionic interaction with different nucleotides. The net charge of the at least one site may be altered by (1) introducing positive charge or negative charge, (2) removing positive or negative charge without replacing it, (3) substituting neutral charge or negative charge with positive charge and/or (4) substituting neutral charge or positive charge with negative charge. The modification(s) cannot alter the net charge in such a manner that it interferes with translocation of the target sequence through the pore. For instance, introducing too much positive charge into the barrel or channel of the pore may reduce the current flowing through the pore and thereby prevent discrimination of different nucleotides. Alternatively, introducing too much negative charge into the barrel or channel of the pore may prevent entry of the target sequence into the pore.
  • The inventors have surprisingly shown that, if a pore contains two or more distinct sites that are capable of discriminating between different nucleotides, modification of one distinct site may alter the ability of the other distinct site(s) to discriminate between different nucleotides. Hence, in a preferred embodiment, the pore is modified at one of the two or more distinct sites and this alters the ability of at least one of the other two or more distinct sites to discriminate between different nucleotides. In another preferred embodiment, the pore is modified at one of the two or more distinct sites and this alters the ability of all of the other distinct sites to discriminate between different nucleotides. In another preferred embodiment, the pore is modified at one of the two or more distinct sites and this alters the ability of all of the distinct sites to discriminate between different nucleotides. Any of the modifications described above may be used. Most preferably, the pore is modified at one of the two or more distinct sites to increase the difference between the currents passing through the pore when a selected nucleotide interacts with each of the two or more distinct sites.
  • It will be necessary to balance the effects of modifications at each of the two or more distinct sites. For instance, altering the net charge at one site may reduce the current flowing through the pore when the site interacts with nucleotides and thereby make it less easy to discriminate between different nucleotides at the other more distal site(s). Alternatively, modifying one site to increase the current flowing the pore may improve discrimination between different nucleotides at the other more distal site(s). This is discussed in more detail below with reference to transmembrane protein pores.
    • Pores
  • The method involves passing the target sequence through a transmembrane pore. A transmembrane pore is a pore that permits ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane. The pore allows a nucleic acid, such as DNA or RNA, to be passed through the pore.
  • The pore is preferably a transmembrane protein pore. A transmembrane protein pore is a polypeptide or a collection of polypeptides that permits ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane.
  • The pore may be isolated, substantially isolated, purified or substantially purified. A pore is isolated or purified if it is completely free of any other components, such as lipids or other pores. A pore is substantially isolated if it is mixed with carriers or diluents which will not interfere with its intended use. For instance, a pore is substantially isolated or substantially purified if it present in a form that comprises less than 10%, less than 5%, less than 2% or less than 1% of other components, such as lipids or other pores. The pore is typically present in a lipid bilayer.
  • The pore may be a monomer or an oligomer. The pore is preferably made up of several repeating subunits, such as 6, 7 or 8 subunits. The pore is more preferably a heptameric pore. The pore typically comprises a barrel or channel through which the ions may flow. The subunits of the pore typically surround a central axis and contribute strands to a transmembrane β barrel or channel or a transmembrane α-helix bundle or channel.
  • The pore comprises at least one site that is capable of discriminating between different nucleotides. The site(s) are preferably in the barrel or channel of the pore. Each site typically comprises several, such as 10, 20 or 30, amino acids that facilitate interaction with nucleotides. If the pore is an oligomer, each monomer may contribute one or more, such as 2, 3, or 4, amino acids to each site. These amino acids are preferably located near a constriction of the barrel or channel. Each site typically comprises one or more positively charged amino acids, such as arginine, lysine or histidine. These amino acids typically facilitate the interaction between the site and the nucleotides. Pores for use in accordance with the invention can be β-barrel pores, α-helix bundle pores or solid state pores. β-barrel pores comprise a barrel or channel that is formed from β-strands. Suitable β-barrel pores include, but are not limited to, β-toxins, such as α-hemolysin, anthrax toxin and leukocidins, and outer membrane proteins/porins of bacteria, such as Mycobacterium smegmatis porin A (MspA), outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A and Neisseria autotransporter lipoprotein (NalP). α-helix bundle pores comprise a barrel or channel that is formed from α-helices. Suitable α-helix bundle pores include, but are not limited to, inner membrane proteins and α outer membrane proteins, such as Wza.
  • The pore may be a solid state pore. Suitable solid state pores include, but are not limited to, silicon nitride pores, silicon dioxide pores and graphene pores. Other suitable solid state pores and methods of producing them are discussed in U.S. Pat. No. 6,464,842, WO 03/003446, WO 2005/061373, U.S. Pat. No. 7,258,838, U.S. Pat. No. 7,466,069, U.S. Pat. No. 7,468,271 and U.S. Pat. No. 7,253,434.
  • The pore is preferably derived from α-hemolysin (α-HL). The wild type α-HL pore is formed of seven identical monomers or subunits (i.e. it is heptameric). The sequence of one wild type monomer or subunit of α-hemolysin is shown in SEQ ID NO: 2. The pore preferably comprises seven subunits comprising the sequence shown in SEQ ID NO: 2 or a variant thereof. The pore may be a homoheptamer comprising seven identical subunits of SEQ ID NO: 2 or a variant thereof. Alternatively, the pore may be a heteroheptamer comprising two or more, such as 2, 3, 4, 5, 6 or 7, different subunits. Each subunit in the heteroheptamer may comprise SEQ ID NO: 2 or a variant thereof.
  • Amino acids 1, 7 to 21, 31 to 34, 45 to 51, 63 to 66, 72, 92 to 97, 104 to 111, 124 to 136, 149 to 153, 160 to 164, 173 to 206, 210 to 213, 217, 218, 223 to 228, 236 to 242, 262 to 265, 272 to 274, 287 to 290 and 294 of SEQ ID NO: 2 form loop regions. Residues 111, 113 and 147 of SEQ ID NO: 2 form part of a constriction of the barrel or channel of α-HL.
  • A variant of SEQ ID NO: 2 is a subunit that has an amino acid sequence which varies from that of SEQ ID NO: 2 and which retains its pore forming ability. The ability of a variant to form a pore can be assayed using any method known in the art. For instance, the variant may be inserted into a membrane along with other appropriate subunits and its ability to oligomerise to form a pore may be determined. Methods are known in the art for inserting subunits into membranes, such as lipid bilayers. For example, subunits may be suspended in a purified form in a solution containing a lipid bilayer such that it diffuses to the lipid bilayer and is inserted by binding to the lipid bilayer and assembling into a functional state. Alternatively, subunits may be directly inserted into the membrane using the “pick and place” method described in M. A. Holden, H. Bayley. J. Am. Chem. Soc. 2005, 127, 6502-6503 and International Application No. PCT/GB2006/001057 (published as WO 2006/100484).
  • As described in the Example, pores formed from SEQ ID NO: 2 or a variant thereof have three sites that are capable of discriminating different nucleotides (named R1, R2 and R3). R1 is near the central constriction at position 147 of SEQ ID NO: 2. R1 has a net charge. R2 is about 20 to about 30 angstroms further down the β-barrel from R1. R2 is near position 139 of SEQ ID NO: 2. R3 is about 20 to about 30 angstroms further down the β-barrel from R2. Hence, R3 is about 40 to about 60 angstroms down the β-barrel from R1. R2 has no net charge. R3 is near the trans exit of the barrel or channel at position(s) 127, 128, 129 and 131 of SEQ ID NO: 2. R3 has a net charge. Variants of SEQ ID NO: 2 may comprise modifications that affect these sites as described above and below.
  • The variant may include one or more modifications that alter the ability of at least one of R1, R2 and R3 to discriminate between different nucleotides. In other words, the variant may be modified to alter the ability of (1) R1, (2) R2, (3) R3, (4) R1 and R2, (5) R2 and R3 (6) R1 and R3, or (7) R1, R2 and R3 to discriminate between different nucleotides. The variant may be modified in any way. The modification(s) may enhance or reduce the ability of at least one of R1, R2 and R3 to discriminate between different nucleotides. The modification(s) can abolish the ability of at least one of R1, R2 and R3 to discriminate between different nucleotides. The modification(s) preferably increase the difference between the currents passing through the pore when a selected nucleotide interacts with at least one of of R1, R2 and R3 compared with the others.
  • It will be necessary to balance the effects of particular modifications at each of R1, R2 and R3. For instance, altering the net charge of R1may reduce the current flowing through the pore when it interacts with and thereby make it less easy to discriminate between different nucleotides at R2 and/or R3. Alternatively, modifying R1 to increase the current flowing the pore when it interacts with nucleotides may improve discrimination between different nucleotides at R2 and/or R3.
  • The modifications may alter the size and/or conformation of at least one of R1, R2 and R3 and thereby alter their steric interactions with different nucleotides. Discrimination between different nucleotides by at least one of R1, R2 and R3 is preferably enhanced by introducing one or more amino acids having large side chains, such as tyrosine, arginine or tryptophan. The one or more amino acids may be introduced by addition. The one or more amino acids are preferably introduced by substitution. Discrimination between different nucleotides by at least one of R1, R2 and R3 is preferably enhanced by substituting one or more amino acids in at least one of R1, R2 and R3 with one or more amino acids having larger side chains.
  • Discrimination between different nucleotides by at least one of R1, R2 and R3 is preferably reduced by introducing one or more amino acids having small side chains, such as glycine, alanine or serine. The one or more amino acids may be introduced by addition. The one or more amino acids are preferably introduced by substitution. Discrimination between different nucleotides by at least one of R1, R2 and R3 is preferably reduced by substituting one or more amino acids in at least one of R1, R2 and R3 with one or more amino acids having larger side chains.
  • The relative size of the side chains of amino acids can be determined by comparing their van der Waal volumes. The relative van der Waal volumes of the side chains of the standard amino acids is as follows (smallest first): glycine (G)<alanine (A)<serine (S)<cysteine (C)<proline (P)<aspartic acid (D)<threonine (T)<asparagine (N)<valine (V)<glutamic acid (E)<glutamine (Q)<histidine (H)<isoleucine (I)=leucine (L)=methionine (M)<phenylalanine (F)=lysine (K)<tyrosine (Y)<arginine (R)<tryptophan (W). Hence, substituting glycine with arginine constitutes substitution with an amino acid having a large side chain.
  • The modification(s) may alter the net charge of at least one of R1, R2 and R3 and thereby alter their ionic interactions with different nucleotides. The modification(s) preferably increase the net positive charge of at least one of R1, R2 and R3 and thereby alter their interaction with different nucleotides. The modification(s) do not have to alter the net charge of at least one of R1, R2 and R3 as long as the ability of at least one of R1, R2 and R3 to discriminate between different nucleotides is altered.
  • The net positive charge of at least one of R1, R2 and R3 is preferably increased by introducing one or more positively charged amino acids. The one or more positively charged amino acids may be introduced by addition. The one or more positively charged amino acids are preferably introduced by substitution.
  • A positively charged amino acid is an amino acid with a net positive charge. The positively charged amino acid(s) can be naturally-occurring or non-naturally-occurring. The positively charged amino acids may be synthetic or modified. For instance, modified amino acids with a net positive charge may be specifically designed for use in the invention. A number of different types of modification to amino acids are well known in the art.
  • Preferred naturally-occurring positively charged amino acids include, but are not limited to, histidine (H), lysine (K) and arginine (R). Any number and combination of H, K and/or R may be introduced.
  • Methods for adding or substituting naturally-occurring amino acids are well known in the art. For instance, methionine (M) may be substituted with arginine (R) by replacing the codon for methionine (ATG) with a codon for arginine (AGA) at the relevant position in a polynucleotide encoding the pore. The polynucleotide can then be expressed as discussed above.
  • Methods for adding or substituting non-naturally-occurring amino acids are also well known in the art. For instance, non-naturally-occurring amino acids may be introduced by including synthetic aminoacyl-tRNAs in the IVTT system used to express the pore. Alternatively, they may be introduced by expressing the pore in E. coli that are auxotrophic for specific amino acids in the presence of synthetic (i.e. non-naturally-occurring) analogues of those specific amino acids. They may also be produced by native ligation if the pore is produced using partial peptide synthesis.
  • Any amino acid may be substituted with a positively charged amino acid. One or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted with one or more positively charged amino acids. Uncharged amino acids have no net charge. Suitable uncharged amino acids include, but are not limited to, cysteine (C), serine (S), threonine (T), methionine (M), asparagine (N) and glutamine (Q). Non-polar amino acids have non-polar side chains. Suitable non-polar amino acids include, but are not limited to, glycine (G), alanine (A), proline (P), isoleucine (I), leucine (L) and valine (V). Aromatic amino acids have an aromatic side chain. Suitable aromatic amino acids include, but are not limited to, histidine (H), phenylalanine (F), tryptophan (W) and tyrosine (Y). Preferably, one or more negatively charged amino acids are substituted with one or more positively charged amino acids. Suitable negatively charged amino acids include, but are not limited to, aspartic acid (D) and glutamic acid (E).
  • Preferred introductions include, but are not limited to, substitution of M with R, substitution of M with H, substitution of M with K, substitution of D with R, substitution of D with H, substitution of D with K, substitution of E with R, substitution of E with H and substitution of E with K.
  • Any number of positively charged amino acids may be introduced. For instance, 1, 2, 5, 10, 15, 20, 25 or more positively charged amino acids may be introduced. In the case of α-HL (i.e. SEQ ID NO: 2 and 4 and variants thereof discussed above), the one or more positively charged amino acids may be introduced into 1, 2, 3, 4, 5, 6 or 7 of the subunits in the pore. In each of the seven subunits, the one or more positively charged amino acids may be introduced at the same or different positions. Preferably, the pore is a homoheptamer and one or more positive amino acids are introduced at the same position(s) in each subunit.
  • The net positive charge of at least one of R1, R2 and R3 may also be increased by replacing by substitution one or more negatively charged amino acids with one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids. The removal of negative charge increases the net positive charge. The uncharged amino acids, non-polar amino acids and/or aromatic amino acids can be naturally-occurring or non-naturally-occurring. They may be synthetic or modified. Suitable uncharged amino acids, non-polar amino acids and aromatic amino acids are discussed above. Preferred substitutions include, but are not limited to, substitution of E with N, substitution of D with N, substitution of E with T, substitution of D with T, substitution of E with G and substitution of D with G.
  • Any number and combination of uncharged amino acids, non-polar amino acids and/or aromatic amino acids may substituted into at least one of R1, R2 and R3. For instance, 1, 2, 5, 10, 15, 20, 25 or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be may substituted. In the case of α-HL (i.e. SEQ ID NO: 2 and 4 and variants thereof discussed above), the uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted into 1, 2, 3, 4, 5, 6 or 7 of the subunits in the pore. In each of the seven subunits, the one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted into the same or different positions. Preferably, the pore is a homoheptamer and uncharged amino acids, non-polar amino acids and/or aromatic amino acids are substituted into the same position(s) in each subunit. Negatively charged amino acids may be substituted with (1) uncharged amino acids; (2) non-polar amino acids; (3) aromatic amino acids; (4) uncharged amino acids and non-polar amino acids; (5) uncharged amino acids and aromatic amino acids; and (5) non-polar amino acids and aromatic amino acids; or (6) uncharged amino acids, non-polar amino acids and aromatic amino acids.
  • The net negative charge of at least one of R1, R2 and R3 is preferably increased by introducing one or more negatively charged amino acids into the barrel or channel and/or entrance of the pore. The one or more negatively charged amino acids may be introduced by addition. The one or more negatively charged amino acids are preferably introduced by substitution. Methods for adding and substituting amino acids are well known in the art.
  • Suitable negatively charged amino acids are discussed above. The negatively charged amino acid(s) can be naturally-occurring or non-naturally-occurring. The negatively charged amino acids may be synthetic or modified.
  • Any amino acid may be substituted with a negatively charged amino acid. One or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids may be substituted with one or more negatively charged amino acids. Preferably, one or more positively charged amino acids are substituted with one or more negatively charged amino acids. Any number of negatively charged amino acids may be introduced as discussed above.
  • The net negative charge may also be increased by replacing by substitution one or more positively charged amino acids with one or more uncharged amino acids, non-polar amino acids and/or aromatic amino acids. The removal of positive charge increases the net negative charge. The uncharged amino acids, non-polar amino acids and/or aromatic amino acids can be naturally-occurring or non-naturally-occurring. They may be synthetic or modified.
  • Any number and combination of uncharged amino acids, non-polar amino acids and/or aromatic amino acids may substituted into the barrel or channel and/or entrance as discussed above.
  • The modification(s) do not have to alter the net charge of at least one of R1, R2 and R3. For instance, at least one of R1, R2 and R3 may be modified by replacing a positively charged amino acid with an uncharged amino acid and a negatively charged amino acid with an uncharged amino acid.
  • The modifications to R1, R2 and/or R3 described above are preferably made to amino acids that face inward into the barrel or channel of the pore. Such amino acids can be identified as described in Song, L., Hobaugh, M. R., Shustak C., Cheley, S., Bayley, H., and Gouaux, J. E. (1996) Science 274, 1859-1866.
  • In a preferred embodiment, the variant of SEQ ID NO: 2 is modified at one of R1, R2 and R3 and this alters the ability of one of the other sites to discriminate between different nucleotides. In another preferred embodiment, the variant is modified at one of R1, R2 and R3 and this alters the ability of all of R1, R2 and R3 to discriminate between different nucleotides. In a most preferred embodiment, the variant is modified at R1 and this alters the ability of all of R1, R2 and R3 to discriminate between different nucleotides. The variant preferably comprises an asparagine at position 111 of SEQ ID NO: 2 and an asparagine at position 147 of SEQ ID NO: 2. SEQ ID NO: 4 shows the sequence of SEQ ID NO: 2 except that it has an asparagine at position 111 of SEQ ID NO: 2 (E111N) and an asparagine at position 147 of SEQ ID NO: 2 (K147N). SEQ ID NO: 4 or a variant thereof may be used to form a pore in accordance with the invention. The variant of SEQ ID NO: 4 may differ from SEQ ID NO: 4 in the same way and to the same extent as discussed for SEQ ID NO: 2 above except that it must have an asparagine at position 111 of SEQ ID NO: 4 and an asparagine at position 147 of SEQ ID NO: 4. A preferred pore for use in the invention comprises one or more, preferably seven, subunits comprising SEQ ID NO: 4.
  • The variant may also include other modifications that facilitate an interaction with nucleotides. In particular, the variant preferably has a glutamine at position 139 of SEQ ID NO: 2. The variant preferably has an arginine or a tyrosine at position 113 of SEQ ID NO: 2.
  • The variant may include modifications that facilitate covalent attachment to or interaction with a nucleic acid handling protein. The variant preferably comprises one or more reactive cysteine residues that facilitate attachment to the nucleic acid handling enzyme. For instance, the variant may include a cysteine at one or more of positions 8, 9, 17, 18, 19, 44, 45, 50, 51, 237, 239 and 287 and/or on the amino or carboxy terminus of SEQ ID NO: 2. Preferred variants comprise a substitution of the residue at position 8, 9, 17, 237, 239 and 287 of SEQ ID NO: 2 with cysteine (K8C, T9C, N17C, K237C, S239C or E287C).
  • The variant may be a naturally occurring variant which is expressed naturally by an organism, for instance by a Staphylococcus bacterium, or expressed recombinantly by a bacterium such as Escherichia coli. Variants also include non-naturally occurring variants produced by recombinant technology. Over the entire length of the amino acid sequence of SEQ ID NO: 2 or 4, a variant will preferably be at least 50% homologous to that sequence based on amino acid identity. More preferably, the variant polypeptide may be at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% and more preferably at least 95%, 97% or 99% homologous based on amino acid identity to the amino acid sequence of SEQ ID NO: 2 or 4 over the entire sequence. There may be at least 80%, for example at least 85%, 90% or 95%, amino acid identity over a stretch of 200 or more, for example 230, 250, 270 or 280 or more, contiguous amino acids (“hard homology”). Homology can be measured as described above.
  • Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO: 2 or 4 in addition to those discussed above, for example up to 1, 2, 3, 4, 5, 10, 20 or 30 substitutions. Conservative substitutions may be made, for example, according to Table 1 above.
  • One or more amino acid residues of the amino acid sequence of SEQ ID NO: 2 may additionally be deleted from the polypeptides described above. Up to 1, 2, 3, 4, 5, 10, 20 or 30 residues may be deleted, or more.
  • Variants may include fragments of SEQ ID NO: 2 or 4. Such fragments retain pore forming activity. Fragments may be at least 50, 100, 200 or 250 amino acids in length. A fragment preferably comprises the pore forming domain of SEQ ID NO: 2 or 4. Fragments typically include residues 119, 121, 135. 113 and 139 of SEQ ID NO: 2 or 4.
  • One or more amino acids may be alternatively or additionally added to the polypeptides described above. An extension may be provided at the amino terminus or carboxy terminus of the amino acid sequence of SEQ ID NO: 2 or 4 or a variant or fragment thereof. The extension may be quite short, for example from 1 to 10 amino acids in length. Alternatively, the extension may be longer, for example up to 50 or 100 amino acids. A carrier protein may be fused to a pore or variant.
  • As discussed above, a variant of SEQ ID NO: 2 or 4 is a subunit that has an amino acid sequence which varies from that of SEQ ID NO: 2 or 4 and which retains its ability to form a pore. A variant typically contains the regions of SEQ ID NO: 2 or 4 that are responsible for pore formation. The pore forming ability of α-HL, which contains a β-barrel, is provided by 3-strands in each subunit. A variant of SEQ ID NO: 2 or 4 typically comprises the regions in SEQ ID NO: 2 that form β-strands. The amino acids of SEQ ID NO: 2 or 4 that form β-strands are discussed above. One or more modifications can be made to the regions of SEQ ID NO: 2 or 4 that form β-strands as long as the resulting variant retains its ability to form a pore. Specific modifications that can be made to the β-strand regions of SEQ ID NO: 2 or 4 are discussed above.
  • A variant of SEQ ID NO: 2 or 4 preferably includes one or more modifications, such as substitutions, additions or deletions, within its α-helices and/or loop regions. Amino acids that form α-helices and loops are discussed above.
  • The variant may be modified for example by the addition of histidine or aspartic acid residues to assist its identification or purification or by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence.
  • Variants may also comprise any of the non-specific modifications discussed above for the nucleic acid handling enzyme. Subunits or pores can be made as discussed above.
  • Any of the specific modifications discussed above with reference to SEQ ID NO: 2 are equally applicable to other transmembrane protein pores disclosed herein.
  • Transmembrane protein pores can be produced as described above for nucleic acid handling enzymes.
    • Attachment
  • If a nucleic acid handling enzyme is used, the enzyme should handle the target nucleic acid sequence in a specific manner. For instance, the target sequence must be passed through the pore in a processive manner as described above. This ensures that a proportion of the nucleotides in the target nucleic acid sequence interacts with the pore and is identified. The lack of any interruption in the signal is important when sequencing nucleic acids. The best way to ensure the specific handling of the target sequence by the enzyme is to attach the enzyme to the pore. In addition, if the enzyme is fixed to the pore, they can be stored together, thereby allowing the production of a ready-to-use sensor.
  • In a preferred embodiment, a nucleic acid handling enzyme is attached to the pore. This allows the target nucleic acid sequence is pushed through the barrel or channel of the pore in a stepwise manner and a proportion of the nucleotides in the target sequence to interacts with site(s) capable of discriminating different nucleotides. Suitable enzymes are discussed above. The enzyme is preferably attached to the pore at a site in close proximity to the opening of the barrel of channel of the pore. The enzyme is more preferably attached to the pore such that its active site is orientated towards the opening of the barrel of channel of the pore. This means that the target nucleic acid sequence is fed into the barrel or channel. The enzyme is preferably attached to the cis side of the pore.
  • The nucleic acid handling enzyme can be attached to the pore using any method known in the art. The nucleic acid handling enzyme and pore may be produced separately and then attached together. If the pore is a protein, the two components may be attached in any configuration. For instance, they may be attached via their terminal (i.e. amino or carboxy terminal) amino acids. Suitable configurations include, but are not limited to, the amino terminus of the nucleic acid handling enzyme being attached to the carboxy terminus of the pore and vice versa. Alternatively, the two components may be attached via amino acids within their sequences. For instance, the nucleic acid handling enzyme may be attached to one or more amino acids in a loop region of the pore. In a preferred embodiment, terminal amino acids of the nucleic acid handling enzyme are attached to one or more amino acids in the loop region of the pore. Terminal amino acids and loop regions are discussed above.
  • The nucleic acid handling enzyme is preferably chemically fused to the pore. A nucleic acid handling enzyme is chemically fused to a pore if the two parts are chemically attached, for instance via a linker molecule. Any method of chemical fusion or attachment can be used. Suitable methods include, but are not limited to, histidine tag binding to a metal affinity matrix, Ni-NTA, biotin binding to streptavidin, antibody binding to an antigen, primary amine coupling, GST tags binding to glutathione, MBP tags binding to dextrin, Protein A binding to IgG, reaction between thiols, nucleic acid hybridization linkers and cysteine linkage. DNA hybridization linkers and cysteine linkage are discussed in more detail below. The nucleic acid handling enzyme is preferably covalently attached to the pore.
  • If the pore is a protein, the nucleic acid handling enzyme may be genetically fused to the pore. A nucleic acid handling enzyme is genetically fused to a protein pore if the whole construct is expressed from a single polynucleotide sequence. The coding sequences of the nucleic acid handling enzyme and pore may be combined in any way to form a single polynucleotide sequence encoding the construct.
  • The nucleic acid handling enzyme and pore may be genetically fused in any configuration, such as via their terminal amino acids. The amino acid sequence of the nucleic acid handling enzyme is typically added in frame into the amino acid sequence of the pore. In a preferred embodiment, the nucleic acid handling enzyme is inserted into a loop region of a transmembrane protein pore. In an especially preferred embodiment, the nucleic acid handling enzyme is inserted between amino acids, 18 and 19, 44 and 45 or 50 and 51 of SEQ ID NO: 2.
  • The nucleic acid handling enzyme retains its ability to bind nucleic acids. This ability is typically provided by its secondary structural elements (α-helices and β-strands) and tertiary structural elements. In order to avoid adversely affecting the nucleic acid binding ability of the protein, it is preferably attached to the pore in a manner that does not affect its secondary or tertiary structure.
  • The pore retains its ability to permit ions driven by an applied potential to flow from one side of a membrane to the other side of the membrane. The pore forming ability of pores is typically provided by their α-helices and β-strands. β-barrel pores comprise a barrel or channel that is formed from β-strands, whereas α-helix bundle pores comprise a barrel or channel that is formed from α-helices. The α-helices and β-strands are typically connected by loop regions. In order to avoid affecting the functioning of the pore, the nucleic acid handling enzyme is preferably attached to a loop region of the pore. The loop regions of specific pore subunits are discussed in more detail above. The nucleic acid handling enzyme is preferably attached to the pore using one or more, such as 2, 3 or 4, linkers. The one or more linkers may be designed to constrain the mobility of the nucleic acid handling enzyme. The linkers are typically attached to the one or more accessible cysteine residues in the nucleic acid handling enzyme. The linkers may be attached to one or more reactive groups, such as cysteine residues, reactive lysine residues or non-natural amino acids, in the pore. Suitable linkers are well known in the art. Suitable linkers include, but are not limited to, chemical crosslinkers and peptide linkers. Preferred chemical crosslinkers are nucleic hybridization linkers. The length, flexibility and hydrophilicity of the nucleic acid hybridization linkers are typically designed such that they do not to disturb the functions of the nucleic acid handling enzyme and pore. The nucleic acid hybridization linkers can comprise any of the nucleic acids discussed above.
  • Linkers may be attached to the nucleic acid handling enzyme first and then the pore, the pore first and then the nucleic acid handling enzyme or the pore and nucleic acid handling enzyme at the same time. When the linker is attached to a pore subunit (as the pore), it may be a monomeric subunit, part of an oligomer of two or more monomers or part of complete oligomeric pore. It is preferred that the linker is reacted before any purification step to remove any unbound linker.
  • The preferred method of attaching the nucleic acid handling enzyme to the pore is via cysteine linkage. This can be mediated by a bi-functional chemical linker or by a polypeptide linker with a terminal presented cysteine residue. α-HL (SEQ ID NO: 2) lacks native cysteine residues so the introduction of a cysteine into the sequence of SEQ ID NO: 2 enables the controlled covalent attachment of the nucleic acid handling enzyme to the subunit. Cysteines can be introduced at various positions, such as position K8, T9 or N17 of SEQ ID NO: 2 or at the carboxy terminus of SEQ ID NO: 2. The length, reactivity, specificity, rigidity and solubility of any bi-functional linker may be designed to ensure that the enzyme is positioned correctly in relation to the subunit and the function of both the subunit and enzyme is retained. Suitable linkers include those described above.
  • Cross-linkage of subunits or enzymes to themselves may be prevented by keeping the concentration of linker in a vast excess of the nucleic acid handling enzyme and/or the pore. Alternatively, a “lock and key” arrangement may be used in which two linkers are used. For instance, click chemistry, such as azide alkyne Huisgen cycloaddition, may be used to ensure that the nucleic acid handling enzyme only binds to the pore and not to itself and vice versa.
  • The nucleic acid handling enzyme is preferably attached to the part of a pore or a subunit thereof that forms part of the cis side of a pore. In electrophysiology, the cis side is the grounded side by convention. If a hemolysin pore is inserted correctly into an electrophysiology apparatus, the Cap region is on the cis side. It is well known that, under a positive potential, nucleotides will migrate from the cis to the trans side of pores used for stochastic sensing. Positioning the nucleic acid handling enzyme at the cis side of a pore allows it to handle the target nucleic acid such that a proportion of the nucleotides in the sequence enters the barrel or channel of the pore and interacts with it. Preferably, at least 20%, at least 40%, at least 50%, at least 80% or at least 90% of the nucleotides in the sequence enters the barrel or channel of the pore and interacts with it.
  • The site and method of covalent attachment is preferably selected such that mobility of the nucleic acid handling enzyme is constrained. This helps to ensure that the protein handles the target nucleic acid sequence in such a way that a proportion of the nucleotides in the target sequence interacts with the pore. For instance, constraining the ability of nucleic acid handling enzyme to move means that its active site can be permanently orientated towards the part of the subunit that forms part of the opening of the barrel of channel of the pore. The mobility of the nucleic acid handling enzyme may be constrained by increasing the number of points at which the protein is attached to the pore and/or the use of specific linkers.
    • Apparatus
  • The method may be carried out using any apparatus that is suitable for investigating a membrane/pore system in which a pore is inserted into a membrane. The method may be carried out using any apparatus that is suitable for stochastic sensing. For example, the apparatus comprises a chamber comprising an aqueous solution and a barrier that separates the chamber into two sections. The barrier has an aperture in which the membrane containing the pore is formed. The target sequence may be contacted with the pore by introducing the sequence into the chamber. The target sequence may be introduced into either of the two sections of the chamber, but, if a nucleic acid handling enzyme used, is preferably introduced into the section of the chamber containing the enzyme.
  • The method may be carried out using the apparatus described in International Application No. PCT/GB08/000562.
  • The method involves measuring the current passing through the pore during interaction with the nucleotides. Therefore the apparatus also comprises an electrical circuit capable of applying a potential and measuring an electrical signal across the membrane and pore. The method may be carried out using a patch clamp or a voltage clamp. The method preferably involves the use of a voltage clamp.
    • Conditions
  • The method of the invention involves the measuring of a current passing through the pore during interaction with nucleotides of a target nucleic acid sequence. Suitable conditions for measuring ionic currents through transmembrane pores are known in the art and disclosed in the Examples. The method is carried out with a voltage applied across the membrane and pore. The voltage used is typically from −400mV to +400mV. The voltage used is preferably in a range having a lower limit selected from −400 mV, −300mV, −200 mV, −150 mV, −100 mV, −50 mV, −20mV and 0 mV and an upper limit independently selected from +10 mV, +20 mV, +50 mV, +100 mV, +150 mV, +200 mV, +300 mV and +400 mV. The voltage used is more preferably in the range 120 mV to 170 mV. It is possible to increase discrimination between different nucleotides by at least one site capable of discriminating between different nucleotides by varying the applied potential.
  • The method is carried out in the presence of any alkali metal chloride salt. In the exemplary apparatus discussed above, the salt is present in the aqueous solution in the chamber. Potassium chloride (KCl), sodium chloride (NaCl) or caesium chloride (CsCl) is typically used. KCl is preferred. The salt concentration is typically from 0.1 to 2.5M, from 0.3 to 1.9M, from 0.5 to 1.8M, from 0.7 to 1.7M, from 0.9 to 1.6M or from 1M to 1.4M. High salt concentrations provide a high signal to noise ratio and allow for currents indicative of the presence of a nucleotide to be identified against the background of normal current fluctuations. However, lower salt concentrations may have to be used so that the enzyme is capable of functioning.
  • The method is typically carried out in the presence of a buffer. In the exemplary apparatus discussed above, the buffer is present in the aqueous solution in the chamber. Any buffer may be used in the method. One suitable buffer is Tris-HCl buffer. The method is typically carried out at a pH of from 4.0 to 13.0, from 4.5 to 12, from 5.0 to 11, from 5.5 to 10, from 6.0 to 9 or from 7.0 to 8.8 or 7.5 to 8.5. DNA denatures at a pH of around 11. The pH used is preferably about 7.5.
  • The method is typically carried out at from 0° C. to 100° C., from 15° C. to 95° C., from 16° C. to 90° C., from 17° C. to 85° C., from 18° C. to 80° C., 19° C. to 70° C., or from 20° C. to 60° C. The method may be carried out at room temperature. The method is preferably carried out at a temperature that supports enzyme function, such as about 37° C. Good nucleotide discrimination can be achieved at low salt concentrations if the temperature is increased. However, lower temperatures, particularly those below room temperature, result in longer dwell times and can therefore be used to obtain a higher degree of accuracy.
  • In addition to increasing the solution temperature, there are a number of other strategies that can be employed to increase the conductance of the solution, while maintaining conditions that are suitable for enzyme activity. One such strategy is to use the lipid bilayer to divide two different concentrations of salt solution, a low salt concentration of salt on the enzyme side and a higher concentration on the opposite side. One example of this approach is to use 200 mM of KCl on the cis side of the membrane and 500 mM KCl in the trans chamber. At these conditions, the conductance through the pore is expected to be roughly equivalent to 400 mM KCl under normal conditions, and the enzyme only experiences 200 mM if placed on the cis side. Another possible benefit of using asymmetric salt conditions is the osmotic gradient induced across the pore. This net flow of water could be used to pull nucleotides into the pore for detection. A similar effect can be achieved using a neutral osmolyte, such as sucrose, glycerol or PEG. Another possibility is to use a solution with relatively low levels of KCl and rely on an additional charge carrying species that is less disruptive to enzyme activity.
    • Method of Improving Pores
  • The invention also provides a method for improving a transmembrane pore for sequencing a target nucleic sequence. The target sequence may be homopolymeric or hetropolymeric. A homopolymeric nucleic acid sequence is one made of one type of nucleotide. The nucleotide may be any of those discussed above.
  • The method is intended to engineer or design an improved transmembrane pore that may be used to sequence nucleic acids as described above. Pores improved in accordance with the invention can be used in a sequencing method of invention.
  • In one embodiment, the method comprises modifying a pore comprising one site that is capable of discriminating between different nucleotides. The pore may be modified in any of the ways discussed above. The pore is typically modified to introduce at least one more site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides. The method then comprises determining whether or not the resulting pore comprises two or more distinct sites that are capable of discriminating between different nucleotides. The determining step can be done using any method known in the art. For instance, it may be done as described in the Example. The advantages of having two or more sites that are capable of discriminating between different nucleotides are discussed above.
  • In another embodiment, the method comprises modifying a pore comprising two or more distinct sites that are capable of discriminating between different nucleotides. The pore may be modified in any of the ways discussed above. The pore is typically modified to remove at least one site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides. The method then comprises determining whether or not the resulting pore comprises only two distinct sites that are capable of discriminating between different nucleotides. The determining step can be done using any method known in the art. For instance, it may be done as described in the Example. The advantages of having two sites that are capable of discriminating between different nucleotides are discussed above.
  • In another embodiment, the method comprises modifying a pore, comprising more than one site, such as 2, 3 or 4 sites, that are capable of discriminating between different nucleotides. The pore may be modified in any of the ways discussed above. The pore is typically modified to remove at least one site, such as 1, 2 or 3 sites, that are capable of discriminating between different nucleotides. The method then comprises determining whether or not the resulting pore comprises only one site that is capable of discriminating between different nucleotides. The determining step can be done using any method known in the art. For instance, it may be done as described in the Example. Pores with only one site that is capable of discriminating between different nucleotides produce a simple current signal when used to sequence target nucleic acid sequences.
  • In another embodiment, the method comprises modifying a pore comprising two or more sites that are capable of discriminating between different nucleotides at one of the distinct sites. The pore may be modified in any of the ways discussed above. The pore is typically modified to enhance or reduce the ability of at least one, such as 2, 3 or 4, of the distinct sites to discriminate between different nucleotides. The method then comprises determining whether or not the resulting pore the ability of at least one of the distinct sites to discriminate between different nucleotides is altered. The determining step can be done using any method known in the art. For instance, it may be done as described in the Example.
  • The invention also provides a pore improved using a method of the invention
  • The following Example illustrates the invention:
    • EXAMPLE 1 Materials and Methods 1.1 Protein Preparation
  • α-HL was produced as described in detail elsewhere (Cheley, S., Braha, O., Lu, X., Conlan, S., & Bayley, H. (1999) A functional protein pore with a “Retro” Transmembrane domain. Protein Sci. 8, 1257-1267). In brief, the protein was expressed in the presence of [35S]methionine in an E. coli in vitro transcription and translation (IVTT) system (E. coli T7 S30 Extract System for Circular DNA, Cat. #L1130, Promega). IVTT reactions (100 μL) containing α-HL monomers were incubated with rabbit red blood cell membranes for 1 h at 37° C. to form α-HL heptamers. The solution was centrifuged at 25,000×g and the pellet containing heptamers was loaded onto a 5% SDS-polyacrylamide gel, which was run for 4 h at 100 V and subsequently vacuum dried for 3 to 4 h onto Whatman 3M filter paper. The dried gel was exposed to photographic film for 2 h and the developed film was used to locate the position of the heptameric protein in the gel. This region of the gel was excised, rehydrated and crushed in 400 μL of 10 mM Tris.HCl, pH 8.0, containing 100 μM EDTA. After 20 min at room temperature, the polyacrylamide was removed by centrifuging the suspension at 25,000×g for 7 min at room temperature through a cellulose micro spin column (Microfilterfuge tubes, Cat. #7016-024, Rainin). Aliquots of the purified protein were stored at −80° C. The mutant α-HL gene was prepared by using a kit for site-directed mutagenesis (QuickChange II XL, Cat. #200522-5, Stratagene). The DNA sequence of each gene was verified.
    • 1.2 Planar Bilayer Recordings
  • Electrical recordings were carried out with a planar lipid bilayer apparatus (Montal, M. & Mueller, P. (1972) Proc. Natl. Acad. Sci. USA 69, 3561-3566) with a bilayer of 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC, Avanti Polar Lipids) formed across an aperture (˜100 μm in diameter) in a 25-μm thick polytetrafluoroethylene film (Teflon) (Goodfellow Cambridge, Cat. #FP301200/10), which separates the apparatus into cis and trans compartments. Bilayers were formed by first pre-treating the aperture with 10 mg mL−1 hexadecane in n-pentane. Electrolyte solution (0.5 mL: 1 M KCl, 25 mM Tris.HCl, 0.1 mM EDTA, pH 8.0) was added to both compartments. Then, DPhPC in n-pentane (10 mg mL−1) was added to both compartments. The solvent was allowed to evaporate and the bilayer was formed by lowering and raising the electrolyte level past the aperture.
  • Lipid bilayers were formed from 1,2-diphytanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids). Both compartments of the recording chamber contained 0.5 mL of 1 M KCl, 25 mM Tris.HCl, pH 8.0, with 0.1 mM EDTA. Planar bilayer current recordings were performed with a patch clamp amplifier (Axopatch 200B, Axon Instruments, Foster City, Calif.) with the cis compartment connected to ground. The α-HL pores and the DNA were added to the cis compartment. ssDNA molecules, with a biotinyl group covalently attached to the 3′ end through a linker, were obtained from Sigma-Aldrich (UK) (FIG. 7). Solutions of the biotinylated ssDNAs, at 100 μM in 10 mM Tris.HCl, pH 8.0, 0.1 mM EDTA, were mixed with equal volumes of 25 μM streptavidin (SA) (Sigma-Aldrich) in the same buffer. Each oligonucleotide (pre-incubated with streptavidin for at least five minutes) was added to the cis compartment to a final concentration of 200 nM (Example 1) or 400 nM (Example 2). Initially, +160 mV was applied to the trans side for 1800 ms (Example 1) or 900 ms (Example 2) to drive the negatively charged, biotinylated DNA into the pore. The capture of a ssDNA strand by an α-HL pore is observed as a stepwise decrease in the open pore current level (IO) to a lower, but stable, current level (IB). A voltage of −140 mV was then applied for 100 ms (Example 1) or 50 ms (Example 2) to eject the immobilized DNA from the pore. The applied potential was then stepped to 0 mV for 100 ms (Example 1) or 50 ms (Example 2). This two-second or one-second sequence was repeated for at least 100 cycles for each ssDNA species added. The amplified signal (arising from the ionic current passing through the pore) was low-pass filtered at 1 kHz and sampled at 5 kHz with a computer equipped with a Digidata 1440A digitizer (Molecular Devices).
  • Under the conditions of the experiments, all of the pores exhibited a stable open-pore current. The current-voltage characteristics of WT pores are weakly rectifying (Gu, L.-Q., Dalla Serra, M., Vincent, J. B., Vigh, G., Cheley, S., Braha, O., & Bayley, H. (2000) Proc. Natl. Acad. Sci. USA 97, 3959-3964). This rectification is lost in E111N/K147N pores (FIG. 6). However, this difference is not relevant to the present work, as both pore types have similar open pore currents at +160 mV, which is the potential at which our experiments were conducted.
    • 1.3 Oligonucleotides
  • The oligonucleotides used are shown in SEQ ID NOs: 13 to 66. All oligonucleotides have a 3′ biotin-TEG tag and linker as shown in FIG. 7.
    • 1.4 Data Analysis
  • Data were analyzed and prepared for presentation with pClamp software (version 10.1, Molecular Devices). Single-channel searches were performed to obtain the average current level for each ssDNA blockade event (IB). The mean IB value for each oligonucleotide was determined by performing a Gaussian fit to a histogram of the IB values. The current blockade for each oligonucleotide was also expressed as the residual current (IRES), wherein the average current level for a DNA blockade (IB) is expressed as a percentage of the open pore current (IO): IRES=(IB/IO)×100. In general, when comparing several oligonucleotide species, a single oligonucleotide species was first added to the cis chamber and the current trace required for the determination of IB and IRES was recorded. Subsequently, a second (and if required, a third and a fourth) oligonucleotide was added and additional currents recorded. For example, the data in FIGS. 4 and 5 come from four oligonucleotide species, with sequences that differ by a single nucleotide. The experiment displayed in FIG. 11, which involves the probing of pores with 16 different sequences, was obtained by adding sets of 4 oligonucleotides at a time rather than adding individual oligonucleotides. Each of the 4 oligonucleotides within a set (N9X14) differed in the base at R1, but had the same base at R2, and each set had a different base at R2. The peaks in the derived histograms were assigned based on previous experiments with the separate sets of 4 oligonucleotides.
  • When such experiments were repeated, the oligonucleotides were added to the chamber in a different order, and in the case of the 16 oligonucleotide experiment (FIG. 11), the sets of oligonucleotides were added in a different order.
    • Example 1 2.1 Improved Discrimination of Oligonucleotides With a Mutant α-HL Pore
  • ssDNA oligonucleotides (SEQ ID NOs: 13 and 14) with biotin tags at the 3′ terminus were allowed to form complexes with streptavidin. In this state, the DNAs were captured and immobilized by α-HL pores in an applied potential, but they were not translocated into the trans compartment (FIG. 1A). The immobilized DNA molecules caused a sequence-dependent decrease in the current flow through the pore (FIG. 1B), and here we quote the residual current (IRES) as a percentage of the open pore current (IO). We examined the WT α-HL pore and the pore formed by E111N/K147N. The latter forms stable pores despite the removal of the electrostatic interactions between Glu-111 and Lys-147 residues at the central constriction (Gu, L.-Q., Cheley, S., & Bayley, H. (2001) J. Gen. Physiol. 118, 481-494). We hoped that the increased space at the constriction would cause more current to flow in the presence of DNA and hence produce a greater dispersion of IRES values. At +160 mV in 1 M KCl, 25 mM Tris.HCl, pH 8.0, containing 0.1 mM EDTA (the conditions for all the experiments reported in this Example), WT α-HL pores have a mean open pore current level (IO WT) of 171±7 pA (n=20), while pores formed from E111N/K147N gave IO E111N/K147=167±7 pA (n=20). Poly(dA)60 oligonucleotides blocked WT pores to a lesser extent (IRES poly(dA)=20.0±1.3%) than poly(dC)60 (IRES poly(dC)=19.4±1.4%) (FIG. 1B). The residual current difference between the poly(dA) and the poly(dC) oligonucleotide blockades (ΔIRES=IRES poly(dA)−IRES poly(dc)) was +0.6±0.1%. It should be noted that the ΔIRES values showed little experimental variation, while the absolute current values showed variation that exceeded ΔIRES (Table 2).
  • TABLE 2
    Residual currents (IRES) for poly(dC) and poly(dA) oligonucleotides
    immobilized within WT and E111N/K147N pores. The Io and IRES values given for each
    oligonucleotide are mean values taken from Gaussian fits to event histograms for
    individual experiments. ΔIRES is the difference in residual current between the poly(dA)
    and poly(dC) blockades (IRES poly(dA) − IRES poly(dC)).
    WT E111N/K147N
    IRES pdC IRES pdA ΔIRES IRES pdC IRES pdA ΔIRES
    Expt Io (pA) (%) (%) (%) Expt Io (pA) (%) (%) (%)
    1 163 17.1 17.8 0.7 1 172 37.1 34.1 −3.0
    2 172 17.6 18.3 0.7 2 162 36.4 33.9 −2.5
    3 187 21.4 21.9 0.5 3 166 35.5 32.6 −2.9
    4 170 19.9 20.5 0.7 4 176 37.1 34.1 −3.0
    5 169 19.8 20.5 0.6 5 167 36.9 33.8 −3.1
    6 163 20.2 20.8 0.6 6 165 36.9 33.9 −3.0
    7 172 19.6 20.0 0.4 7 192 37.2 35.3 −1.9
    8 173 19.9 20.5 0.6 8 171 35.8 33.5 −2.3
    Mean 171 19.4 20.0 0.6 Mean 171 36.6 33.9 −2.7
    SD 8 1.4 1.3 0.1 SD 9 0.6 0.7 0.4
  • In practice, the small ΔIRES values were readily determined from event histograms (FIG. 1B). Although the IO levels of WT and E111N/K147N pores are similar, IRES values, as we had hoped, were higher when oligonucleotides were immobilized within the E111N/K147N pores (FIG. 1C): IRES poly(dA)=33.9±0.7% and IRES poly(dA)=36.6±0.6%. Remarkably, as well as an increase in the residual current, there is also a change in the sign of ΔIRES, with poly(dA) blockades giving a lower IRES than poly(dC) oligonucleotide blockades in the E111N/K147N pores: ΔIRES=−2.7±0.4% (FIG. 1C).
  • Nucleic acid homopolymers have been distinguished with the WT α-HL pore by several groups on the basis of differences in IRES. Meller and colleagues found that poly(dA) and poly(dC) were difficult to distinguish during translocation through the pore, in part due to the broad distributions of IRES values (Meller, A., Nivon, L., Brandin, E., Golovchenko, J., & Branton, D. (2000) Proc. Natl. Acad. Sci. USA 97, 1079-1084). By contrast, when ssDNA was immobilized in the pore with a 3′ hairpin (5′ threading), Ashkenasy found a ΔIRES poly(dA)−poly(dC) value of −10.5% (Ashkenasy and colleagues, supra). The value for 3′ threading was similar. Interestingly, Purnell and colleagues, using biotin-streptavidin immobilization, found that ΔIRES depends on whether the 5′ or 3′ end of the DNA enters the pore first (5′ entry, ΔIRES poly(dA)−poly(dC)=+1.2%; 3′ entry, ΔIRES poly(dA)−poly(dC)=—2.9%) (Purnell, R. F., Mehta, K. K., & Schmidt, J. J. (2008) Nucleotide identification and orientation discrimination of DNA homopolymers immobilized in a protein nanopore. Nano Lett 8, 3029-3034). Our results (5′ entry: ΔIRES poly(dA)−poly(dC)=+0.6%) are in rough agreement with the latter work. We note that that ΔIRES is voltage-dependent (FIG. 8), and that Purnell and colleagues worked at a lower applied potential. It is worth noting that IRES is greater when the DNAs are attached to streptavidin. Perhaps, DNA is more stretched in the electric field within the pore when it is anchored on the cis side. If this is the so, it would be preferable to sequence DNA under similar conditions. This would be the case, for example, when DNA is ratcheted through the pore by an enzyme (Cockroft, S. L., Chu, J., Amorin, M., & Ghadiri, M. R. (2008) J. Am. Chem. Soc. 130, 818-820).
  • Interestingly, the open pore current carried by the WT pore and E111N/K147N are similar at +160 mV (FIG. 6), but the residual currents in the presence of ssDNA are almost twice as high in the mutant pore (e.g. FIG. 1B, C), which be the basis of why E111N/K147N gives better discrimination between poly(dA) and poly(dC). We suggest that the ring of charged lysine and glutamatic acid side chains in the constriction (residues 147 and 111, FIG. 1A), which are replaced with asparagines in the mutant, might have one or more effects, including: a coulombic block to ion transport, or a steric block based either simply on the bulk of the large amino acid side chains, which might “grip” the translocating DNA, or a collapse of the barrel around the DNA. In either case, the current, which is carried largely by hydrated K+ ions while the negatively charged DNA strand is in the pore (Sanchez-Quesada, J., Saghatelian, A., Cheley, S., Bayley, H., & Ghadiri, M. R. (2004) Angew. Chem. Int. Ed. Engl. 43, 3063-3067), is reduced in the WT pore and so is base discrimination in terms of differences in absolute current or as percentages of the open pore current (ΔIRES). The actual current levels that are observed cannot be readily rationalized, especially when it is noted that poly(dA) gives the higher residual current in the WT pore and poly(dC) in the E111N/K147N pore. A simplistic conclusion is that the central constriction (comprising residues Lys-147, Glu-111 and Met-113 in the WT) forms a recognition site. This is interesting because Ashkenasy and colleagues (supra) concluded that recognition occurs at the trans exit. In the latter case, the ssDNA was immobilized by 5′ or 3′ terminal hairpins, which probably enter the pore and perturb recognition that occurs at the constriction. Together, the results imply that more than one recognition element might be present in the β barrel of the α-HL pore. Further experimentation, as described below, supports this view.
    • 2.2 Defining Recognition Elements Within the α-HL Pore
  • We attempted to better define the regions of the α-HL pore that interact with DNA in a base-specific manner (recognition elements) by probing the length of the pore with a set of five oligonucleotides (SEQ ID NOs: 16 to 20), each of which contained a stretch of 5 consecutive adenine nucleotides (A5 oligonucleotides) in an otherwise poly(dC) sequence (FIG. 2A, the locations of the A5 sequences in the figure are justified below). A similar approach for the discovery of base recognition sites was established by Ashkenasay and colleagues (supra). We determined ΔIRES with respect to a reference poly(dC) oligonucleotide for each of the A5 oligonucleotides (i-v, FIG. 2A) for both the WT and E111N/K147N pores (FIG. 2BC, Table 3).
  • TABLE 3
    Residual currents (IRES) for poly(dC) oligonucleotides containing a stretch
    of five consecutive adenine nucleotides immobilized within WT and E111N/K147N
    pores. The IO and IRES values shown are the mean values from n experiments. ΔIRES is the
    difference in residual current between each A5 oligonucleotide (i-v) (FIG. 2A) and poly(dC)
    (IRES A5oligo − IRES poly(dC)). The errors given are standard deviations.
    WT E111N/K147N
    Oligo Io IRES i-v IRES pdC ΔIRES Oligo Io IRES i-v IRES pdC ΔIRES
    i-v (pA) (%) (%) n (%) i-v (pA) (%) (%) n (%)
    i 168 ± 2  19.3 ± 0.7 19.3 ± 0.7 3 0.0 ± 0.0 i 158 ± 1 35.8 ± 1.8 35.8 ± 1.8 3 0.0 ± 0.0
    ii 171 ± 4  19.7 ± 0.8 19.3 ± 0.7 3 0.4 ± 0.2 ii 162 ± 7 35.2 ± 0.1 36.8 ± 0.1 3 −1.6 ± 0.1 
    iii 178 ± 13 22.3 ± 1.3 21.1 ± 1.1 5 1.2 ± 0.3 iii 169 ± 8 39.0 ± 1.2 37.5 ± 0.9 4 1.5 ± 0.4
    iv 175 ± 11 20.1 ± 1.3 21.1 ± 1.5 3 −1.0 ± 0.2  iv 171 ± 7 35.3 ± 0.5 37.5 ± 0.9 3 −2.2 ± 0.5 
    v 166 ± 14 21.3 ± 1.3 21.3 ± 1.3 3 0.0 ± 0.0 v 168 ± 8 37.8 ± 1.4 37.8 ± 1.4 3 0.0 ± 0.0
  • Our data suggest that when the A5 sequence is closest to the streptavidin anchor (positions 1-5 from the 3′ end), the bases are not recognized by the α-HL pore, i.e. ΔIRES A5oligo−poly(dC)=0, for both WT α-HL and E111N/K147N, and the A5 sequence is likely lie within the vestibule. However, when the A5 sequence was in positions 6-10, 11-15, and 16-20, the bases were recognized in both pores (FIG. 2C). Importantly, when the A5 sequence was in positions 6-10, the WT and the E111N/K147N pores recognized the DNA in a different way, i.e. for WT α-HL, ΔIRE5 A5oligo−poly(dC) was positive (+0.4±0.2%) and for E111N/K147N, ΔIRES A5oligo−poly(dC) was negative (−1.6±0.1%), suggesting that in this case the A5 sequence lies at the constriction where the mutations are located. Finally, when the A5 sequence was in positions 21-25, no discrimination was seen suggesting that this sequence protrudes through the trans entrance of the pore. Therefore the sequence bounded by positions 6 and 20 from the 3′ end of the DNA is likely to lie within the narrow confines of the β barrel, where recognition should be at its strongest. Ashkenasy and colleagues (supra) performed a similar experiment and found that stretches of adenine nucleotides were recognized near the trans entrance, but as noted above they used DNA immobilized with hairpins.
  • The ssDNA in the pore is elongated compared to its conformation in solution. First, the applied potential produces a force on the DNA, which can be estimated to be ˜8 pN, by the following argument. Let there be ˜30 nt in the entire lumen of the pore (about the same as there would be for a strand in a double helix 10 nm in length) and therefore ˜15 nt in the transmembrane β barrel. The experimentally determined effective charge on each base is ˜0.1e (Sauer-Budge, A. F., Nyamwanda, J. A., Lubensky, D. K., & Branton, D. (2003) Phys. Rev. Lett. 90, 238101-238101-238101-238104). This low value is consistent with the theory of Zhang and Shklovskii (Zhang, J. & Shklovskii, B. I. (2007) Phys Rev E Stat Nonlin Soft Matter Phys 75, 021906). Therefore, the overall charge is ˜2.4×10−19 C. The field is 0.16 V over the 5 nm of the barrel or 3.2×107 Vm−1. Therefore, the force (F=QE) is ˜8 pN. Under this force, ssDNA has a similar extension to the B-form of dsDNA (Bustamante, C., Smith, S. B., Liphardt, J., & Smith, D. (2000) Curr. Op. Struct. Biol. 10, 279-285), so there would indeed be ˜30 nt in the full length of the pore and about 15 nt in the β barrel. Second, the effects of enforced confinement would serve to elongate the DNA still further (Han, J. & Craighead, H. G. (2000) Science 288, 1026-1029). Taking into account how streptavidin might dock on the cis surface of the α-HL pore, the location of the biotin binding site within streptavidin and the length of the linker between the DNA and the biotinyl group (FIG. 7), the 3′ end of the DNA would be within the lumen and about 15 — from the cis entrance (FIG. 1). Therefore, it is reasonable that the DNA strand is located with residues 6 to 20 within the β barrel (FIG. 2).
    • 2.3 Discrimination of Single Adenine Nucleotides
  • The results of the A5 scan show that the α-HL pore can recognize bases in ssDNA and contains at least three recognition sites within the β barrel. Of course, to be of use in sequencing intact ssDNA strands, the α-HL pore must be able to detect single nucleotides. Therefore, we further defined the recognition sites by moving a single A base through a poly(dC) background and comparing the residual current with that of poly(dC) itself. A set of fourteen poly(dC) oligonucleotides was made (SEQ ID NOs: 21 to 34), each containing a single adenine (A1) nucleotide (Askenashay and colleagues, supra). The A1 substitutions were in positions 7 to 20 relative to the 3′ biotin tag (FIG. 3). ΔIRES (with respect to poly(dC)) was plotted against the position of the adenine nucleotide for both the WT and E111N/K147N pores (FIG. 3, Table 4).
  • TABLE 4
    Residual currents (IRES) for poly(dC) and oligonucleotides that contain a
    single adenine nucleotide. The position of the adenine in the A1 nucleotide (nucleotides 7-20)
    is numbered relative to the 3′ biotin tag. The IO and IRES values are the mean values
    from n experiments. ΔIRES is defined as the difference in residual current between an A1
    oligonucleotides and poly(dC) (IRES A1oligo − IRES dC). The errors given are standard
    deviations.
    Position WT Position E111N/K147N
    of Io IRES A1 IRES pdC ΔIRES of Io IRES A1 IRES pdC ΔIRES
    adenine (pA) (%) (%) n (%) adenine (pA) (%) (%) n (%)
    7 167 ± 1 20.4 ± 0.4 20.2 ± 0.6 3 0.3 ± 0.2 7  169 ± 10 37.0 ± 0.4 37.0 ± 0.4 3 0.0 ± 0.0
    8 170 ± 4 20.1 ± 0.4 19.6 ± 0.4 3 0.6 ± 0.1 8 163 ± 2 34.9 ± 3.9 34.9 ± 3.9 3 0.0 ± 0.0
    9 169 ± 3 20.5 ± 0.5 19.9 ± 0.4 3 0.6 ± 0.1 9 163 ± 1 34.3 ± 3.8 34.9 ± 3.7 3 −0.6 ± 0.1 
    10 173 ± 2 20.3 ± 0.2 20.0 ± 0.2 4 0.3 ± 0.0 10 175 ± 4 36.1 ± 0.4 37.0 ± 0.4 3 −0.9 ± 0.1 
    11 168 ± 8 20.0 ± 0.2 20.0 ± 0.2 3 0.0 ± 0.0 11 165 ± 5 36.6 ± 0.1 37.2 ± 0.1 3 −0.6 ± 0.1 
    12  173 ± 12 20.1 ± 0.1 20.0 ± 0.2 3 0.1 ± 0.1 12 164 ± 6 35.0 ± 2.2 35.0 ± 2.2 3 0.0 ± 0.0
    13 168 ± 6 20.4 ± 0.3 19.8 ± 0.3 3 0.5 ± 0.1 13 164 ± 6 37.0 ± 1.8 36.3 ± 1.7 3 0.7 ± 0.1
    14 170 ± 8 20.5 ± 0.7 19.7 ± 0.6 3 0.8 ± 0.1 14 167 ± 9 37.1 ± 1.5 35.5 ± 1.4 3 1.6 ± 0.1
    15 172 ± 5 20.7 ± 0.3 20.0 ± 0.3 3 0.6 ± 0.1 15 164 ± 3 38.4 ± 2.2 36.5 ± 2.2 3 1.9 ± 0.1
    16 170 ± 5 19.9 ± 0.2 20.0 ± 0.1 3 −0.1 ± 0.1  16 161 ± 5 37.4 ± 1.3 36.4 ± 1.2 3 1.0 ± 0.2
    17 172 ± 5 19.3 ± 0.4 19.8 ± 0.4 3 −0.4 ± 0.0  17 165 ± 3 37.0 ± 0.3 36.9 ± 0.1 3 0.2 ± 0.3
    18 171 ± 6 20.2 ± 0.9 20.5 ± 0.9 3 −0.3 ± 0.1  18 165 ± 4 36.2 ± 0.3 37.0 ± 0.4 3 −0.9 ± 0.0 
    19 172 ± 5 20.0 ± 0.3 20.0 ± 0.3 3 0.0 ± 0.0 19  170 ± 17 36.1 ± 1.6 36.6 ± 1.5 3 −0.5 ± 0.1 
    20 173 ± 7 20.5 ± 0.9 20.5 ± 0.9 3 0.0 ± 0.0 20 166 ± 5 35.9 ± 1.3 35.9 ± 1.3 3 0.0 ± 0.0
  • Both pores were able to discriminate single adenine nucleotides at multiple positions within the oligonucleotide chain. Remarkably, the pattern of ΔIRES values for the A1 oligonucleotides mirrored the pattern seen with the A5 oligonucleotides (FIGS. 2, 3). Further, the data suggest that there are indeed three recognition sites within the barrel, which have been designated R1, R2 and R3 (FIG. 3). These experiments further demonstrate that a single base (A versus C) can be recognized in an otherwise identical strand at all three sites. By contrast, in the hairpin-anchor experiments of Ashkenasy (supra), recognition was confined to the trans entrance. When the WT and E111N/K147N pores are compared, the A1 scans appear to be about 1 nt out of phase, suggesting that the extent of elongation of the ssDNA may differ slightly in the two pores.
    • 2.4 Probing the Three Recognition Sites of α-HL For Four-Base Discrimination
  • In addition to the detection of individual bases, to sequence ssDNA, α-HL pores must also be able to distinguish between G, A, T and C within a DNA chain. To examine this possibility, the WT and E111N/K147N pores were probed with three sets of four oligonucleotides (SEQ ID NOs: 35 to 46). Each oligonucleotide was a homopolymer (poly(dC)), except at a specific position, where it was substituted with either G, A, T and C (the latter oligonucleotide being poly(dC) itself). Each of the three sets had substitutions at a different position in the sequence, which were designed to probe the R1, R2 and R3 recognition sites.
  • The first set of oligonucleotides had the G, A, T or C substitution at position 9 (from the 3′ end) and was designed to probe R1 (FIG. 4A). Although there is some discrimination between the four oligonucleotides in this set, neither the WT nor the E111N/K147N pore is able to distinguish all four bases. The second set had the G, A, T or C substitution at position 14 and was designed to probe R2 (FIG. 4B). In this case, both the WT and E111N/K147N pores clearly separated C, T, A and G, in order of increasing IRES. The span between C and G is far greater for the E111N/K147N pores (ΔIRES=2.8%) than it is for WT pores (ΔIRES=1.2%). The final set had the G, A, T or C substitution at position 18 to probe R3 (FIG. 4C). In this case, only the E111N/K147N pores are able distinguish the four bases, but in the reverse order, viz. G, A, T and C, and the spread of IRES values is not as large as seen with the set substituted at position 14.
  • For exonuclease sequencing, in which bases are sequentially cleaved from a DNA strand, all four DNA bases can be identified as deoxyribonucleoside 5′-monophosphates by using an engineered α-HL pore (Astier, Y., Braha, O., & Bayley, H. (2006) J Am Chem Soc 128, 1705-1710). In this case there are no interfering neighboring bases during detection. By contrast, the ability to sequence ssDNA would require the recognition of individual nucleotides in a heteropolymeric background and therefore we tested this possibility. We were uncertain of the outcome because homopolymeric nucleic acids have been reported to form secondary structure including extended helices. (Buhot, A. & Halperin, A. (2004) Phys Rev E Stat Nonlin Soft Matter Phys 70, 020902). Therefore, it was possible that the pronounced differences in residual current that we had observed were the result of disruptions in the DNA structure that caused changes in the conformation of the DNA within the nanopore, which in turn affected current flow.
    • 2.5 Single Nucleotide Discrimination Within a Heteropolymeric Sequence
  • To examine discrimination within a heteropolymer, the most promising site, namely R2 in E111N/K147N was tested using SEQ ID NOs: 47 to 50. All four bases at position 14 in a heteropolymer were recognized with the same order of residual current (C, T, A and G) as seen in the homopolymeric background (FIG. 5). The immediate context of the identified bases (N) was 5′ . . . CTGNACA . . . 3′, by comparison with 5′ . . . CCCNCCC . . . 3′ in the homopolymer. The span between C and G in the residual current histogram (ΔIRES=2.9%) was similar to that seen in the homopolymeric background (ΔIRES=2.8%), although the spacing between the four peaks differed in detail (FIG. 5). The sequence we chose does not contain secondary structure such as hairpins, as predicted by the mfold algorithm (Zuker, M. (2003) Nucleic Acids Res 31, 3406-3415), and is unlikely to form π-stacked helices (Buhot and colleagues, supra).
    • 3 Example 2
  • To facilitate the observation of base recognition derived from current block, DNA strands can be immobilized within the α-HL pore by using a terminal hairpin or a biotin•streptavidin complex, which improves the resolution of the currents associated with individual nucleotides, because of the prolonged observation time (N. Ashkenasy, J. Sánchez-Quesada, H. Bayley, M. R. Ghadiri, Angew. Chem. Int. Ed. Engl. 2005, 44, 1401). The immobilized strands reduce the open pore current level, IO, to a level IB. In this Example, we quote the residual current IRES as a percentage of the open pore current: IRES=(IB/IO)×100. By using the biotin•streptavidin approach, we recently demonstrated that the 5 nm-long β barrel of the α-HL nanopore contains three recognition sites, R1, R2 and R3, each capable of recognizing single nucleotides within DNA strands (D. Stoddart, A. Heron, E. Mikhailova, G. Maglia, H. Bayley, Proc. Natl. Acad. Sci. USA 2009, 106, 7702). R1 is located near the internal constriction in the lumen of the pore and recognizes bases at positions ˜8 to 12 (bases are numbered from the 3′ end of synthetic oligonucleotide probes). R2 is located near the middle of the □ barrel and discriminates bases at positions ˜12 to 16. R3 recognizes bases at positions ˜17 to 20 and is located near the trans entrance of the barrel.
  • We surmised that it might be advantageous to use more than one of the recognition points for DNA sequence determination. Consider a nanopore with two reading heads, R1 and R2, each capable of recognizing all four bases (FIG. 9). If the first site, R1 produces a large dispersion of current levels for the four bases and the second site, R2 produces a more modest dispersion, 16 current levels, one for each of the 16 possible base combinations, would be observed as DNA molecules are translocated through the nanopore. Therefore, at any particular moment, the current signal would offer information about two positions in the sequence, rather than just one, providing redundant information; each base is read twice, first at R1 and secondly at R2. This built-in proof-reading mechanism would improve the overall quality of sequencing.
  • In the WT α-HL pore, R2 is capable of discriminating between each of the four DNA bases (when the bases are placed at position 14, in an otherwise poly(dC) oligonucleotide). With the E111N/K147N mutant (NN), in which the charged residues at the constriction have been removed, a greater current flows through the pore when it is blocked with a DNA•streptavidin complex. This increase in IRES in the NN mutant leads to a greater dispersion of the current levels arising from different DNAs, and thereby improves base discrimination at R2 and R3, compared to WT. However, in NN, the ability of R1 to recognize bases is weakened, presumably due to a reduced interaction between the pore and the DNA at the constriction, where amino acid residues 111 and 147 are located. Therefore, to further tune recognition at R1, substitutions at position 113, which also forms part of the constriction, were examined. The mutation M113Y was the most effective.
  • The E111N/K147N/M113Y (NNY) and NN pores displayed similar discrimination of bases by R2; bases at position 14, within poly(dC), are separated in the same order, namely C, T, A and G, in order of increasing IRES, and with a similar dispersion between C and G: ΔIRES G−C=IRES G−IRES C+2.8±0.1% (n=3) for NN and +2.9±0.1% (n=3) for NNY (FIG. 10a ). It should be noted that the ΔIRES values, which were readily determined from event histograms, showed little experimental variation, while the residual current values (IRES) showed variation that exceeded ΔIRES. NNY displayed vastly improved base recognition properties at R1 compared to the WT and NN pores. In the NN mutant, R1 is not capable of discriminating all four bases (when they are located at position 9 within poly(dC)), and the magnitude of the current differences between the bases is quite small; the difference between the most widely dispersed bases, A and C (ΔIRES A−C) is only −0.4±0.1% (n=5, A giving a lower residual current than C). However, the NNY mutant is capable of discriminating between T, G, A and C, in order of increasing IRES (FIG. 10b ), and the dispersion of current levels is much larger, ΔIRES T−C=−2.8±0.2% (n=5). It is remarkable that the single M113Y mutation is capable of turning a weakly discriminating R1 site in the NN mutant into a strong site in the NNY mutant. Possibly, the tyrosines at position 113 improve discrimination at R1 through aromatic stacking or hydrogen bonding interactions with the immobilized bases (G. Hu, P. D. Gershon, A. E. Hodel, F. A. Quiocho, Proc. Natl. Acad. Sci. USA 1999, 96, 7149). But, we are unsure of what properties of the bases cause the dispersion of the current levels, although it is clear that size is not the only factor, as a T at R1 produces a greater current block than the larger purine bases.
  • We determined whether the NNY mutant, which has two strong recognition points (R1 and R2), could behave like the two-head sensor envisaged in FIG. 9 by using a library containing 16 oligonucleotides comprising poly(dC) with substitutions at position 9 (to probe R1) and position 14 (to probe R2). The sequence of a given oligonucleotide is designated: X9X14, where X represents a defined base; G, A, T or C, and 9 and 14 gives the position of the base (relative to the biotin tag). These oligonucleotides are shown in SEQ ID NOs: 51 to 66 and Table 5 below.
  • TABLE 5
    Sequences of the oligonucleotides used in this study. B
    represents the 3′ biotin-TEG tag and linker. Each oligo
    X9X14 is a member of the set N9N14.
    Oligo- SEQ
    nucleotide ID
    name NO: Oligonucleotide sequence (5′→3′)
    C9C14 51 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCB
    C9T14 52 CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCCB
    C9A14 53 CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCB
    C9G14 54 CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCCCCCCB
    T9C14 55 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCB
    A9C14 56 CCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCACCCCCCCCB
    G9C14 57 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCB
    T9A14 58 CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCTCCCCCCCCB
    A9A14 59 CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCACCCCCCCCB
    G9A14 60 CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCGCCCCCCCCB
    T9G14 61 CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCTCCCCCCCCB
    A9G14 62 CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCACCCCCCCCB
    G9G14 63 CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCGCCCCCCCCB
    T9T14 64 CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCTCCCCCCCCB
    A9T14 65 CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCACCCCCCCCB
    G9T14 66 CCCCCCCCCCCCCCCCCCCCCCCCCCTQCCCGCCCCCCCCB
  • First, we tested whether the identity of the base at position 14 (R2) affected base recognition at position 9 (R1). NNY pores were separately probed with 4 sets of 4 oligonucleotides: N9C14, N9A14, N9T14 and N9G14 (where N=G, A, T or C, FIG. 10b-e , respectively). Despite the variation of the base at position 14, the distribution of the current levels for each set of 4 oligonucleotides, is remarkably similar (Table 6). This suggests that recognition at R1 (i.e. the order and dispersion of the peaks in the histograms) is only weakly influenced by the base occupying R2.
  • TABLE 6
    Mean residual current differences (ΔIRES) between poly(dC)
    oligonucleotides that contain nucleotide substitutions at
    position 9 (to probe R1) and/or position 14 (to probe R2).
    The positions of the substitutions are relative to the 3′
    biotin tag. The sequence of each oligonucleotide is abbreviated
    as X9X14 (SEQ ID NOs: 51 to 66). The mean
    ΔIRES value (± s.d.) is for at least three experiments. ΔIRES
    is directly measured as the difference
    between the residual current levels of two specified
    oligonucleotides (FIG. 10). In the uppermost row (oligonucleotide
    set C9N14), ΔIRES = IRES C9N14 − IRES C9C14
    (FIG. 10a). In the other four rows, ΔIRES = IRES N9X14 − IRES C9X14
    (FIG. 10b-e).
    Oligonu-
    cleotide
    set Residual Current difference (%)
    C9N14 ΔIRES C9A14-C9C14 ΔIRES C9T14-C9C14 ΔIRES C9G14-C9C14
    +1.4 ± 0.0 +1.1 ± 0.0 +2.9 ± 0.1
    N9N14 ΔIRES A9C14-C9C14 ΔIRES T9C14-C9C14 ΔIRES G9C14-C9C14
    −1.4 ± 0.1 −2.8 ± 0.2 −2.0 ± 0.1
    N9A14 ΔIRES A9A14-C9A14 ΔIRES T9A14-C9A14 ΔIRES G9A14-C9A14
    −1.5 ± 0.1 −3.2 ± 0.1 −2.1 ± 0.1
    N9T14 ΔIRES A9T14-C9T14 ΔIRES T9T14-C9T14 ΔIRES G9T14-C9T14
    −1.6 ± 0.1 −2.9 ± 0.1 −2.1 ± 0.1
    N9G14 ΔIRES A9G14-C9G14 ΔIRES T9G14-C9G14 ΔIRES G9G14-C9G14
    −1.1 ± 0.1 −2.8 ± 0.1 −1.7 ± 0.2
  • In the postulated two-head sensor, recognition point R1 produces a large current dispersion, while that produced by R2 is more modest (FIG. 9b ). However, in the case tested, the NNY pore, R1 and R2 produce dispersions of similar magnitude (ΔIRES T−C=−2.8±0.2% and □IRES G−C+2.9±0.1%, respectively, FIG. 10 ab). Further, the slight dependence of recognition at R1 on the base occupying R2 (Table 6, compare the columns for rows two through five) was not considered in the proposed scheme (FIG. 9). Assuming that the effects of each base at each recognition point on the change in current level are additive, and by using the directly determined ΔIRES values in Table 6, we can predict the distribution of ΔIRES values for each of the sixteen sequences N9N14 (SEQ ID NOs: 51 to 66), relative to poly(dC), which is set as zero (FIG. 11).
  • For example, consider the sequence T9A14 (SEQ ID NO: 58). We can predict the unknown ΔIRES T9A14-C9C14 (these two sequences were not compared directly, FIG. 10) by using experimentally determined ΔIRES values (Table 5): ΔIRES T9A14-C9A14=−3.2±0.1% and ΔIRES C9A14-C9C141.4±0.0%. By adding these values together, we find ΔIRES T9A14-C9C14=−1.8 +0.1%. The use of IRES rather than experimental ΔIRES values leads to unacceptable errors in predicted ΔIRES values.
  • All remaining ΔIRES values were predicted in the same way and are shown in FIG. 11 as dashed grey lines. Only two sequences (T9T14 and T9A14) were predicted to overlap directly. However, given the present resolution of our electrical recordings, three additional sequences were expected to remain unresolved; for example, A9A14 was predicted to have ΔIRES A9A14-C9C14=−0.1±0.1% and it was therefore likely to overlap with C9C14. Indeed, when all 16 sequences (N9N14, Table 5) were used simultaneously to probe NNY pores, the histograms of the residual current levels consistently contained 11 resolvable sequence-specific peaks (FIG. 11). The predicted ΔIRES values match well with the measured ΔIRES values, with the observed mean ΔIRES values within the error of the predicted values. We surmise that current flow is restricted at R1 and R2, and that the effects of the two recognition points are approximately additive, when ΔIRES values are small, like the effect of two small resistances in series in an electrical circuit.
  • Although, the 16 DNA sequences did not produce 16 discrete current levels, we were able to resolve 11. A perfect 16-level system of two reading heads would read each position in a sequence twice, while a perfect single reading head would read the sequence just once. Therefore, although the 11-level system is imperfect, it does yield additional, redundant information about each base, which would provide more secure base identification than a single reading head. It might be thought that a third reading head would improve matters. However, in this case, the number of possible base combinations would increase from 16 to 64. Even if these levels could be dispersed across the entire current spectrum of the α-HL pore (from almost open to almost closed), it is unlikely that the 64 levels could be separated owing to the electrical noise in the system, even under the low bandwidth conditions used here. Under the high applied potentials required for threading, DNA translocates very quickly through the α-HL pore (at a few μs per base) and the situation would be exacerbated by the need for high data acquisition rates and the consequential increase in noise. Even enzyme-mediated threading at one-thousandth of the rate for free DNA will present difficulties. Therefore, it seems likely that a two reading-head sensor is optimal, and our next step will be to remove the superfluous reading head R3.
  • Sequence listing
    SEQ ID NO: 1 (WT α-HL)
      1 ATGGCAGATT CTGATATTAA TATTAAAACC GGTACTACAG ATATTGGAAG CAATACTACA GTAAAAACAG
     71 GTGATTTAGT CACTTATGAT AAAGAAAATG GCATGCACAA AAAAGTATTT TATAGTTTTA TCGATGATAA
    141 AAATCACAAT AAAAAACTGC TAGTTATTAG AACAAAAGGT ACCATTGCTG GTCAATATAG AGTTTATAGC
    211 GAAGAAGGTG CTAACAAAAG TGGTTTAGCC TGGCCTTCAG CCTTTAAGGT ACAGTTGCAA CTACCTGATA
    281 ATGAAGTAGC TCAAATATCT GATTACTATC CAAGAAATTC GATTGATACA AAAGAGTATA TGAGTACTTT
    351 AACTTATGGA TTCAACGGTA ATGTTACTGG TGATGATACA GGAAAAATTG GCGGCCTTAT TGGTGCAAAT
    421 GTTTCGATTG GTCATACACT GAAATATGTT CAACCTGATT TCAAAACAAT TTTAGAGAGC CCAACTGATA
    491 AAAAAGTAGG CTGGAAAGTG ATATTTAACA ATATGGTGAA TCAAAATTGG GGACCATACG ATCGAGATTC
    561 TTGGAACCCG GTATATGGCA ATCAACTTTT CATGAAAACT AGAAATGGTT CTATGAAAGC AGCAGATAAC
    631 TTCCTTGATC CTAACAAAGC AAGTTCTCTA TTATCTTCAG GGTTTTCACC AGACTTCGCT ACAGTTATTA
    701 CTATGGATAG AAAAGCATCC AAACAACAAA CAAATATAGA TGTAATATAC GAACGAGTTC GTGATGATTA
    771 CCAATTGCAT TGGACTTCAA CAAATTGGAA AGGTACCAAT ACTAAAGATA AATGGACAGA TCGTTCTTCA
    841 GAAAGATATA AAATCGATTG GGAAAAAGAA GAAATGACAA AT
    SEQ ID NO: 2 (WT α-HL)
      1 ADSDINIKTG TTDIGSNTTV KTGDLVTYDK ENGMHKKVFY SFIDDKNHNK KLLVIRTKGT IAGQYRVYSE
     71 EGANKSGLAW PSAFKVQLQL PDNEVAQISD YYPRNSIDTK EYMSTLTYGF NGNVTGDDTG KIGGLIGANV
    141 SIGHTLKYVQ PDFKTILESP TDKKVGWKVI FNNMVNQNWG PYDRDSWNPV YGNQLFMKTR NGSMKAADNF
    211 LDPNKASSLL SSGFSPDFAT VITMDRKASK QQTNIDVIYE RVRDDYQLHW TSTNWKGTNT KDKWTDRSSE
    281 RYKIDWEKEE MTN
    SEQ ID NO: 3 (α-HL E111N/K147N)
      1 ATGGCAGATT CTGATATTAA TATTAAAACC GGTACTACAG ATATTGGAAG CAATACTACA GTAAAAACAG
     71 GTGATTTAGT CACTTATGAT AAAGAAAATG GCATGCACAA AAAAGTATTT TATAGTTTTA TCGATGATAA
    141 AAATCACAAT AAAAAACTGC TAGTTATTAG AACAAAAGGT ACCATTGCTG GTCAATATAG AGTTTATAGC
    211 GAAGAAGGTG CTAACAAAAG TGGTTTAGCC TGGCCTTCAG CCTTTAAGGT ACAGTTGCAA CTACCTGATA
    281 ATGAAGTAGC TCAAATATCT GATTACTATC CAAGAAATTC GATTGATACA AAAAACTATA TGAGTACTTT
    351 AACTTATGGA TTCAACGGTA ATGTTACTGG TGATGATACA GGAAAAATTG GCGGCCTTAT TGGTGCAAAT
    421 GTTTCGATTG GTCATACACT GAACTATGTT CAACCTGATT TCAAAACAAT TTTAGAGAGC CCAACTGATA
    491 AAAAAGTAGG CTGGAAAGTG ATATTTAACA ATATGGTGAA TCAAAATTGG GGACCATACG ATCGAGATTC
    561 TTGGAACCCG GTATATGGCA ATCAACTTTT CATGAAAACT AGAAATGGTT CTATGAAAGC AGCAGATAAC
    631 TTCCTTGATC CTAACAAAGC AAGTTCTCTA TTATCTTCAG GGTTTTCACC AGACTTCGCT ACAGTTATTA
    701 CTATGGATAG AAAAGCATCC AAACAACAAA CAAATATAGA TGTAATATAC GAACGAGTTC GTGATGATTA
    771 CCAATTGCAT TGGACTTCAA CAAATTGGAA AGGTACCAAT ACTAAAGATA AATGGACAGA TCGTTCTTCA
    841 GAAAGATATA AAATCGATTG GGAAAAAGAA GAAATGACAA AT
    SEQ ID NO: 4 (α-HL E111N/K147N)
      1 ADSDINIKTG TTDIGSNTTV KTGDLVTYDK ENGMHKKVFY SFIDDKNHNK KLLVIRTKGT IAGQYRVYSE
     71 EGANKSGLAW PSAFKVQLQL PDNEVAQISD YYPRNSIDTK NYMSTLTYGF NGNVTGDDTG KIGGLIGANV
    141 SIGHTLNYVQ PDFKTILESP TDKKVGWKVI FNNMVNQNWG PYDRDSWNPV YGNQLFMKTR NGSMKAADNF
    211 LDPNKASSLL SSGFSPDFAT VITMDRKASK QQTNIDVIYE RVRDDYQLHW TSTNWKGTNT KDKWTDRSSE
    281 RYKIDWEKEE MTN
    SEQ ID NO: 5 (WT EcoExo I)
       1 ATGATGAACG ATGGCAAACA GCAGAGCACC TTCCTGTTTC ATGATTATGA AACCTTCGGT ACCCATCCGG
      71 CCCTGGATCG TCCGGCGCAG TTTGCGGCCA TTCGCACCGA TAGCGAATTC AATGTGATTG GCGAACCGGA
     141 AGTGTTTTAT TGCAAACCGG CCGATGATTA TCTGCCGCAG CCGGGTGCGG TGCTGATTAC CGGTATTACC
     211 CCGCAGGAAG CGCGCGCGAA AGGTGAAAAC GAAGCGGCGT TTGCCGCGCG CATTCATAGC CTGTTTACCG
     281 TGCCGAAAAC CTGCATTCTG GGCTATAACA ATGTGCGCTT CGATGATGAA GTTACCCGTA ATATCTTTTA
     351 TCGTAACTTT TATGATCCGT ATGCGTGGAG CTGGCAGCAT GATAACAGCC GTTGGGATCT GCTGGATGTG
     421 ATGCGCGCGT GCTATGCGCT GCGCCCGGAA GGCATTAATT GGCCGGAAAA CGATGATGGC CTGCCGAGCT
     491 TTCGTCTGGA ACATCTGACC AAAGCCAACG GCATTGAACA TAGCAATGCC CATGATGCGA TGGCCGATGT
     561 TTATGCGACC ATTGCGATGG CGAAACTGGT TAAAACCCGT CAGCCGCGCC TGTTTGATTA TCTGTTTACC
     631 CACCGTAACA AACACAAACT GATGGCGCTG ATTGATGTTC CGCAGATGAA ACCGCTGGTG CATGTGAGCG
     701 GCATGTTTGG CGCCTGGCGC GGCAACACCA GCTGGGTGGC CCCGCTGGCC TGGCACCCGG AAAATCGTAA
     771 CGCCGTGATT ATGGTTGATC TGGCCGGTGA TATTAGCCCG CTGCTGGAAC TGGATAGCGA TACCCTGCGT
     841 GAACGCCTGT ATACCGCCAA AACCGATCTG GGCGATAATG CCGCCGTGCC GGTGAAACTG GTTCACATTA
     911 ACAAATGCCC GGTGCTGGCC CAGGCGAACA CCCTGCGCCC GGAAGATGCG GATCGTCTGG GTATTAATCG
     981 CCAGCATTGT CTGGATAATC TGAAAATCCT GCGTGAAAAC CCGCAGGTGC GTGAAAAAGT GGTGGCGATC
    1051 TTCGCGGAAG CGGAACCGTT CACCCCGAGC GATAACGTGG ATGCGCAGCT GTATAACGGC TTCTTTAGCG
    1121 ATGCCGATCG CGCGGCGATG AAAATCGTTC TGGAAACCGA ACCGCGCAAT CTGCCGGCGC TGGATATTAC
    1191 CTTTGTTGAT AAACGTATTG AAAAACTGCT GTTTAATTAT CGTGCGCGCA ATTTTCCGGG TACCCTGGAT
    1261 TATGCCGAAC AGCAGCGTTG GCTGGAACAT CGTCGTCAGG TTTTCACCCC GGAATTTCTG CAGGGTTATG
    1331 CGGATGAACT GCAGATGCTG GTTCAGCAGT ATGCCGATGA TAAAGAAAAA GTGGCGCTGC
    SEQ ID NO: 6 (WT EcoExo I)
      1
    Figure US20170233803A1-20170817-P00001
    MNDGKQQST FLEHDYETFG THPALDRPAQ FAAIRTDSEF NVIGEPEVFY
     51 CKPADDYLPQ PGAVLITGIT PQEARAKGEN EAAFAARIHS LFTVPKTCIL
    101 GYNNVRFDDE VTRNIFYRNF YDPYAWSWQH DNSRWDLLDV MRACYALRPE
    151 GINWPENDDG LPSFRLEHLT KANGIEHSNA HDAMADVYAT IAMAKLVKTR
    201 QPRLFDYLFT HRNKHKLMAL IDVPQMKPLV HVSGMFGAWR GNTSWVAPLA
    251 WHPENRNAVI MVDLAGDISP LLELDSDTLR ERLYTAKTDL GDNAAVPVKL
    301 VHINKCPVLA QANTLRPEDA DRLGINRQHC LDNLKILREN PQVREKVVAI
    351 FAEAEPFTPS DNVDAQLYNG FFSDADRAAM KIVLETEPRN LPALDITFVD
    401 KRIEKLLFNY RARNFPGTLD YAEQQRWLEH RRQVFTPEFL QGYADELQML
    451 VQQYADDKEK VALLKALWQY AEEIV SGSGH HHHHH
    SEQ ID NO: 7 (WT Exo III)
      1 ATGAAATTTG TCTCTTTTAA TATCAACGGC CTGCGCGCCA GACCTCACCA GCTTGAAGCC ATCGTCGAAA
     71 AGCACCAACC GGATGTGATT GGCCTGCAGG AGACAAAAGT TCATGACGAT ATGTTTCCGC TCGAAGAGGT
    141 GGCGAAGCTC GGCTACAACG TGTTTTATCA CGGGCAGAAA GGCCATTATG GCGTGGCGCT GCTGACCAAA
    211 GAGACGCCGA TTGCCGTGCG TCGCGGCTTT CCCGGTGACG ACGAAGAGGC GCAGCGGCGG ATTATTATGG
    281 CGGAAATCCC CTCACTGCTG GGTAATGTCA CCGTGATCAA CGGTTACTTC CCGCAGGGTG AAAGCCGCGA
    351 CCATCCGATA AAATTCCCGG CAAAAGCGCA GTTTTATCAG AATCTGCAAA ACTACCTGGA AACCGAACTC
    421 AAACGTGATA ATCCGGTACT GATTATGGGC GATATGAATA TCAGCCCTAC AGATCTGGAT ATCGGCATTG
    491 GCGAAGAAAA CCGTAAGCGC TGGCTGCGTA CCGGTAAATG CTCTTTCCTG CCGGAAGAGC GCGAATGGAT
    561 GGACAGGCTG ATGAGCTGGG GGTTGGTCGA TACCTTCCGC CATGCGAATC CGCAAACAGC AGATCGTTTC
    631 TCATGGTTTG ATTACCGCTC AAAAGGTTTT GACGATAACC GTGGTCTGCG CATCGACCTG CTGCTCGCCA
    701 GCCAACCGCT GGCAGAATGT TGCGTAGAAA CCGGCATCGA CTATGAAATC CGCAGCATGG AAAAACCGTC
    771 CGATCACGCC CCCGTCTGGG CGACCTTCCG CCGC
    SEQ ID NO: 8 (WT Exo III)
      1 MKFVSFNING LRARPHQLEA IVEKHQPDVI GLQETKVHDD MFPLEEVAKL GYNVFYHGQK GHYGVALLTK
     71 ETPIAVRRGF PGDDEEAQRR IIMAEIPSLL GNVTVINGYF PQGESRDHPI KFPAKAQFYQ NLQNYLETEL
    141 KRDNPVLIMG DMNISPTDLD IGIGEENRKR WLRTGKCSFL PEEREWMDRL MSWGLVDTFR HANPQTADRF
    211 SWFDYRSKGF DDNRGLRIDL LLASQPLAEC CVETGIDYEI RSMEKPSDHA PVWATFRR
    SEQ ID NO: 9 (WT RecJ)
       1 ATGTTTCGTC GTAAAGAAGA TCTGGATCCG CCGCTGGCAC TGCTGCCGCT GAAAGGCCTG CGCGAAGCCG
      71 CCGCACTGCT GGAAGAAGCG CTGCGTCAAG GTAAACGCAT TCGTGTTCAC GGCGACTATG ATGCGGATGG
     141 CCTGACCGGC ACCGCGATCC TGGTTCGTGG TCTGGCCGCC CTGGGTGCGG ATGTTCATCC GTTTATCCCG
     211 CACCGCCTGG AAGAAGGCTA TGGTGTCCTG ATGGAACGCG TCCCGGAACA TCTGGAAGCC TCGGACCTGT
     281 TTCTGACCGT TGACTGCGGC ATTACCAACC ATGCGGAACT GCGCGAACTG CTGGAAAATG GCGTGGAAGT
     351 CATTGTTACC GATCATCATA CGCCGGGCAA AACGCCGCCG CCGGGTCTGG TCGTGCATCC GGCGCTGACG
     421 CCGGATCTGA AAGAAAAACC GACCGGCGCA GGCGTGGCGT TTCTGCTGCT GTGGGCACTG CATGAACGCC
     491 TGGGCCTGCC GCCGCCGCTG GAATACGCGG ACCTGGCAGC CGTTGGCACC ATTGCCGACG TTGCCCCGCT
     561 GTGGGGTTGG AATCGTGCAC TGGTGAAAGA AGGTCTGGCA CGCATCCCGG CTTCATCTTG GGTGGGCCTG
     631 CGTCTGCTGG CTGAAGCCGT GGGCTATACC GGCAAAGCGG TCGAAGTCGC TTTCCGCATC GCGCCGCGCA
     701 TCAATGCGGC TTCCCGCCTG GGCGAAGCGG AAAAAGCCCT GCGCCTGCTG CTGACGGATG ATGCGGCAGA
     771 AGCTCAGGCG CTGGTCGGCG AACTGCACCG TCTGAACGCC CGTCGTCAGA CCCTGGAAGA AGCGATGCTG
     841 CGCAAACTGC TGCCGCAGGC CGACCCGGAA GCGAAAGCCA TCGTTCTGCT GGACCCGGAA GGCCATCCGG
     911 GTGTTATGGG TATTGTGGCC TCTCGCATCC TGGAAGCGAC CCTGCGCCCG GTCTTTCTGG TGGCCCAGGG
     981 CAAAGGCACC GTGCGTTCGC TGGCTCCGAT TTCCGCCGTC GAAGCACTGC GCAGCGCGGA AGATCTGCTG
    1051 CTGCGTTATG GTGGTCATAA AGAAGCGGCG GGTTTCGCAA TGGATGAAGC GCTGTTTCCG GCGTTCAAAG
    1121 CACGCGTTGA AGCGTATGCC GCACGTTTCC CGGATCCGGT TCGTGAAGTG GCACTGCTGG ATCTGCTGCC
    1191 GGAACCGGGC CTGCTGCCGC AGGTGTTCCG TGAACTGGCA CTGCTGGAAC CGTATGGTGA AGGTAACCCG
    1261 GAACCGCTGT TCCTG
    SEQ ID NO: 10 (WT RecJ)
      1 MFRRKEDLDP PLALLPLKGL REAAAILEEA LRQGKRIRVH GDYDADGLTG TAILVRGLAA LGADVHPFIP
     71 HRLEEGYGVL MERVPEHLEA SDLFLTVDCG ITNHAELREL LENGVEVIVT DHHTPGKTPP PGLVVHPALT
    141 PDLKEKPTGA GVAFLLLWAL HERLGLPPPL EYADLAAVGT IADVAPLWGW NRALVKEGLA RIPASSWVGL
    211 RLLAEAVGYT GYAVEVAFRI APRINAASRL GEAEKALRLL LTDDAAEAQA LVGELHRLNA RRQTLEEAML
    281 RYLLPQADPE AKAIVLLDPE GHPGvMGIVA SRILEATLRP VFLVAQGKGT VRSLAPISAV EALRSAEDLL
    351 LRYGGHKEAA GFAMDEALFP AFKARVEAyA ARFRDRVREV ALLDLLPEPG LLPQVFRELA LLEPYGEGNP
    421 EPLFL
    SEQ ID NO: 11 (WT lambda Exo)
      1 TCCGGAAGCG GCTCTGGTAG TGGTTCTGGC ATGACACCGG ACATTATCCT GCAGCGTACC GGGATCGATG
     71 TGAGAGCTGT CGAACAGGGG GATGATGCGT GGCACAAATT ACGGCTCGGC GTCATCACCG CTTCAGAAGT
    141 TCACAACGTG ATAGCAAAAC CCCGCTCCGG AAAGAAGTGG CCTGACATGA AAATGTCCTA CTTCCACACC
    211 CTGCTTGCTG AGGTTTGCAC CGGTGTGGCT CCGGAAGTTA ACGCTAAAGC ACTGGCCTGG GGAAAACAGT
    281 ACGAGAACGA CGCCAGAACC CTGTTTGAAT TCACTTCCGG CGTGAATGTT ACTGAATCCC CGATCATCTA
    351 TCGCGACGAA AGTATGCGTA CCGCCTGCTC TCCCGATGGT TTATGCAGTG ACGGCAACGG CCTTGAACTG
    421 AAATGCCCGT TTACCTCCCG GGATTTCATG AAGTTCCGGC TCGGTGGTTT CGAGGCCATA AAGTCAGCTT
    491 ACATGGCCCA GGTGCAGTAC AGCATGTGGG TGACGCGAAA AAATGCCTGG TACTTTGCCA ACTATGACCC
    561 GCGTATGAAG CGTGAAGGCC TGCATTATGT CGTGATTGAG CGGGATGAAA AGTACATGGC GAGTTTTGAC
    631 GAGATCGTGC CGGAGTTCAT CGAAAAAATG GACGAGGCAC TGGCTGAAAT TGGTTTTGTA TTTGGGGAGC
    701 AATGGCGATC TGGCTCTGGT TCCGGCAGCG GTTCCGGA
    SEQ ID NO: 12 (WT lambda Exo)
      1 MTPDIILQRT GIDVRAVEQG DDAWHKLRLG VITASEVHNV IAKPRSGKKW PDMKMSYFHT LLAEVCTGVA
     71 PEVNAKALAw GKQYENDART LFEFTSGVNV TESPIIYRDE SMRTACSPDG LCSDGNGLEL KCPFTSRDFM
    141 KFRLGGFEAI KSAyMAQVQY SMWVTRKNAW YFANyDpRMK REGLHYVVIE RDEKYMASFD EIVPEFIEKM
    211 DEALAEIGFV FGEQWR
    SEQ ID NO: 13
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 14
    AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
    SEQ ID NO: 15
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 16
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAAA
    SEQ ID NO: 17
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCAAAAACCCCC
    SEQ ID NO: 18
    CCCCCCCCCCCCCCCCCCCCCCCCCAAAAACCCCCCCCCC
    SEQ ID NO: 19
    CCCCCCCCCCCCCCCCCCCCAAAAACCCCCCCCCCCCCCC
    SEQ ID NO: 20
    CCCCCCCCCCCCCCCAAAAACCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 21
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCC
    SEQ ID NO: 22
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCC
    SEQ ID NO: 23
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCC
    SEQ ID NO: 24
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCC
    SEQ ID NO: 25
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCC
    SEQ ID NO: 26
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCC
    SEQ ID NO: 27
    CCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCC
    SEQ ID NO: 28
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCC
    SEQ ID NO: 29
    CCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCC
    SEQ ID NO: 30
    CCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCC
    SEQ ID NO: 31
    CCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCCC
    SEQ ID NO: 32
    CCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCCCC
    SEQ ID NO: 33
    CCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCCCCC
    SEQ ID NO: 34
    CCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 35
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCC
    SEQ ID NO: 36
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCC
    SEQ ID NO: 37
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCC
    SEQ ID NO: 38
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 39
    CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCCCCCC
    SEQ ID NO: 40
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCC
    SEQ ID NO: 41
    CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCC
    SEQ ID NO: 42
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 43
    CCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCCCCCCCCCC
    SEQ ID NO: 44
    CCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCCCCC
    SEQ ID NO: 45
    CCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCCCCCC
    SEQ ID NO: 46
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
    SEQ ID NO: 47
    ACTACCTAGTTTACGTAATCCATCTGAACAATGCAGCATT
    SEQ ID NO: 48
    ACTACCTAGTTTACGTAATCCATCTGTACAATGCAGCATT
    SEQ ID NO: 49
    ACTACCTAGTTTACGTAATCCATCTGGACAATGCAGCATT
    SEQ ID NO: 50
    ACTACCTAGTTTACGTAATCCATCTGCACAATGCAGCATT
    SEQ ID NO: 51
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCB
    SEQ ID NO: 52
    CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCCCCCCB
    SEQ ID NO: 53
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCCCCCCB
    SEQ ID NO: 54
    CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCCCCCCB
    SEQ ID NO: 55
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCCCB
    SEQ ID NO: 56
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCCCCB
    SEQ ID NO: 57
    CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCCCCCB
    SEQ ID NO: 58
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCTCCCCCCCCB
    SEQ ID NO: 59
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCACCCCCCCCB
    SEQ ID NO: 60
    CCCCCCCCCCCCCCCCCCCCCCCCCCACCCCGCCCCCCCCB
    SEQ ID NO: 61
    CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCTCCCCCCCCB
    SEQ ID NO: 62
    CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCACCCCCCCCB
    SEQ ID NO: 63
    CCCCCCCCCCCCCCCCCCCCCCCCCCGCCCCGCCCCCCCCB
    SEQ ID NO: 64
    CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCTCCCCCCCCB
    SEQ ID NO: 65
    CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCACCCCCCCCB
    SEQ ID NO: 66
    CCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCGCCCCCCCCB

Claims (1)

1. A method for sequencing a heteropolymeric target nucleic acid sequence, comprising:
(a) passing the target sequence through a transmembrane pore so that a proportion of the nucleotides in the target sequence interacts one at a time with at least one site in the pore that is capable of discriminating between different nucleotides; and
(b) measuring the current passing through the pore during each interaction and thereby determining the sequence of the target sequence.
US15/491,505 2009-03-25 2017-04-19 Method for sequencing a heteropolymeric target nucleic acid sequence Abandoned US20170233803A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/491,505 US20170233803A1 (en) 2009-03-25 2017-04-19 Method for sequencing a heteropolymeric target nucleic acid sequence
US15/848,116 US10669581B2 (en) 2009-03-25 2017-12-20 Method for sequencing a heteropolymeric target nucleic acid sequence
US16/858,859 US20200407785A1 (en) 2009-03-25 2020-04-27 Method for sequencing a heteropolymeric target nucleic acid sequence

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0905140.0 2009-03-25
GBGB0905140.0A GB0905140D0 (en) 2009-03-25 2009-03-25 Method
PCT/GB2010/000567 WO2010109197A2 (en) 2009-03-25 2010-03-25 Method
US201213260178A 2012-01-17 2012-01-17
US15/491,505 US20170233803A1 (en) 2009-03-25 2017-04-19 Method for sequencing a heteropolymeric target nucleic acid sequence

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US13/260,178 Continuation US9732381B2 (en) 2009-03-25 2010-03-25 Method for sequencing a heteropolymeric target nucleic acid sequence
PCT/GB2010/000567 Continuation WO2010109197A2 (en) 2009-03-25 2010-03-25 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/848,116 Continuation US10669581B2 (en) 2009-03-25 2017-12-20 Method for sequencing a heteropolymeric target nucleic acid sequence

Publications (1)

Publication Number Publication Date
US20170233803A1 true US20170233803A1 (en) 2017-08-17

Family

ID=40640152

Family Applications (4)

Application Number Title Priority Date Filing Date
US13/260,178 Active 2030-05-18 US9732381B2 (en) 2009-03-25 2010-03-25 Method for sequencing a heteropolymeric target nucleic acid sequence
US15/491,505 Abandoned US20170233803A1 (en) 2009-03-25 2017-04-19 Method for sequencing a heteropolymeric target nucleic acid sequence
US15/848,116 Active US10669581B2 (en) 2009-03-25 2017-12-20 Method for sequencing a heteropolymeric target nucleic acid sequence
US16/858,859 Pending US20200407785A1 (en) 2009-03-25 2020-04-27 Method for sequencing a heteropolymeric target nucleic acid sequence

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/260,178 Active 2030-05-18 US9732381B2 (en) 2009-03-25 2010-03-25 Method for sequencing a heteropolymeric target nucleic acid sequence

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/848,116 Active US10669581B2 (en) 2009-03-25 2017-12-20 Method for sequencing a heteropolymeric target nucleic acid sequence
US16/858,859 Pending US20200407785A1 (en) 2009-03-25 2020-04-27 Method for sequencing a heteropolymeric target nucleic acid sequence

Country Status (5)

Country Link
US (4) US9732381B2 (en)
EP (2) EP2411538B1 (en)
CN (1) CN102365371B (en)
GB (1) GB0905140D0 (en)
WO (1) WO2010109197A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10006905B2 (en) 2013-03-25 2018-06-26 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US10167503B2 (en) 2014-05-02 2019-01-01 Oxford Nanopore Technologies Ltd. Mutant pores
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
US10400014B2 (en) 2014-09-01 2019-09-03 Oxford Nanopore Technologies Ltd. Mutant CsgG pores
US10472673B2 (en) 2015-02-19 2019-11-12 Oxford Nanopore Technologies Ltd. Hetero-pores
US10669581B2 (en) 2009-03-25 2020-06-02 Oxford University Innovation Limited Method for sequencing a heteropolymeric target nucleic acid sequence
US10882889B2 (en) 2012-04-10 2021-01-05 Oxford Nanopore Technologies Ltd. Mutant lysenin pores
US10976300B2 (en) 2015-12-08 2021-04-13 Katholieke Universiteit Leuven Modified nanopores, compositions comprising the same, and uses thereof
US10975428B2 (en) 2016-03-02 2021-04-13 Oxford Nanopore Technologies Ltd. Mutant pore
US11104709B2 (en) 2016-04-06 2021-08-31 Oxford Nanopore Technologies Ltd. Mutant pore
US11169138B2 (en) 2015-04-14 2021-11-09 Katholieke Universiteit Leuven Nanopores with internal protein adaptors
US11307192B2 (en) 2015-02-19 2022-04-19 Oxford Nanopore Technologies Plc Method for producing a hetero-oligomeric pore comprising two different monomers in a specific stiochiometric ratio
US11572387B2 (en) 2017-06-30 2023-02-07 Vib Vzw Protein pores
US11725235B2 (en) 2014-01-22 2023-08-15 Oxford Nanopore Technologies Plc Method for attaching one or more polynucleotide binding proteins to a target polynucleotide
US12024541B2 (en) 2017-05-04 2024-07-02 Oxford Nanopore Technologies Plc Transmembrane pore consisting of two CsgG pores

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889348B2 (en) 2006-06-07 2014-11-18 The Trustees Of Columbia University In The City Of New York DNA sequencing by nanopore using modified nucleotides
CN103695530B (en) 2008-07-07 2016-05-25 牛津纳米孔技术有限公司 Enzyme-hole construct
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
KR101797773B1 (en) 2009-01-30 2017-11-15 옥스포드 나노포어 테크놀로지즈 리미티드 Adaptors for nucleic acid constructs in transmembrane sequencing
US8986928B2 (en) 2009-04-10 2015-03-24 Pacific Biosciences Of California, Inc. Nanopore sequencing devices and methods
ES2641871T3 (en) 2010-12-17 2017-11-14 The Trustees Of Columbia University In The City Of New York DNA sequencing by synthesis using modified nucleotides and nanopore detection
US9121059B2 (en) 2010-12-22 2015-09-01 Genia Technologies, Inc. Nanopore-based single molecule characterization
KR101939420B1 (en) 2011-02-11 2019-01-16 옥스포드 나노포어 테크놀로지즈 리미티드 Mutant pores
CN103827320B (en) 2011-07-25 2017-04-26 牛津纳米孔技术有限公司 Hairpin loop method for sequencing double-stranded polynucleotides using transmembrane pores
CN104066850B (en) * 2011-09-23 2017-11-10 牛津楠路珀尔科技有限公司 The analysis of polymer comprising polymer unit
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US8688388B2 (en) 2011-10-11 2014-04-01 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9758823B2 (en) * 2011-10-21 2017-09-12 Oxford Nanopore Technologies Limited Enzyme method
WO2013098561A1 (en) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Method for characterising a polynucelotide by using a xpd helicase
WO2013098562A2 (en) * 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Enzyme method
EP2807476A4 (en) * 2012-01-20 2015-12-09 Genia Technologies Inc Nanopore based molecular detection and sequencing
AU2013220156B2 (en) 2012-02-15 2018-08-09 Oxford Nanopore Technologies Limited Aptamer method
EP3736339B1 (en) 2012-02-16 2022-07-27 Oxford Nanopore Technologies plc Analysis of measurements of a polymer
EP2814939B1 (en) * 2012-02-16 2018-04-18 The Regents of the University of California Nanopore sensor for enzyme-mediated protein translocation
ES2906186T3 (en) 2012-04-09 2022-04-13 Univ Columbia Method for the preparation of nanopore and uses thereof
JP2015525077A (en) 2012-06-15 2015-09-03 ジェニア・テクノロジーズ・インコーポレイテッド Chip configuration and highly accurate nucleic acid sequencing
US20150119259A1 (en) 2012-06-20 2015-04-30 Jingyue Ju Nucleic acid sequencing by nanopore detection of tag molecules
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10808231B2 (en) 2012-07-19 2020-10-20 Oxford Nanopore Technologies Limited Modified helicases
CA2879355C (en) * 2012-07-19 2021-09-21 Oxford Nanopore Technologies Limited Helicase construct and its use in characterising polynucleotides
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
EP2895618B1 (en) 2012-09-14 2017-07-26 Oxford Nanopore Technologies Limited Sample preparation method
WO2014072703A1 (en) 2012-11-06 2014-05-15 Oxford Nanopore Technologies Limited Quadruplex method
US9605309B2 (en) * 2012-11-09 2017-03-28 Genia Technologies, Inc. Nucleic acid sequencing using tags
GB201222928D0 (en) 2012-12-19 2013-01-30 Oxford Nanopore Tech Ltd Analysis of a polynucleotide
KR102168813B1 (en) 2013-03-08 2020-10-22 옥스포드 나노포어 테크놀로지즈 리미티드 Enzyme stalling method
GB201318465D0 (en) 2013-10-18 2013-12-04 Oxford Nanopore Tech Ltd Method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
WO2014144898A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Method for detecting multiple predetermined compounds in a sample
WO2014144883A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Raman cluster tagged molecules for biological imaging
GB201316849D0 (en) 2013-09-23 2013-11-06 Isis Innovation Method
GB201406151D0 (en) 2014-04-04 2014-05-21 Oxford Nanopore Tech Ltd Method
CN118256603A (en) 2013-10-18 2024-06-28 牛津纳米孔科技公开有限公司 Modified enzymes
US9322062B2 (en) 2013-10-23 2016-04-26 Genia Technologies, Inc. Process for biosensor well formation
EP3060918B1 (en) 2013-10-23 2019-09-18 Genia Technologies, Inc. High speed molecular sensing with nanopores
CA2926871C (en) 2013-11-26 2022-08-16 Illumina, Inc. Compositions and methods for polynucleotide sequencing
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
WO2015148402A1 (en) 2014-03-24 2015-10-01 The Trustees Of Columbia Univeristy In The City Of New York Chemical methods for producing tagged nucleotides
GB201417712D0 (en) 2014-10-07 2014-11-19 Oxford Nanopore Tech Ltd Method
GB201411285D0 (en) * 2014-06-25 2014-08-06 Prosser Joseph Sequencer
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
EP4397972A3 (en) 2014-10-16 2024-10-09 Oxford Nanopore Technologies PLC Alignment mapping estimation
EP3207155B1 (en) 2014-10-17 2019-06-05 Oxford Nanopore Technologies Limited Method for nanopore rna charicterisation
CN107533045B (en) 2015-02-05 2020-10-09 哈佛大学校长及研究员协会 Nanopore sensor including fluidic channel
EP3268050B1 (en) * 2015-03-09 2021-07-14 The Trustees of Columbia University in the City of New York Pore-forming protein conjugate compositions and methods
GB201508003D0 (en) 2015-05-11 2015-06-24 Oxford Nanopore Tech Ltd Apparatus and methods for measuring an electrical current
CN109563140B (en) 2016-04-21 2022-10-28 豪夫迈·罗氏有限公司 Alpha-hemolysin variants and uses thereof
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
GB201707138D0 (en) 2017-05-04 2017-06-21 Oxford Nanopore Tech Ltd Machine learning analysis of nanopore measurements
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
GB201814369D0 (en) 2018-09-04 2018-10-17 Oxford Nanopore Tech Ltd Method for determining a polymersequence
CA3111488A1 (en) 2018-09-11 2020-03-19 Rijksuniversiteit Groningen Biological nanopores having tunable pore diameters and uses thereof as analytical tools
GB201819378D0 (en) 2018-11-28 2019-01-09 Oxford Nanopore Tech Ltd Analysis of nanopore signal using a machine-learning technique
GB201907243D0 (en) 2019-05-22 2019-07-03 Oxford Nanopore Tech Ltd Sensing interactions between molecular entities and nanapores
CN111413383B (en) * 2020-04-20 2021-03-02 深圳市梅丽纳米孔科技有限公司 Method for constructing double-recognition-site nanopore
CN115867797A (en) 2020-07-02 2023-03-28 伊鲁米纳公司 Device with field effect transistor
GB2610380A (en) 2021-08-23 2023-03-08 Cambridge Entpr Ltd Nucleic acid detection
GB202113935D0 (en) 2021-09-29 2021-11-10 Cambridge Entpr Ltd Nucleic acid characterisation
GB202401864D0 (en) 2024-02-12 2024-03-27 Fund Centre De Regulacio Genòmica A method of detecting non-canonical bases in sequencing data

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
US5777078A (en) 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
DE4320201A1 (en) 1993-06-18 1995-01-12 Asta Medica Ag Use of Cetrorelix and other nona and decapeptides for the manufacture of a medicament for combating AIDS and for growth stimulation
US7569341B2 (en) 1994-01-31 2009-08-04 Trustees Of Boston University Nucleic acid directed immobilization arrays and methods of assembly
US5561043A (en) 1994-01-31 1996-10-01 Trustees Of Boston University Self-assembling multimeric nucleic acid constructs
US6362002B1 (en) 1995-03-17 2002-03-26 President And Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
US5795782A (en) 1995-03-17 1998-08-18 President & Fellows Of Harvard College Characterization of individual polymer molecules based on monomer-interface interactions
JP3891620B2 (en) 1996-11-14 2007-03-14 株式会社アイシン・コスモス研究所 Nucleic acid probe molecule having a hairpin structure, and nucleic acid detection method using the nucleic acid probe molecule
WO1999005167A1 (en) 1997-07-25 1999-02-04 University Of Massachusetts Designed protein pores as components for biosensors
US6087099A (en) 1997-09-08 2000-07-11 Myriad Genetics, Inc. Method for sequencing both strands of a double stranded DNA in a single sequencing reaction
US6127166A (en) 1997-11-03 2000-10-03 Bayley; Hagan Molluscan ligament polypeptides and genes encoding them
JPH11137260A (en) 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk Anti-influenza viral cyclic dumbbell type rna-dna chimera compound and anti-influenza viral agent
US6123819A (en) * 1997-11-12 2000-09-26 Protiveris, Inc. Nanoelectrode arrays
DE19826758C1 (en) 1998-06-15 1999-10-21 Soft Gene Gmbh Production of closed, double-stranded DNA molecules for use in gene therapy or genetic vaccination
US6743605B1 (en) 1998-06-24 2004-06-01 Enzo Life Sciences, Inc. Linear amplification of specific nucleic acid sequences
US7588900B2 (en) 2001-07-03 2009-09-15 The Regents Of The University Of California Mammalian sweet and amino acid heterodimeric taste receptors
US6267872B1 (en) 1998-11-06 2001-07-31 The Regents Of The University Of California Miniature support for thin films containing single channels or nanopores and methods for using same
US6426231B1 (en) 1998-11-18 2002-07-30 The Texas A&M University System Analyte sensing mediated by adapter/carrier molecules
NO986133D0 (en) 1998-12-23 1998-12-23 Preben Lexow Method of DNA Sequencing
US6627067B1 (en) * 1999-06-22 2003-09-30 President And Fellows Of Harvard College Molecular and atomic scale evaluation of biopolymers
US7258838B2 (en) 1999-06-22 2007-08-21 President And Fellows Of Harvard College Solid state molecular probe device
US6464842B1 (en) 1999-06-22 2002-10-15 President And Fellows Of Harvard College Control of solid state dimensional features
WO2001002425A2 (en) 1999-06-29 2001-01-11 University Health Network Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes
AU1804001A (en) 1999-12-02 2001-06-12 Molecular Staging, Inc. Generation of single-strand circular dna from linear self-annealing segments
US6916665B2 (en) 2000-02-11 2005-07-12 The Texas A&M University System Biosensor compositions and methods of use
WO2001070174A2 (en) 2000-03-21 2001-09-27 Curagen Corporation Vegf-modulated genes and methods employing them
DE60132075T2 (en) 2000-03-22 2009-03-12 Curagen Corp., New Haven WNT-1 RELATED POLYPEPTIDES AND NUCLEIC ACIDS THEREFOR
US7001792B2 (en) * 2000-04-24 2006-02-21 Eagle Research & Development, Llc Ultra-fast nucleic acid sequencing device and a method for making and using the same
US6936433B2 (en) 2000-11-27 2005-08-30 The Regents Of The University Of California Methods and devices for characterizing duplex nucleic acid molecules
US20030087232A1 (en) 2001-01-25 2003-05-08 Fred Christians Methods for screening polypeptides
US7807408B2 (en) 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
JP2005520178A (en) 2001-06-27 2005-07-07 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Control solid-state dimension features
US6863833B1 (en) * 2001-06-29 2005-03-08 The Board Of Trustees Of The Leland Stanford Junior University Microfabricated apertures for supporting bilayer lipid membranes
DE60223050T2 (en) 2001-08-31 2008-07-17 Gentex Corp., Zeeland VEHICLE LIGHT ARRANGEMENT WITH COOLING BODY
ATE414769T1 (en) 2002-03-15 2008-12-15 Nuevolution As AN IMPROVED METHOD FOR SYNTHESIS OF MATTRESS-DEPENDENT MOLECULES
EP1504114B1 (en) 2002-05-10 2017-07-12 The Texas A & M University System Stochastic sensing through covalent interactions
AU2003304248A1 (en) 2002-10-29 2005-01-13 President And Fellows Of Harvard College Carbon nanotube device fabrication
US7253434B2 (en) 2002-10-29 2007-08-07 President And Fellows Of Harvard College Suspended carbon nanotube field effect transistor
US7163658B2 (en) 2003-04-23 2007-01-16 Rouvain Bension Rapid sequencing of polymers
US7344882B2 (en) 2003-05-12 2008-03-18 Bristol-Myers Squibb Company Polynucleotides encoding variants of the TRP channel family member, LTRPC3
AU2003904237A0 (en) * 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
WO2005056750A2 (en) 2003-12-11 2005-06-23 Quark Biotech, Inc. Inversion-duplication of nucleic acids and libraries prepared thereby
EP1708957B1 (en) 2003-12-19 2009-05-06 The President and Fellows of Harvard College Analysis of molecules by translocation through a coated aperture
JP2005253427A (en) 2004-03-15 2005-09-22 Aisin Seiki Co Ltd Method for detecting nucleic acid and method for isolating nucleic acid
US7238485B2 (en) 2004-03-23 2007-07-03 President And Fellows Of Harvard College Methods and apparatus for characterizing polynucleotides
JP5190263B2 (en) 2004-08-13 2013-04-24 プレジデント アンド フェローズ オブ ハーバード カレッジ Ultra-high throughput optical-nanopore DNA reading platform
WO2007084103A2 (en) 2004-12-21 2007-07-26 The Texas A & M University System High temperature ion channels and pores
GB0505971D0 (en) 2005-03-23 2005-04-27 Isis Innovation Delivery of molecules to a lipid bilayer
JP4891313B2 (en) 2005-04-06 2012-03-07 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ Molecular characterization using carbon nanotube control
WO2007024997A2 (en) 2005-08-22 2007-03-01 Fermalogic, Inc. Methods of increasing production of secondary metabolites
GB0523282D0 (en) * 2005-11-15 2005-12-21 Isis Innovation Methods using pores
CA2633476C (en) 2005-12-22 2015-04-21 Pacific Biosciences Of California, Inc. Active surface coupled polymerases
US7932029B1 (en) 2006-01-04 2011-04-26 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
US7849581B2 (en) * 2006-05-05 2010-12-14 University Of Utah Research Foundation Nanopore electrode, nanopore membrane, methods of preparation and surface modification, and use thereof
MX2009002547A (en) 2006-09-06 2009-06-19 Phasebio Pharmaceuticals Inc Fusion peptide therapeutic compositions.
WO2008045575A2 (en) 2006-10-13 2008-04-17 J. Craig Venter Institute, Inc. Sequencing method
AU2008217579A1 (en) 2007-02-20 2008-08-28 Oxford Nanopore Technologies Limited Formation of lipid bilayers
JP5646987B2 (en) 2007-04-04 2014-12-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Compositions, devices, systems, and methods for using nanopores
US8158344B2 (en) 2007-06-29 2012-04-17 Duke University Methods and compositions for correlating genetic markers with multiple sclerosis
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
JP5288143B2 (en) 2007-12-31 2013-09-11 富士レビオ株式会社 Cluster of microresonators for cavity mode optical detection
US8231969B2 (en) 2008-03-26 2012-07-31 University Of Utah Research Foundation Asymmetrically functionalized nanoparticles
WO2009120372A2 (en) 2008-03-28 2009-10-01 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
CN103695530B (en) 2008-07-07 2016-05-25 牛津纳米孔技术有限公司 Enzyme-hole construct
US9447152B2 (en) * 2008-07-07 2016-09-20 Oxford Nanopore Technologies Limited Base-detecting pore
EP3686602A1 (en) 2008-09-22 2020-07-29 University of Washington Msp nanopores and related methods
GB0820927D0 (en) * 2008-11-14 2008-12-24 Isis Innovation Method
KR101797773B1 (en) 2009-01-30 2017-11-15 옥스포드 나노포어 테크놀로지즈 리미티드 Adaptors for nucleic acid constructs in transmembrane sequencing
US20120100530A1 (en) 2009-01-30 2012-04-26 Oxford Nanopore Technologies Limited Enzyme mutant
BRPI1011384A2 (en) 2009-02-23 2016-03-15 Cytomx Therapeutics Inc proproteins and their methods of use
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
AU2010326349B2 (en) 2009-12-01 2015-10-29 Oxford Nanopore Technologies Limited Biochemical analysis instrument
FR2955773B1 (en) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
CN102116783B (en) 2010-12-31 2013-05-29 北京普源精电科技有限公司 Waveform display method
GB201100516D0 (en) 2011-01-12 2011-02-23 Isis Innovation Method using fluorinated amphiphiles
KR101939420B1 (en) 2011-02-11 2019-01-16 옥스포드 나노포어 테크놀로지즈 리미티드 Mutant pores
EP3848706B1 (en) 2011-05-27 2023-07-19 Oxford Nanopore Technologies PLC Coupling method
EP2807476A4 (en) 2012-01-20 2015-12-09 Genia Technologies Inc Nanopore based molecular detection and sequencing
AU2013220156B2 (en) 2012-02-15 2018-08-09 Oxford Nanopore Technologies Limited Aptamer method
CN112646019B (en) 2012-04-10 2022-08-16 牛津纳米孔科技公开有限公司 Mutant lysenin pore
TWI655213B (en) 2012-07-13 2019-04-01 目立康股份有限公司 Method for producing self-organizing peptide derivative
US20140206842A1 (en) 2013-01-22 2014-07-24 Muhammed Majeed Peptides Modified with Triterpenoids and Small Organic Molecules: Synthesis and use in Cosmeceutical
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
CN111534504B (en) 2014-01-22 2024-06-21 牛津纳米孔科技公开有限公司 Method of ligating one or more polynucleotide binding proteins to a target polynucleotide
CN106574300A (en) 2014-05-02 2017-04-19 牛津纳米孔技术公司 Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
CA2959220A1 (en) 2014-09-01 2016-03-10 Vib Vzw Mutant csgg pores
WO2016055778A1 (en) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Mutant pores
GB201502809D0 (en) 2015-02-19 2015-04-08 Oxford Nanopore Tech Ltd Mutant pore
EP3283887B1 (en) 2015-04-14 2021-07-21 Katholieke Universiteit Leuven Nanopores with internal protein adaptors
JP7237586B2 (en) 2015-12-08 2023-03-13 カトリック ユニヴェルシテット ルーヴェン カーユー ルーヴェン リサーチ アンド ディベロップメント Modified Nanopores, Compositions Containing Them and Uses Thereof
EP3423485B1 (en) 2016-03-02 2021-12-29 Oxford Nanopore Technologies plc Mutant pore

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669581B2 (en) 2009-03-25 2020-06-02 Oxford University Innovation Limited Method for sequencing a heteropolymeric target nucleic acid sequence
US10882889B2 (en) 2012-04-10 2021-01-05 Oxford Nanopore Technologies Ltd. Mutant lysenin pores
US11845780B2 (en) 2012-04-10 2023-12-19 Oxford Nanopore Technologies Plc Mutant lysenin pores
US11761956B2 (en) 2013-03-25 2023-09-19 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US10006905B2 (en) 2013-03-25 2018-06-26 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US10976311B2 (en) 2013-03-25 2021-04-13 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US10514378B2 (en) 2013-03-25 2019-12-24 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US10802015B2 (en) 2013-03-25 2020-10-13 Katholieke Universiteit Leuven Nanopore biosensors for detection of proteins and nucleic acids
US11725235B2 (en) 2014-01-22 2023-08-15 Oxford Nanopore Technologies Plc Method for attaching one or more polynucleotide binding proteins to a target polynucleotide
US11739377B2 (en) 2014-05-02 2023-08-29 Oxford Nanopore Technologies Plc Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US10167503B2 (en) 2014-05-02 2019-01-01 Oxford Nanopore Technologies Ltd. Mutant pores
US10844432B2 (en) 2014-05-02 2020-11-24 Oxford Nanopore Technologies, Ltd. Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US10443097B2 (en) 2014-05-02 2019-10-15 Oxford Nanopore Technologies Ltd. Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
US11034734B2 (en) 2014-09-01 2021-06-15 Oxford Nanopore Technologies Ltd. Mutant pores
US10400014B2 (en) 2014-09-01 2019-09-03 Oxford Nanopore Technologies Ltd. Mutant CsgG pores
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
US10472673B2 (en) 2015-02-19 2019-11-12 Oxford Nanopore Technologies Ltd. Hetero-pores
US11307192B2 (en) 2015-02-19 2022-04-19 Oxford Nanopore Technologies Plc Method for producing a hetero-oligomeric pore comprising two different monomers in a specific stiochiometric ratio
US11169138B2 (en) 2015-04-14 2021-11-09 Katholieke Universiteit Leuven Nanopores with internal protein adaptors
US10976300B2 (en) 2015-12-08 2021-04-13 Katholieke Universiteit Leuven Modified nanopores, compositions comprising the same, and uses thereof
US11685949B2 (en) 2016-03-02 2023-06-27 Oxford Nanopore Technologies Plc Mutant pore
US11597970B2 (en) 2016-03-02 2023-03-07 Oxford Nanopore Technologies Plc Mutant pores
US12018326B2 (en) 2016-03-02 2024-06-25 Oxford Nanopore Technologies Plc Mutant pore
US10995372B2 (en) 2016-03-02 2021-05-04 Oxford Nanopore Technologies Ltd. Mutant pores
US10975428B2 (en) 2016-03-02 2021-04-13 Oxford Nanopore Technologies Ltd. Mutant pore
US11186868B2 (en) 2016-03-02 2021-11-30 Oxford Nanopore Technologies Plc Mutant pore
US11104709B2 (en) 2016-04-06 2021-08-31 Oxford Nanopore Technologies Ltd. Mutant pore
US11939359B2 (en) 2016-04-06 2024-03-26 Oxford Nanopore Technologies Plc Mutant pore
US12024541B2 (en) 2017-05-04 2024-07-02 Oxford Nanopore Technologies Plc Transmembrane pore consisting of two CsgG pores
US11572387B2 (en) 2017-06-30 2023-02-07 Vib Vzw Protein pores
US11945840B2 (en) 2017-06-30 2024-04-02 Vib Vzw Protein pores
US12084477B2 (en) 2017-06-30 2024-09-10 Vib Vzw Protein pores

Also Published As

Publication number Publication date
US10669581B2 (en) 2020-06-02
US20180334707A1 (en) 2018-11-22
US9732381B2 (en) 2017-08-15
CN102365371B (en) 2014-03-12
CN102365371A (en) 2012-02-29
EP2411538B1 (en) 2019-10-23
EP2411538A2 (en) 2012-02-01
EP3677691B1 (en) 2021-07-28
WO2010109197A3 (en) 2011-03-17
EP3677691A1 (en) 2020-07-08
WO2010109197A2 (en) 2010-09-30
US20200407785A1 (en) 2020-12-31
US20120107802A1 (en) 2012-05-03
GB0905140D0 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
US20200407785A1 (en) Method for sequencing a heteropolymeric target nucleic acid sequence
US20230065890A1 (en) Adaptors for nucleic acid constructs in transmembrane sequencing
US9447152B2 (en) Base-detecting pore
US8785211B2 (en) Methods using pores
AU2012324639B2 (en) Method of characterizing a target polynucleotide using a pore and a Hel308 helicase

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION